<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>peregrine_10k.htm
<TEXT>
<!-- saved from url=(0022)http://internet.e-mail -->
<!-- saved from url=(0022)http://internet.e-mail -->
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>
<hr size="5" noshade  style="margin-top: -2px">
<hr size="1" noshade style="margin-top: -10px">
<div align="center"><b><font size="4" face="Times New Roman, Times, serif">UNITED STATES<br>
  SECURITIES AND EXCHANGE COMMISSION</font><font face="Times New Roman, Times, serif"></font></b><font face="Times New Roman, Times, serif"><br>
   <font size="2">Washington, D.C. 20549</font>  </font>
</div>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><hr align="center" width="125" size="1"></td>
  </tr>
  <tr>
    <td align="center"><B><font size="4" face="Times New Roman, Times, serif">FORM 10-K</font></B></td>
  </tr>
</table>
<br>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td height="25" valign="top"><FONT face="Times New Roman, Times, Serif" size=2>(Mark One)</FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td width="10%"><font size="3" face="Wingdings">x</font></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>For the Fiscal Year Ended April 30, 2005</B></FONT></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td align="center">&nbsp;</td>
  </tr>
  <tr align="center">
    <td colspan="2"><font size="2" face="Times New Roman, Times, serif">or</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><font size="3" face="Wingdings">o</font></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </B></FONT></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><b>Commission file number: 0-17085</b></FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><IMG height=67 src="image001.jpg" width=318><B><br>
</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>(Exact name of Registrant as specified in its charter)</I></FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="10%">&nbsp;</td>
    <td width="60%"><FONT face="Times New Roman, Times, Serif" size=2><B>Delaware</B> </FONT></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>95-3698422</B></FONT></td>
    <td width="5%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>(State or other jurisdiction of</I></FONT></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>(I.R.S. Employer</I></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>incorporation or organization)</I></FONT></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>Identification No.)</I></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>14272 Franklin Avenue,  Tustin, California </B></FONT></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>92780-7017</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>(Address of principal executive offices)</I></FONT></td>
    <td><FONT face="Times New Roman, Times, Serif" size=2><I>(Zip Code)</I></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr align="center">
    <td colspan="4"><FONT face="Times New Roman, Times, Serif" size=2><B>(714) 508-6000</B></FONT></td>
  </tr>
  <tr align="center">
    <td colspan="4"><FONT face="Times New Roman, Times, Serif" size=2><i>(Registrant&#146;s telephone number, including area code)</i></FONT></td>
  </tr>
  <tr align="center">
    <td colspan="4">&nbsp;</td>
  </tr>
  <tr align="center">
    <td colspan="4"><FONT face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section 12(b) of the Act: <B>&nbsp;None</B></FONT></td>
  </tr>
  <tr align="center">
    <td colspan="4">&nbsp;</td>
  </tr>
  <tr align="center">
    <td colspan="4"><FONT face="Times New Roman, Times, Serif" size=2>Securities registered pursuant to Section 12(g) of the Act:</FONT></td>
  </tr>
</table>

<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr align="center">
    <td width="20%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td height="23" valign="bottom" nowrap><font size="2" face="Times New Roman, Times, serif"><B>Title of Class</B></font></td>
    <td width="5%" valign="bottom" nowrap><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="30%" valign="bottom" nowrap><font size="2" face="Times New Roman, Times, serif"><B>Name of Each Exchange on Which Registered</B></font></td>
    <td width="20%"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="center">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="bottom"><hr align="center" size="1"></td>
    <td valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="bottom"><hr align="center" size="1">
    </td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr align="center">
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="top" nowrap><font size="2" face="Times New Roman, Times, serif">Common Stock ($0.001 par value)</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">The Nasdaq Stock Market,&nbsp;Inc. under <br>
      symbol&nbsp;&#147;PPHM&#148;</font></td>
    <td><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
</table>
<table cellspacing="0" cellpadding="0" width="100%" border="0">
  <tr>
    <td valign=top>&nbsp;</td>
  </tr>
  <tr>
    <td valign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.</FONT><font face="Times New Roman, Times, Serif" size=2> Yes&nbsp;</font><font size="3" face="Wingdings">x</font><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;No&nbsp;</font><font size="3" face="Wingdings">o</font></td>
  </tr>
  <tr>
    <td valign=top>&nbsp;</td>
  </tr>
  <tr>
    <td valign=top><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of Registrant&#146;s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K</font><font face="Times New Roman, Times, Serif" size=2>.&nbsp;</font><font size="3" face="Wingdings">o</font></td>
  </tr>
  <tr>
    <td valign=top>&nbsp;</td>
  </tr>
  <tr>
    <td valign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act). Yes&nbsp;</FONT><font size="3" face="Wingdings">x</font><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;No&nbsp;</font><font size="3" face="Wingdings">o</font></td>
  </tr>
  <tr>
    <td valign=top>&nbsp;</td>
  </tr>
  <tr>
    <td valign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The approximate aggregate market value of voting stock held by non-affiliates of the registrant was&nbsp;approximately $166,186,000&nbsp;as of October 31, 2004.<SUP> (1)</SUP></FONT></td>
  </tr>
</table>
<p align="center"><FONT face="Times New Roman, Times, Serif" size=2><B>165,690,677 <br>
</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>(Number of shares of common stock outstanding as of July 6, 2005)</I></FONT>
</p>
<hr size="1" noshade  style="margin-top: -2px">
<hr size="5" noshade style="margin-top: -10px">
<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>Documents incorporated by reference:</B></FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td width="90%"><font size="2" face="Times New Roman, Times, serif">Definitive Proxy Statement with respect to the 2005&nbsp;Annual Meeting of Stockholders to be filed by Peregrine Pharmaceuticals, Inc. with the Securities and Exchange Commission (hereinafter referred to as &#147;Proxy Statement&#148;)</font></td>
    <td align="right"><font size="2" face="Times New Roman, Times, serif"><BR>
      Part&nbsp;III</font></td>
  </tr>
</table>
<P><FONT face="Times New Roman, Times, Serif" size=2>(1) Excludes 13,722,191 shares of common stock held by directors and officers, and any stockholder
whose ownership exceeds five percent of the shares outstanding as of October 31, 2004, except for
Barclays Global Investors, which information was provided as of September 30, 2004. </FONT></P>
<P align=center>&nbsp;</P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>FORM 10-K ANNUAL REPORT<br>
</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><B>FISCAL YEAR ENDED APRIL 30, 2005</B></FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>
<a name="TABLE_OF_CONTENTS_">TABLE OF CONTENTS</a></B></FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td colspan="3" align="center" valign="bottom"><FONT face="Times New Roman, Times, Serif" size=2><B>PART I</B></FONT></td>
  </tr>
  <tr>
    <td width="16%" height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;1.</FONT></td>
    <td height="20"><A href="#a1"><FONT face="Times New Roman, Times, Serif" size=2>Business</FONT></A></td>
    <td width="8%" height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>1</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;2. &nbsp;</FONT></td>
    <td height="20"><A href="#a2"><FONT face="Times New Roman, Times, Serif" size=2>Properties</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>29</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;3.</FONT></td>
    <td height="20"><A href="#a3"><FONT face="Times New Roman, Times, Serif" size=2>Legal Proceedings</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>30</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;4. </FONT></td>
    <td height="20"><A href="#a4"><FONT face="Times New Roman, Times, Serif" size=2>Submission of Matters to a Vote of Security Holders</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>30</FONT></td>
  </tr>
  <tr>
    <td height="20">&nbsp;</td>
    <td height="20">&nbsp;</td>
    <td height="20" align="center">&nbsp;</td>
  </tr>
  <tr>
    <td height="20" colspan="3" align="center"><FONT face="Times New Roman, Times, Serif" size=2><B>PART II</B></FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;5. </FONT></td>
    <td height="20"><A href="#a5"><FONT face="Times New Roman, Times, Serif" size=2>Market for Registrant&#146;s Common Equity and Related Stockholders&#146; Matters</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>31</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;6. </FONT></td>
    <td height="20"><A href="#a6"><FONT face="Times New Roman, Times, Serif" size=2>Selected Financial Data</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>32</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;7.</FONT></td>
    <td height="20"><A href="#a7"><FONT face="Times New Roman, Times, Serif" size=2>Management&#146;s Discussion and Analysis of&nbsp;Financial Condition and Results of Operations</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>33</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;7A. </FONT></td>
    <td height="20"><A href="#a8"><FONT face="Times New Roman, Times, Serif" size=2>Quantitative and Qualitative Disclosures About Market Risk</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>43</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;8. </FONT></td>
    <td height="20"><A href="#a9">
    <FONT face="Times New Roman, Times, Serif" size=2>Financial Statements and Supplementary Data</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>43</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;9. </FONT></td>
    <td height="20"><A href="#a10"><FONT face="Times New Roman, Times, Serif" size=2>Changes in and Disagreements with Accountants on Accounting and Financial Disclosures</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>43</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item&nbsp;&nbsp;9A.</FONT></td>
    <td height="20"><A href="#a11"><FONT face="Times New Roman, Times, Serif" size=2>Controls and Procedures</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>44</FONT></td>
  </tr>
  <tr>
    <td height="20">&nbsp;</td>
    <td height="20">&nbsp;</td>
    <td height="20" align="center">&nbsp;</td>
  </tr>
  <tr align="center">
    <td height="20" colspan="3"><FONT face="Times New Roman, Times, Serif" size=2><B>PART III</B></FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 10. &nbsp;</FONT></td>
    <td height="20"><A href="#a12"><FONT face="Times New Roman, Times, Serif" size=2>Directors and Executive Officers of the Registrant</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>47</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 11. &nbsp;&nbsp;</FONT></td>
    <td height="20"><A href="#a13"><FONT face="Times New Roman, Times, Serif" size=2>Executive Compensation</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>47</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 12. </FONT></td>
    <td height="20"><A href="#a14"><FONT face="Times New Roman, Times, Serif" size=2>Security Ownership of Certain Beneficial Owners and Management</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>47</FONT></td>
  </tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 13. </FONT></td>
    <td height="20"><A href="#a15"><FONT face="Times New Roman, Times, Serif" size=2>Certain Relationships and Related Transactions</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>47</FONT></td>
  </tr>
  <tr>
    <td height="20">&nbsp;</td>
    <td height="20">&nbsp;</td>
    <td height="20" align="center">&nbsp;</td>
  </tr>
  <tr align="center">
    <td height="20" colspan="3"><FONT face="Times New Roman, Times, Serif" size=2><B>PART IV</B></FONT></td>
  </tr>
<tr>
<td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 14. </FONT></td>
<td height="20"><A href="#a16"><FONT face="Times New Roman, Times, Serif" size=2>Principal Accountant Fees and Services</FONT></A></td>
<td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>47</FONT></td>
</tr>
  <tr>
    <td height="20"><FONT face="Times New Roman, Times, Serif" size=2>Item 15. </FONT></td>
    <td height="20"><A href="#a17"><FONT face="Times New Roman, Times, Serif" size=2>Exhibits, Consolidated Financial Statement Schedules, and Reports on Form 8-K</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>48</FONT></td>
  </tr>
  <tr>
    <td height="20">&nbsp;</td>
    <td height="20"><A href="#a18"><FONT face="Times New Roman, Times, Serif" size=2>Signatures</FONT></A></td>
    <td height="20" align="center"><FONT face="Times New Roman, Times, Serif" size=2>55</FONT></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>The terms &#147;we&#148;, &#147;us&#148;, &#147;our&#148;, &#147;Company&#148; and &#147;Peregrine&#148; as used in this report refers to Peregrine Pharmaceuticals, Inc., and its wholly-owned subsidiary, Avid Bioservices, Inc.</I></FONT></P>
<I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2><i>i</i></FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART I</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a1"></A>Item 1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>BUSINESS</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Except for historical information contained herein, this Annual Report on Form 10-K contains certain
forward-looking information based on our current expectations. The inclusion of forward-looking statements
should not be regarded as a representation by us or any other person that the objectives or plans
will be achieved because our actual results may differ materially from any forward-looking statement.
The words &#147;may,&#148; &#147;should,&#148; &#147;plans,&#148; &#147;believe,&#148; &#147;anticipate,&#148;
&#147;estimate,&#148; &#147;expect,&#148; their opposites and similar expressions are intended to
identify forward-looking statements, but the absence of these words does not necessarily mean that
a statement is not forward-looking. We caution readers that such statements are not guarantees of
future performance or events and are subject to a number of factors that may tend to influence the
accuracy of the statements, including but not limited to, those risk factors outlined in the section
titled &#147;Risk Factors and Forward-Looking Statements&#148;. You should not unduly rely on these
forward-looking statements, which speak only as of the date of this Annual Report. We undertake no
obligation to publicly revise any forward-looking statement to reflect circumstances or events after
the date of this Annual Report or to reflect the occurrence of unanticipated events. You should,
however, review the factors and risks we describe in the reports we file from time to time with the
Securities and Exchange Commission (&#147;SEC&#148;) after the date of this Annual Report.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Annual Report on Form&nbsp;10-K, quarterly reports on Form&nbsp;10-Q, current reports on Form&nbsp;8-K,
and all amendments to those reports filed with or furnished to the SEC are available, free of charge,
through our website at <u><font color="#0000FF">www.peregrineinc.com</font></u> as soon as reasonably practicable after such reports are electronically filed with or furnished to
the SEC.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain
technical terms used in the following description of our business are defined in the &#147;Glossary
of Terms&#148;.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we own or have rights to various trademarks including Cotara&#174; and Tarvacin&#153;.
All other company names, registered trademarks, trademarks and service marks included in this Annual
Report are trademarks, registered trademarks, service marks or trade names of their respective owners.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Company Overview</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>About Us.</I> &nbsp;Peregrine Pharmaceuticals, Inc., located in Tustin, California, is a biopharmaceutical company
primarily engaged in the research, development, manufacture and commercialization of biotherapeutics
directed towards the treatment of cancer, viruses and other diseases using targeted antibodies. In
January 2002, we commenced contract manufacturing operations through our wholly-owned subsidiary,
Avid Bioservices, Inc. (&#147;Avid&#148;), which was formed from the facilities and expertise of
Peregrine. Our antibody-based product candidates and those of our customers are manufactured in-house
under current Good Manufacturing Practices (&#147;cGMP&#148;).</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The Company was originally incorporated in California in June 1981 and was reincorporated in the state
of Delaware on September 25, 1996. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Our Location.</I> <B>&nbsp;&nbsp;</B> Our principal executive offices are located at 14272 Franklin Avenue, Tustin, California, 92780 and
our telephone number is (714) 508-6000. Our internet website address is <u>
<font color="#0000FF">www.peregrineinc.com</font></u>. Information
contained on our website does not constitute any part of this report.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>1</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Our</I> &nbsp;<I>Products in Research and Development</I>. &nbsp;Our product development efforts, including those of our partners, have been primarily focused
on cancer therapeutics. This year we began to expand our therapeutic focus beyond cancer into the
treatment of infectious diseases. During fiscal year 2005, we filed two new Investigation New Drug
(&#147;IND&#148;) applications with the Food &amp; Drug Administration (&#147;FDA&#148;) for Tarvacin&#153;,
our lead Anti-Phospholipid Therapy agent. The first IND filing relates to our plans to evaluate Tarvacin&#153;
for the treatment of solid tumors and represents our first new product IND filing since 1997. The
second IND filing relates to our plans to evaluate Tarvacin&#153; for the treatment of chronic hepatitis
C virus (&#147;HCV&#148;) infection. The HCV filing marked the first time in our history that we
had filed an IND for a non-cancer indication indicating our broadening research and development efforts.
The FDA has approved both of these INDs. The following table represents our products in clinical trials: </FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD colspan=9 valign=top bgcolor="#0000FF">
    <font size="2" face="Times New Roman, Times, serif" color="#FFFFFF"><B>Products in Clinical Trials</B></font></TD>
  </TR>
  <TR align="center" valign="bottom">
    <TD colspan="9"><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
  </TR>
<TR align="center" valign="bottom">
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Technology</B> <B><br>
  Platform</B></font></TD>
  <TD>&nbsp;</TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Product Name </B></font></TD>
  <TD>&nbsp;</TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Disease</B></font></TD>
  <TD>&nbsp;</TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Stage of <br>
    Development</B></font></TD>
  <TD>&nbsp;</TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Development Status Overview</B></font></TD>
</TR>
  <TR>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
</TR>
<TR>
<TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
<TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
<TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
</TR>
<TR>
  <TD width=10% valign=top><font size="2" face="Times New Roman, Times, serif">Tumor Necrosis Therapy (&#147;TNT&#148;)</font></TD>
  <TD width=2% valign=top>&nbsp;</TD>
  <TD width=10% valign=top><font size="2" face="Times New Roman, Times, serif">Cotara&#174;</font></TD>
  <TD width=2% valign=top>&nbsp;</TD>
  <TD width=10% valign=top><font size="2" face="Times New Roman, Times, serif">Brain Cancer</font></TD>
  <TD width=2% valign=top>&nbsp;</TD>
  <TD width=10% valign=top><font size="2" face="Times New Roman, Times, serif">Phase II/III <br>
    registration trial</font></TD>
  <TD width=2% valign=top>&nbsp;</TD>
  <TD valign=top><font size="2" face="Times New Roman, Times, serif">Peregrine this fiscal year entered into a collaboration with New Approaches to Brain Tumor Therapy (&#147;NABTT&#148;), a brain tumor treatment consortium, to run a clinical study to evaluate Cotara&#174; for the treatment of brain cancer. This study is partially funded by the National Cancer Institute (&#147;NCI&#148;) and will treat up to 28 patients. This study represents the first part of the Phase II/III product registration study. </font></TD>
</TR>
  <TR>
    <TD colspan="9" valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Anti-Phospholipid Therapy</font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Tarvacin&#153;</font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Advanced Solid Cancers</font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Phase I</font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">We filed an Investigational New Drug (&#147;IND&#148;) application this year and initiated patient enrollment in June 2005 for our initial Tarvacin&#153; anti-cancer clinical trial. The Phase I study will treat up to 28 patients in a single and repeat dose escalation study at three clinical sites. </font></TD>
  </TR>
  <TR>
    <TD colspan="9" valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Anti-Phospholipid Therapy </font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Tarvacin&#153;</font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Hepatitis C Virus </font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Phase I </font></TD>
    <TD valign=top>&nbsp;</TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">We filed our initial anti-viral IND in April 2005 and subsequently received FDA clearance in May 2005. The initial trial is a
    Phase I dose escalation study designed to treat up to 32 patients at one or more clinical sites.</font></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>2</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, we remain committed to existing collaborations and the pursuit of select partnerships
with pharmaceutical, biopharmaceutical and diagnostic companies. The below table is a summary of
our technologies that have been licensed to third parties:</FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD colspan=9 valign=top bgcolor="#0000FF">
    <font size="2" face="Times New Roman, Times, serif" color="#FFFFFF"><B>Licensed Products</B></font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
  </TR>
<TR align="center" valign="bottom">
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Technology</B> <B><br>
  Platform</B></font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Partner </B></font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Disease</B></font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Stage of <br>
    Development</B></font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD><font size="2" face="Times New Roman, Times, serif"><B>Licensed Technology</B></font></TD>
</TR>
  <TR>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top><HR size=1  color=BLACK></TD>
</TR>
  <TR>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
    <TD valign=top><font size="1">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></TD>
  </TR>
<TR>
  <TD width="10%" valign=top><font size="2" face="Times New Roman, Times, serif">Tumor Necrosis Therapy (&#147;TNT&#148;)</font></TD>
  <TD width=2% valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD width="10%" align="center" valign=top><font size="2" face="Times New Roman, Times, serif">Medipharm Biotech through a sub-license with Cancer Therapeutics, Inc.</font></TD>
  <TD width=2% valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD width="10%" valign=top><font size="2" face="Times New Roman, Times, serif">Lung Cancer</font></TD>
  <TD width=2% valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD width="10%" valign=top><font size="2" face="Times New Roman, Times, serif">Product approved in China; pending manufacturing approval</font></TD>
  <TD width=2% valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  <TD valign=top><font size="2" face="Times New Roman, Times, serif">We licensed certain TNT rights exclusively in the territory of China. We expect to receive
  50% of the distributed profits received by Cancer Therapeutics, Inc. and equity as defined in the agreement. </font></TD>
</TR>
  <TR>
    <TD colspan="9" valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Tumor Necrosis Therapy (&#147;TNT&#148;)</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD align="center" valign=top><font size="2" face="Times New Roman, Times, serif">Merck KGaA</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Cancer Therapeutics</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Information not publicly available</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">We licensed the TNT-based antibodies for producing immunocytokines (antibody-cytokine fusion proteins) for the treatment of various diseases. We may receive royalties if products are successfully developed and commercialized under the agreement.</font></TD>
  </TR>
  <TR>
    <TD colspan="9" valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;</font><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Vascular Targeting Agents (&#147;VTAs&#148;)</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD align="center" valign=top><font size="2" face="Times New Roman, Times, serif">Schering AG&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Cancer Diagnostics</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Information not publicly available</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">We sub-licensed exclusive imaging and diagnostic rights to Schering AG under our VTA technology platform. We may receive milestone payments and royalties if products are successfully developed and commercialized under the agreement. </font></TD>
  </TR>
  <TR>
    <TD colspan="9" valign=top><font size="1" face="Times New Roman, Times, serif">&nbsp;</font><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Vascular Targeting Agents (&#147;VTAs&#148;)</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD align="center" valign=top><font size="2" face="Times New Roman, Times, serif">SuperGen, Inc.</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Cancer Therapeutics</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">Information not publicly available</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD valign=top><font size="2" face="Times New Roman, Times, serif">We sub-licensed the rights under our VTA technology using VEGF to target tumor blood vessels for cancer therapy. We may receive milestone payments and royalties if products are successfully developed and commercialized under the agreement.</font></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following is a comprehensive discussion of our most advanced technology platforms, including clinical
trial information, partnering arrangements, and other details pertaining to our broad technology
platforms. In addition, we have provided you an expanded overview of Avid&#146;s operations following
our technology platform discussions. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following represent our key technology platforms, which are further discussed below:&nbsp;</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR valign="middle">
<TD width=144></TD>
<TD width=24><FONT face="Times New Roman, Times, Serif" size=2>1.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Tumor Necrosis Therapy Technology (acquired technology);</FONT></TD>
</TR>
<TR valign="middle">
<TD></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="middle">
<TD width=144></TD>
<TD width=24><FONT face="Times New Roman, Times, Serif" size=2>2.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Anti-Phospholipid Therapy Technology (in-licensed technology);</FONT></TD>
</TR>
<TR valign="middle">
<TD></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="middle">
<TD width=144></TD>
<TD width=24><FONT face="Times New Roman, Times, Serif" size=2>3.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Anti-Angiogenesis Technology (in-licensed technology);</FONT></TD>
</TR>
<TR valign="middle">
<TD></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="middle">
<TD width=144></TD>
<TD width=24><FONT face="Times New Roman, Times, Serif" size=2>4.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Vascular Targeting Agent Technology (in-licensed technology); and</FONT></TD>
</TR>
<TR valign="middle">
<TD></TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="middle">
<TD width=144></TD>
<TD width=24><FONT face="Times New Roman, Times, Serif" size=2>5.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Vasopermeation Enhancement Agent Technology (in-licensed technology).</FONT></TD>
</TR></TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>3</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
&nbsp;<P></P>
&nbsp;<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">Tumor
    Necrosis Therapy (&#147;TNT&#148;) / Cotara</font></b><font face="Times New Roman, Times, serif"><B><font size="2" color="#FFFFFF"><sup>&reg;</sup></font></B></font></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Technology Overview.</I> &nbsp;We acquired the rights to the Tumor Necrosis Therapy<B>
(</B>&#147;TNT&#148;) technology in fiscal year 1995 through the acquisition of Cancer Biologics, Inc. TNT, our
  most clinically advanced technology, acts by binding to dead and dying cells found primarily at the
  necrotic core of the tumor. TNT antibodies are potentially capable of carrying a variety of agents
  including radioisotopes, chemotherapeutic agents and cytokines to the interior of solid tumors. Our
  first TNT-based product, Cotara&#174;, is an antibody conjugated to Iodine 131, a therapeutic radioisotope.
  In November 2004, we entered into a collaboration with New Approaches to Brain Tumor Therapy, a brain
  cancer consortium funded by the National Cancer Institute, to conduct the initial part of our product
  registration trial as a stand-alone protocol. This trial is designed to further evaluate safety,
  radiation exposure and efficacy of a single Cotara&#174; infusion in patients with first or second
  recurrence of glioblastoma multiforme, a particularly deadly form of brain cancer. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>The TNT Concept</I>. The concept behind TNT is that almost all solid tumors develop a core of dead or dying cells known
as necrosis or necrotic cells in the center of the tumor mass as it grows. The outer membrane of
necrotic cancer cells becomes leaky, thus exposing the DNA on the inside of the cell. Instead of
targeting living cancer cells, TNT targets the necrotic and dead cells, which can account for up
to 50% of the mass of a tumor found throughout the tumor mass but primarily at the tumor core. TNT
binds to Deoxyribonucleic Acid (&#147;DNA&#148;) or DNA-associated proteins, such as histones, found
within the nucleus of virtually every cell. TNT is only able to reach the DNA target in cells having
porous nuclear and cellular membranes, since porosity is a property uniquely associated with dead
and dying cells found within solid tumors. As such, DNA functions as a highly abundant but selective
target. This DNA target is not believed to modulate as is commonly seen with tumor-specific cell
surface antigens that are commonly used as targets with other antibody-based therapeutic modalities.
Thus, compared to a cell surface marker, the DNA target may be a more stable and reliable target.
Once concentrated in necrotic regions throughout the tumor, TNT can deliver a toxic payload to neighboring
viable cancer cells, resulting in death of the tumor cells surrounding the necrotic core.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Each successive treatment with TNT potentially kills more cancer cells, thereby increasing the necrotic
area of the tumor. Thus, TNT potentially becomes more effective upon subsequent doses, contrary to
conventional chemotherapy, which becomes less effective with subsequent doses due to increased drug
resistance. The TNT targeting mechanism could be the basis for a class of new products effective
across a wide-range of solid tumor types, including brain, lung, colon, breast, liver, prostate and
pancreatic cancers.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peregrine
&#150; NABTT Cotara&#174; Clinical Trial</I>. The collaborative clinical trial represents the initial part of our Food &amp; Drug Administration
(&#147;FDA&#148;) approved product registration clinical trial. The Peregrine &#150; NABTT study
will treat up to 28 patients and may be expanded upon mutual agreement by the parties. The study
will also collect important drug distribution and safety data that would support future clinical
development. </FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">Anti-Phospholipid
    Therapy / Tarvacin&#153;</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Technology Overview. </I>In August 2001, we exclusively in-licensed a new technology platform from th
e Univecense agreement,
  we paid an upnt license fee, annual maintenance fees, and are obligated to pay future milestone
  payments based on development progress, plus a royalty on net sales. To augment this technology,
  in August 2004, we in-licensed additional technology related to the Anti-Phospholipid Therapy platform
  from The University of Texas M. D. Anderson Cancer Center. Under this additional license agreement,
  we paid an up-front license fee, annual maintenance fees, and are obligated to pay future milestone
  payments based on development progress, plus a royalty on net sales. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>4</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Anti-Phospholipid
Therapy is our novel approach to treating cancer, viral infections and certain other diseases. This
approach is based on the finding that basic components of cells normally not accessible become exposed
under certain conditions. These structural components are known generically as phospholipids and
fall into two general classes, those found on the outer surface of the cell membrane and those found
on the inner surface of the membrane. Scientists working with us discovered that the inside phospholipids
become exposed on tumor blood vessels, virally infected cells and on a broad class of viruses know
as enveloped viruses (including human immunodeficiency virus (&#147;HIV&#148;), influenza, cytomegalovirus, hepatitis
C virus (&#147;HCV&#148;) and Lassa, Marburg, and Ebloa viruses,&nbsp;which cause hemorrhagic fevers) making
them a specific target for the potential treatment of those diseases. Tarvacin&#153; is a monoclonal
antibody that binds to the inside phospholipids and is Peregrine&#146;s lead Anti-Phospholipid Therapy
agent. In pre-clinical studies, Tarvacin&#153; bound to tumor blood vessels and inhibited growth
and development of multiple solid tumor types. In other pre-clinical studies, Tarvacin&#153; has
been shown to recognize a broad spectrum of enveloped viral types and has provided significant protection
against lethal viral infections in an animal model of Lassa fever and cytomegalovirus. Peregrine
has received FDA clearance to initiate Phase 1 clinical trials this year, under two separate INDs,
in advanced solid cancer and chronic HCV infection.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Solid Cancer Phase I Clinical Trial and Supporting Pre-Clinical Data.</I> &nbsp;During June 2005, we opened our first two clinical sites to enroll patients with advanced refractory solid tumor malignancy. The clinical trial is designed to enroll up to 28 patients with advanced
solid tumors that no longer respond to standard cancer treatments. The initial clinical centers open
for patient enrollment are the Scottsdale and Tucson sites of the Arizona Cancer Center. The objectives
of this open-label dose escalation study are to (i) determine the safety and tolerability of Tarvacin&#153;
administered intravenously to patients with advanced cancer; (ii) characterize the pharmacokinetic
profile of Tarvacin&#153; and; (iii) define the dose-limiting toxicities, maximum tolerated dose
and/or maximum effective dose of Tarvacin&#153;. Patients who demonstrate an objective response to
therapy may be offered continued treatment on an extension protocol. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Phase I clinical trial is supported by promising pre-clinical data generated by our researchers.
In pre-clinical studies, 3G4, the parent antibody of Tarvacin&#153;, was shown to reduce the growth
of breast cancer tumors in animal models by 60% when given alone and by 93% when given in combination
with the commonly used chemotherapy drug docetaxel. These experiments clearly demonstrated that the
inclusion of 3G4 significantly improved the therapeutic value of the key breast cancer drug docetaxel
with no additional toxicity. This data in combination with other pre-clinical data has intensified
our focus on the development of Tarvacin&#153; as a cancer therapeutic. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Hepatitis C Virus Phase I Clinical Trial and Supporting Pre-Clinical Data.</I> &nbsp;In May 2005, we received clearance from the FDA to initiate a Phase I clinical trial for the
treatment of chronic Hepatitis C Virus (&#147;HCV&#148;) infection. The Phase I study is a dose escalation
study designed to evaluate the safety, tolerability, pharmacokinetics and viral kinetics following
a single intravenous infusion of Tarvacin&#153; in up to 32 patients with chronic HCV infection. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Phase I study was supported by promising anti-viral pre-clinical data. Research into the anti-viral
potential of Tarvacin&#153; has been funded by a 3-year, $1.68 million grant received by the University
of Texas Southwestern Medical Center at Dallas from the National Institute of Allergy and Infectious
Disease (&#147;NIAID&#148;), which is part of the National Institutes of Health (&#147;NIH&#148;) and a sponsored
research agreement from Peregrine Pharmaceuticals. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>5</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Highlights
of pre-clinical results presented at the American Association of Immunologists annual meeting in
April 2005 and the Biotechnology Industry Organization annual meeting in June 2005 include:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Tarvacin&#153; binds to 6 different families of enveloped viruses including HIV1, HIV2, influenza A,
influenza B, cytomegalovirus, hepatitis C and Lassa fever model viruses; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>100% of animals lethally infected with murine cytomegalovirus (&#147;CMV&#148;) and treated with Tarvacin&#153;
survived as compared with 20% survival in control treated animals; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Tarvacin&#153; binds to virally infected cells in multiple virus systems; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Animals lethally infected with Pichinde virus (a model for Lassa fever, a fatal viral hemorrhagic fever
that is on the U.S. government&#146;s biodefense Category A watch list) and then treated with Tarvacin&#153;
showed a 50% survival rate as compared to zero survivors in the control treated group; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Surviving animals
infected with Pichinde virus did not show any signs of viral infection several months after treatment with Tarvacin&#153;
and were considered to have been disease free; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Surviving animals had long-term immunity to further infection with the Pichinde virus; </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Tarvacin&#153; protected lethally infected animals whether treated at the time of viral challenge or
once symptoms had developed indicating an active viral infection; and </FONT></TD></TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD width=26></TD>
<TD width=26 valign=top><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Tarvacin&#153; binds to both Pichinde viral particles and Pichinde-infected cells. </FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above pre-clinical data demonstrated that Tarvacin&#153; and related Anti-Phospholipid Therapy agents
exhibit significant anti-viral therapy. Since Tarvacin&#153; targets a basic, universal property
of enveloped viruses that is host-derived and independent of the viral genome, it may be effective
against a broad spectrum of enveloped viruses. Our researchers believe that the target which Tarvacin&#153;
binds to may also be difficult for viruses to overcome via resistance mechanisms.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Enveloped
viruses account for many of the most concerning viral health risks including HIV, HCV, cytomegalovirus,
hemorrhagic fever, SARS and various types of influenza including Avian influenza. We are continuing
to evaluate Tarvacin&#146;s&#153; potential for the treatment of other enveloped virus infections,
including HIV, influenza as well as viruses included on the government&#146;s bioterrorism watchlist
such as Lassa fever, Ebola and Marburg virus. As part of this ongoing effort, during April 2005,
we entered into a collaboration with National Institute of Allergy and Infectious Disease (&#147;NIAID&#148;)
in which their testing laboratories will screen Tarvacin&#153; for binding activity against a broad
spectrum of enveloped viral pathogens of health and bioterrorism concern. Up to 32 virus types will
be screened as part of the collaboration potentially to include herpes viruses, respiratory viruses,
pox viruses, HCV, Papillomavirus and viruses of biodefense concern including Pichinde, Yellow Fever,
West Nile and Dengue.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>About Phospholipids.</I> &nbsp;Phospholipids are normal cellular structures that are present in all cells of the human body
and form the building blocks that make up the outer surface of cells responsible for maintaining
integrity and normal functions. The study of phospholipids as targets for therapeutic and diagnostic
intervention forms the basis of our Anti-Phospholipid Therapy technology platform. We and our collaborators
have been studying the characteristics of phospholipids in a variety of different diseases. Phospholipids
can be classified under several different subtypes including choline-containing phospholipids (normally
facing outward from the cell&#146;s membrane) and aminophospholipids (normally facing inward from
the cell&#146;s membrane). In normal healthy cells, there are a number of systems that are responsible
for keeping aminophospholipids facing the interior of the cell and choline-containing phospholipids
facing the exterior of the cell. Our scientists have demonstrated that tumor blood vessels, virally
infected cells and viral particles differ significantly from normal cells with regard to the orientation
of their phospholipids. Our lead Anti-Phospholipid Therapy antibody, Tarvacin&#153;, preferentially
binds to aminophospholipids. </FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>6</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
&nbsp;<p></p>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">
    Anti-Angiogenesis Technology / 2C3</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Technology Overview</I>. During August 2001, the Company in-licensed the exclusive worldwide right for a new pre-clinical
  compound from the University of Texas Southwestern Medical Center. This new compound, named 2C3,
  added to Peregrine&#146;s anti-cancer platform technologies in the anti-angiogenesis field. Under
  this license agreement, we paid an up-front license fee, annual maintenance fees, and are obligated
  to pay future milestone payments based on development progress, plus a royalty on net sales. Our
  mouse derived antibody, 2C3, works by inhibiting a key tumor blood vessel growth factor known as
  Vascular Endothelial Growth Factor (&#147;VEGF&#148;) from inducing the formation of blood vessels
  in solid tumors. The 2C3 antibody is part of Peregrine&#146;s anti-angiogenesis compound family under
  development for the treatment of cancer and other diseases dependent on aberrant blood vessel formation. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>About VEGF.</I> &nbsp;VEGF is a potent growth factor that plays a role in a number of normal processes including blood
vessel formation (angiogenesis), bone formation and immune system regulation. The 2C3 antibody selectively
blocks VEGF binding to one of its two key receptors, VEGF receptor 2, without blocking binding to
VEGF receptor 1. VEGF binding to VEGF receptor 2 is believed to be the primary signal involved in
angiogenesis. VEGF binding to VEGF receptor 1 is believed to be involved in a number of normal VEGF-mediated
processes. Anti-angiogenesis agents that selectively block the blood vessel growth function of VEGF
without blocking other VEGF-mediated functions may have advantages over VEGF inhibition strategies
that block all VEGF functions.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Virtually
all detectable tumors are dependent upon a tumor vascular network to obtain oxygen and nutrients.
As the tumor increases in size, it produces angiogenic factors (formation of new blood vessels),
chief among them VEGF, to expand the vascular tree and increase the delivery of oxygen and nutrients
to the growing tumor. 2C3 is an anti-angiogenic agent that blocks VEGF-induced angiogenesis associated
with VEGF binding to VEGF receptor 2 but does not interfere with the VEGF activities associated with
binding to VEGF receptor 1. In pre-clinical studies presented last year at the American Association
of Cancer Research (&#147;AACR&#148;) annual meeting, the 2C3 antibody inhibited growth of blood vessels by up
to 85% in breast cancer tumor metastases. These results indicate that anti-VEGF agents that selectively
block the angiogenic functions of VEGF may be effective at treating cancer while potentially having
a better safety profile. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Pre-clinical Studies.</I> &nbsp;Pre-clinical research is currently being conducted by a number of investigators including Drs.
Rolf Brekken and Philip Thorpe at the University of Texas Southwestern Medical Center at Dallas.
VEGF-dependent angiogenesis is a key factor in pancreatic tumor growth, metastasis, and cancer-related
death. One of the studies presented evaluated the effect of 2C3 on the growth of tumors in various
pre-clinical models. Consistent with its anti-angiogenic activity, 2C3 decreased total blood vessel
density in these tumor models. 2C3 also controlled the growth of human pancreatic tumor cells injected
in the pancreas such that the 2C3 treated mice had primary tumors 50% smaller than tumors in mice
that received a control treatment. In addition, 2C3 therapy reduced the number and size of metastatic
colonies in the liver as well as the number of mice with metastatic disease. No therapy-related toxicity
was observed in any of these studies. In March, 2005 we presented data&nbsp;relating to the production
and characterization of human antibody versions of the 2C3 antibody at the 7th International Symposium
on Anti-Angiogenic Agents held in La Jolla, CA. These antibody candidates are currently being evaluated
as potential clinical candidates. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>7</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
&nbsp;<p></p>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">Vascular
    Targeting Agents (&#147;VTAs&#148;)</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Technology Overview. </I>Vascular Targeting Agents (&#147;VTAs&#148;) utilize monoclonal antibodies and other targeting agents
  that recognize markers found on tumor blood vessels but not on normal blood vessels. VTAs act in
  a two-step process: the VTA first binds to the tumor blood vessels and then induces a blood clot
  in the tumor blood vessels. The formation of the blood clot stops the flow of oxygen and nutrients
  to the tumor cells, ultimately resulting in tumor cell death. VTAs have the potential to be effective
  against a wide variety of solid tumors since: 1) the solid tumors studied to date in excess of two
  millimeters in size form a vascular network to enable the tumor to continue to grow, and 2) tumor
  vasculature markers are believed to be consistent across various tumor types. Another potential advantage
  of the VTA technology is that the cells targeted by VTAs (the vascular endothelial cells) are less
  likely to change due to mutation and therefore are less likely to become resistant to drugs. Drug
  resistance is caused by the genetic instability and increased mutation rates of cancer cells and
  is a significant problem with conventional therapeutic agents that must directly target the cancer
  cells of the tumor.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>The VTA Concept.</I> &nbsp;The VTA technology is based on the concept that virtually all detectable tumors rely on a tumor
vascular network to obtain oxygen and nutrients. In pre-clinical animal studies, VTAs have been shown
to be potent anti-cancer agents that act to cut off the supply of oxygen and nutrients to tumor cells
by causing blood clots to form within the tumor&#146;s blood supply network. VTAs localize within
the tumor vasculature by selectively binding to the endothelial cells that line tumor blood vessels.
Once the VTA binds to its target, it initiates local blood clotting. VTAs could be very potent anti-tumor
agents because they create two amplified processes that have a devastating effect on the tumor. The
first process is the initiation of the coagulation cascade, which is a&nbsp;self-sustaining chain
reaction in which a huge number of blood clotting molecules are generated, ultimately leading to
complete occlusion of the tumor blood vessels within a matter of minutes. A second level of amplification
occurs at the structural level where the blockage of a single capillary can lead to the destruction
of thousands of tumor cells. As a result, small quantities of VTAs localized in the tumor&#146;s
vascular system may cause an avalanche of tumor cell death.</FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">
    Vasopermeation Enhancement Agents (&#147;VEAs&#148;)</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Technology Overview.</I> &nbsp;Vasopermeation Enhancement Agents (&#147;VEAs&#148;) are a new class of drugs which are designed
to increase the uptake of cancer therapeutics and imaging agents into the tumor at the tumor site,
potentially resulting in greater efficacy. VEAs work by using monoclonal antibodies to deliver known
vasoactive compounds (i.e., molecules that cause tissues to become more permeable) selectively to
solid tumors. VEAs currently use the same targeting agent as TNT to deliver an agent that makes the
blood vessels inside the tumor more permeable (leaky). Once localized at the tumor site, VEAs alter
the physiology and the permeability of the vessels and capillaries that supply the tumor. In pre-clinical
studies, drug uptake has been increased up to almost 400% in solid tumors when VEAs were administered
several hours prior to the chemotherapeutic treatment. VEAs are intended to be used as a pre-treatment
for most existing cancer therapies and imaging agents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increased permeability of the tumor blood vessels makes it possible to deliver an increased concentration
of killing agents into the tumor where they can potentially kill the living tumor cells. VEAs are
intended to be used as a pre-treatment for most existing cancer therapies and imaging agents and
may be effective across multiple tumor types. </FONT></P><I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>8</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Barriers to Existing Cancer Therapies.</I> &nbsp;Most traditional approaches to cancer therapy attempt to directly destroy individual cancer
cells. Drugs that target cancer cells must overcome a significant number of structural barriers within
the tumor in order to be effective. They must first exit the tumor blood vessels, migrate past the
support structures that underlie the vessels and eventually make their way to the cancer cells. As
a result of these structural barriers, very little drug injected into the blood stream of a patient
is able to reach and destroy cancer cells. One potential solution to this problem is to increase
the permeability of the blood vessels within the tumor which will permit more therapeutic drug to
reach and kill substantially more cancer cells. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Pre-clinical Studies.</I> &nbsp;VEAs are currently in pre-clinical development. In pre-clinical studies, chemotherapy drug uptake
has been increased up to almost 400% in solid tumors when VEAs were administered several hours prior
to the therapeutic treatment. In April 2005, pre-clinical data was published in <I>Clinical Cancer Research</I> showing that our initial VEA compound, NHS76/PEP2, as a pre-treatment, enhanced the efficacy of chemotherapy
in tumors known to be sensitive to specific drugs. In addition, the published report showed that
NHS76/PEP2 plus chemotherapy also generated responses in tumors normally resistant to specific therapies,
such as mouse lung carcinoma treated with paclitaxel, vinblastine or 5-FU. Moreover, improvements
in drug uptake were seen in as little as one to two hours following pre-treatment with NHS76/PEP2.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
data from the VEA program was presented at the American Society of Clinical Oncology (&#147;ASCO&#148;)
in 2002. The pre-clinical studies demonstrated the ability of the VEA technology to significantly
increase the anti-tumor activity of several leading chemotherapy drugs including 5-FU, doxorubicin,
vinblastine, BCNU, Taxol, or VP-16. In general, the enhancement of chemotherapeutic drug effects
from these studies could be divided into two categories: (1) those tumors which normally respond
to a given drug, such as human colon carcinoma treated with doxorubicin, which were found to have
a significant increase in anti-tumor response following VEA pre-treatment; (2) those tumors which
normally do not respond to a given drug, such as lung carcinoma treated with Taxol, which were found
to have an increase in response following VEA pre-treatment. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We currently have a fully human targeting antibody for the VEA technology known as NHS76. In January
2005, we entered into an agreement with Merck KGaA that will provide us access to Merck&#146;s protein
expression technology and expertise in protein expression which should allow us to advance the development
of a clinical candidate under our VEA technology platform.</FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">
    Out-Licensing Collaborations</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>TNT Licensing Collaborations</I> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2000, we entered into a licensing agreement with Merck KGaA of Darmstadt, Germany providing
Merck the rights to use our proprietary TNT antibodies for producing immunocytokines (antibody-cytokine
fusion proteins) for the treatment of various diseases in exchange for an up-front fee and a royalty
on net sales. Within Merck, the international team of its affiliate Lexigen, based in Lexington,
MA, will develop these immunocytokines using our TNT targeting technology. To our knowledge, Merck
KGaA has not publicly disclosed the development status of the project. Financial information pertaining
to the collaboration is included in the notes to the consolidated financial statements. In January
2005, we extended our collaboration with Merck KGaA to gain access to their protein expression system
for the production of VEA and other protein therapeutics.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted to
Cancer Therapeutics, Inc. the exclusive right to sublicense TNT to a major pharmaceutical company
solely in the People&#146;s Republic of China. We refer you to the footnotes to the consolidated
financial statements for additional information regarding this collaboration.</FONT></P><I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>9</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>VTA Licensing Collaborations</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During December 2002, we granted the exclusive rights for the development of diagnostic and imaging
agents in the field of oncology to Schering A.G. under our Vascular Targeting Agent (&#147;VTA&#148;)
technology. Under the terms of the agreement, we received an up-front payment and could also receive
future milestone payments and a royalty on net sales, as defined in the agreement, based on development
success of each product candidate. Under the same agreement, we granted Schering an option to obtain
certain non-exclusive rights to the VTA technology with predetermined up-front fees and milestone
payments as defined in the agreement. To our knowledge, Schering A.G. has not publicly disclosed
the developmental status of the project. Financial information pertaining to this collaboration is
included in the notes to the consolidated financial statements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2001, we completed a licensing deal with SuperGen, Inc. (&#147;SuperGen&#148;) to license
a segment of our VTA technology, specifically related to Vascular Endothelial Growth Factor (&#147;VEGF&#148;)
in combination with certain toxins or killing agents. Under the terms of the licensing agreement,
we received an initial equity investment, continue to receive an annual license fee until an IND
is filed, and we could receive additional milestone payments based on the development success, plus
receive a royalty on net sales of all drugs commercialized by SuperGen utilizing the VEGF technology.
To our knowledge, SuperGen has not publicly disclosed the development status of the project. Financial
information pertaining to this collaboration is included in the notes to the consolidated financial
statements.</FONT></P>
<TABLE width=100% border="0" cellpadding="0" cellspacing="0">
  <TR align="center">
    <TD valign=top bgcolor="#0000FF"><b>
    <font face="Times New Roman, Times, serif" size="2" color="#FFFFFF">Contract
    Manufacturing Capabilities</font></b></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During January 2002, we commenced the operations of our wholly-owned subsidiary, Avid Bioservices,
Inc., which was formed from the facilities and expertise of Peregrine. Avid provides an array of
contract manufacturing services, including contract manufacturing of antibodies and proteins, cell
culture development, process development, and testing of biologics for biopharmaceutical and biotechnology
companies under current Good Manufacturing Practices (&#147;cGMP&#148;). Avid&#146;s current manufacturing
capacity includes four bioreactors:&nbsp;1,000 liter, 300 liter, 100 liter and 22.5 liter.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Operating a cGMP facility requires highly specialized personnel and equipment that must be maintained
on a continual basis. Prior to the formation of Avid, we manufactured our own antibodies for over
10 years and developed the manufacturing expertise and quality systems to provide the same service
to other biopharmaceutical and biotechnology companies. We believe Avid&#146;s existing facility
is well positioned to meet the growing needs of the industry. Avid is also well positioned to increase
its capacity in the future in order to become a significant supplier of contract manufacturing services.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Avid can provide an array of services to a variety of companies in the biotechnology and pharmaceutical
industries. Even though much of the process is very technical, knowledge of the process should assist
you in understanding the overall business. The manufacturing of monoclonal antibodies and recombinant
proteins under cGMP is a complex process and includes several phases before the finished drug product
is released to the client. The first phase of the manufacturing process is to receive the production
cell line (the cells that produce the desired protein) and any available process information from
the client. The cell line must be adequately tested according to FDA guidelines by an outside laboratory
to certify that it is suitable for cGMP manufacturing. This testing generally takes between one and
three months to complete, depending on the necessary testing. The cell line that is sent may either
be from a master cell bank (base cells from which all future cells will be grown), which is already
fully tested or may represent a research cell line. In the case of a research cell line, Avid can
use the research cell line to produce master and working cell banks. Clients often request further
development through media screening and adaptation followed by small scale bioreactor process development
in 1 to 5 liter bioreactor systems. In parallel to the production of the master and working cell
banks, the growth and productivity characteristics of the cell line may be evaluated in the research
and development labs and paper work to support the production plan. The whole manufacturing process
(master cell bank characterization, process development, assay development, raw materials specifications,
test methods, downstream processing methods, purification methods, testing methods and final release
specifications) must be developed and documented prior to the commencement of manufacturing in the
bioreactors. The second phase of the process is in the manufacturing facility. Once the process is
developed, pilot runs are performed using smaller scale bioreactors, such as the 22.5 liter bioreactor,
in order to verify the process. Once the process is set, a pilot run or runs at full scale will be
performed to finalize batch record development. Material produced during these runs is often used
for toxicology studies. After the pilot batch run(s) is completed, full-scale cGMP manufacturing
is typically initiated. Once the cGMP run(s) is completed, batch samples are sent to an outside lab
for various required tests, including sterility and viral testing. Once the test results verify the
antibodies meet specifications, the product is released and shipped to the client. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>10</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Each contract is tailored to meet the specific needs of the client. Full process development from start
to product release can take ten months or longer. Research and development work can take from two
months to over six months. All stages of manufacturing can generally take between one to several
weeks depending on the manufacturing method and process. Product testing and release can take up
to three months to complete. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Given its inherent complexity, necessity for detail, and magnitude (contracts may be into the millions
of dollars), the contract negotiations and sales cycle for cGMP manufacturing services can take a
significant amount of time. Our anticipated sales cycle from client introduction to signing an agreement
will take anywhere from between three to six months to over one year. Introduction to Avid&#146;s
services will usually come from word of mouth, exposure from direct mailings, exposure from attendance
at conferences or from advertising in trade journals. The sales cycle consists of the introduction
phase, the proposal phase, the audit phase, the contract phase and the project initiation phase.
The client sets the speed at which the process moves.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To
date, Avid has been audited and qualified by both large and small, domestic and foreign&nbsp;biotechnology
companies interested in the production of monoclonal antibodies for clinical trial use. Additionally,
Avid has been audited by the European Agency for the Evaluation of Medicinal Products (&#147;EMEA&#148;), the
United States Food and Drug Administration (&#147;FDA&#148;) and the California Department of Health. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Government Regulation</B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Regulation
by governmental authorities in the United States and other countries is a significant factor in our
ongoing research and development activities and in the production of our products under development.
Our products and our research and development activities, are subject to extensive governmental regulation
in the U.S. and in other countries, including the Federal Food, Drug, and Cosmetic Act, as amended,
the Public Health Service Act, also as amended, as well as to other federal, state, and local statutes
and regulations. These laws, and similar laws outside the U.S., govern the clinical and non-clinical
testing, manufacture, safety, effectiveness, approval, labeling, distribution, sale, import, export,
storage, record keeping, reporting, advertising and promotion of our products, if approved. Violations
of regulatory requirements at any stage may result in various adverse consequences, including regulatory
delay in approving or refusal to approve a product, enforcement actions, including withdrawal of
approval, labeling restrictions, seizure of products, fines, injunctions and/or civil or criminal
penalties. Any product that we develop must receive all relevant regulatory approvals or clearances
before it may be marketed in a particular country. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
regulatory process, which includes extensive pre-clinical testing and clinical trials of each clinical
candidate to study its safety and efficacy, is uncertain, takes many years and requires the expenditure
of substantial resources. We cannot assure you that the clinical trials of our product candidates
under development will demonstrate the safety and efficacy of those product candidates to the extent
necessary to obtain regulatory approval.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>11</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
activities required before a product may be marketed in the United States, such as Cotara&#174; or
Tarvacin&#153;, are generally performed in the following sequential steps:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>1.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT><U>Pre-clinical testing.</U> &nbsp;This includes laboratory testing of our products in animals to determine safety, efficacy and
potential toxicity. Pre-clinical studies must be conducted by laboratories that comply with FDA regulations
regarding good laboratory practice.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>2.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT><U>Submission to the FDA of an investigational new drug application (&#147;IND&#148;).</U> &nbsp;The results of pre-clinical studies, together with manufacturing information, analytical data
and proposed clinical trial protocols, are submitted to the FDA as part of an IND, which must become
effective before the clinical trials can begin. Once the IND is filed, the FDA has 30 days to review
it. The IND will automatically become effective 30&nbsp;days after the FDA receives it, unless the
FDA indicates prior to the end of the 30-day period that the proposed protocol raises concerns that
must be resolved to the FDA&#146;s satisfaction before the trials may proceed. If the FDA raises
concerns, we may be unable to resolve the proposed protocol to the FDA&#146;s approval in a timely
fashion, if at all.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>3.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT><U>Completion of clinical trials</U>. Human clinical trials are necessary to seek approval for a new drug or biologic and typically involve
a three-phase process. In phase I, small clinical trials are generally conducted to determine the
safety of the product. In phase II, clinical trials are generally conducted to assess safety, acceptable
dose, and gain preliminary evidence of the efficacy of the product. In phase&nbsp;III, clinical trials
are generally conducted to provide sufficient data for the statistically valid proof of safety and
efficacy. Clinical trials must be conducted according to good clinical practices under protocols
that detail the trial&#146;s objectives, inclusion and exclusion criteria, the parameters to be used
to monitor safety and the efficacy criteria to be evaluated, and informed consent must be obtained
from all study subjects. Each protocol must be submitted to the FDA as part of the IND. The FDA may
impose a clinical hold on an ongoing clinical trial if, for example, safety concerns arise, in which
case the study cannot recommence without FDA authorization under terms sanctioned by the agency.
In addition, before a clinical trial can be initiated, each clinical site or hospital administering
the product must have the protocol reviewed and approved by an independent institutional review board
(&#147;IRB&#148;). The independent IRB will consider, among other things, ethical factors and the
safety of human subjects. The independent IRB may require changes in a protocol, which may delay
initiation or completion of a study. Phase&nbsp;I, Phase&nbsp;II or Phase&nbsp;III clinical trials
may not be completed successfully within any specific period of time, if at all, with respect to
any of our potential products. Furthermore, we, the FDA or an independent IRB may suspend a clinical
trial at any time for various reasons, including a finding that the healthy individuals or the patients
are being exposed to an unacceptable health risk.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>4.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT><U>Submission to the FDA of a Biologics License Application (&#147;BLA&#148;) or New Drug Application
(&#147;NDA&#148;).</U> &nbsp;After completion of clinical studies for a biologics product, a Biologics License Application
(&#147;BLA&#148;) or New Drug Application (&#147;NDA&#148;) is submitted to the FDA for product marketing
approval. No action can be taken to market any new drug or biologic product in the United States
until the FDA has approved an appropriate marketing application. </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>5.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT><U>FDA review and approval of the BLA or NDA before the product is commercially sold or shipped.</U> &nbsp;The results of pre-clinical studies and clinical trials and manufacturing information are submitted
to the FDA in the form of a BLA or NDA for approval of the manufacture, marketing and commercial
shipment of the product. The FDA may take a number of actions after the BLA or NDA is filed, including
but not limited to, denying the BLA or NDA if applicable regulatory criteria are not satisfied, requiring
additional clinical testing or information;&nbsp;or requiring post-market testing and surveillance
to monitor the safety or efficacy of the product. Adverse events that are reported after marketing
approval can result in additional limitations being placed on the product&#146;s use and, potentially,
withdrawal of the product from the market. Any adverse event, either before or after marketing approval,
can result in product liability claims against us. </FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>12</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, we are subject to regulation under state, federal, and international laws and regulations
regarding occupational safety, laboratory practices, the use and handling of radioactive isotopes,
environmental protection and hazardous substance control, and other regulations. Our clinical trial
and research and development activities involve the controlled use of hazardous materials, chemicals
and radioactive compounds. Although we believe that our safety procedures for handling and disposing
of such materials comply with the standards prescribed by state and federal regulations, the risk
of accidental contamination or injury from these materials cannot be completely eliminated. In the
event of such an accident, we could be held liable for any damages that result and any such liability
could exceed our financial resources. In addition, disposal of radioactive materials used in our
clinical trials and research efforts may only be made at approved facilities. We believe that we
are in material compliance with all applicable laws and regulations including those relating to the
handling and disposal of hazardous and toxic waste.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our product candidates, if approved, may also be subject to import laws in other countries, the food
and drug laws in various states in which the products are or may be sold and subject to the export
laws of agencies of the United States government. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, we must also adhere to current Good Manufacturing Practice (&#147;cGMP&#148;) and product-specific
regulations enforced by the FDA through its facilities inspection program. Failure to comply with
manufacturing regulations can result in, among other things, warning letters, fines, injunctions,
civil penalties, recall or seizure of products, total or partial suspension of production, refusal
of the government to renew marketing applications and criminal prosecution. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 1999, the Office of Orphan Products Development of the FDA determined that Cotara&#174;
qualified for orphan designation for the treatment of glioblastoma multiforme and anaplastic astrocytoma
(both brain cancers). The 1983 Orphan Drug Act (with amendments passed by Congress in 1984, 1985,
and 1988) includes various incentives that have stimulated interest in the development of orphan
drug and biologic products. These incentives include a seven-year period of marketing exclusivity
for approved orphan products, tax credits for clinical research, protocol assistance, and research
grants. Additionally, legislation re-authorizing FDA user fees also created an exemption for orphan
products from fees imposed when an application to approve the product for marketing is submitted.
A grant of an orphan designation is not a guarantee that a product will be approved. If a sponsor
receives orphan drug exclusivity upon approval, there can be no assurance that the exclusivity will
prevent another entity from receiving approval for the same or a similar drug for the same or other uses.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Manufacturing and Raw Materials</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Manufacturing</I>. We manufacture pharmaceutical-grade products to supply our previous and ongoing clinical trials through
our wholly-owned subsidiary, Avid Bioservices, Inc. We have assembled a team of experienced scientific,
production and regulatory personnel to facilitate the manufacturing of our antibodies, including
Cotara&#174; and Tarvacin&#153;. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Tarvacin&#153; product is shipped directly from our facility to the clinical trial sites. Our Cotara&#174;
antibodies are shipped to a third party facility for radiolabeling (the process of attaching the
radioactive agent, Iodine 131, to the antibody). From the radiolabeling facility, the radiolabeled
Cotara&#174; antibodies are shipped directly to the clinical site for use in clinical trials. We
are evaluating other options for commercial radiolabeling, including the development of a product
kit that will enable hospitals to combine the antibody and radioactive isotope locally at each site.
Any commercial radiolabeling supply arrangement will require a significant investment of funds by
us in order for a radiolabeling vendor to develop the expanded facilities necessary to support our
product. There can be no assurance that material produced by our current radiolabeling supplier will
be suitable for commercial quantities to meet the possible demand of Cotara&#174;, if approved. We
will continue with our research in radiolabeling scale-up, but we believe this research will be eventually
supported by a potential licensing or marketing partner for Cotara&#174;.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>13</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Raw Materials.</I> &nbsp;&nbsp;Various common raw materials are used in the manufacture of our products and in the development
of our technologies. These raw materials are generally available from several alternate distributors
of laboratory chemicals and supplies. We have not experienced any significant difficulty in obtaining
these raw materials and we do not consider raw material availability to be a significant factor in
our business. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Patents and Trade Secrets</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Peregrine
continues to seek patents on inventions originating from ongoing research and development activities
within the Company and in collaboration with other companies and university researchers. Patents,
issued or applied for, cover inventions relating in general to cancer therapy and anti-viral therapy
and in particular to different antibodies and conjugates, methods and devices for labeling antibodies,
and therapeutic uses of the antibodies and conjugates. We intend to pursue opportunities to license
these technologies and any advancements or enhancements, as well as to pursue the incorporation of
our technologies in the development of our own products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our issued patents extend for varying periods according to the date of patent application filing or
grant and the legal term of patents in the various countries where patent protection is obtained.
The actual protection afforded by a patent, which can vary from country to country, depends upon
the type of patent, the scope of its coverage and the availability of legal remedies in the country.
We have either been issued patents or have patent applications pending that relate to a number of
current and potential products including products licensed to others. We consider that in the aggregate
our patent applications, patents and licenses under patents owned by third parties are of material
importance to our operations. In general, we have obtained licenses from various parties that we
deem to be necessary or desirable for the manufacture, use or sale of our products. These licenses
(both exclusive and non-exclusive) generally require us to pay royalties to the parties. The terms
of the licenses, obtained and that we expect to be obtained, are not expected to significantly impact
the cost structure or marketability of the Company&#146;s products.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In general, the patent position of a biotechnology firm is highly uncertain and no consistent policy
regarding the breadth of issued claims has emerged from the actions of the U.S. Patent Office with
respect to biotechnology patents. Similar uncertainties also exist for biotechnology patents in important
overseas markets. Accordingly, there can be no assurance that our patents, including those issued
and those pending, will provide protection against competitors with similar technology, nor can there
be any assurance that such patents will not be legally challenged, invalidated, infringed upon or
designed around by others.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>International patents relating to biologics are numerous and there can be no assurance that current
and potential competitors have not filed or in the future will not file patent applications or receive
patents relating to products or processes utilized or proposed to be used by the Company. In addition,
there is certain subject matter which is patentable in the United States but which may not generally
be patentable outside of the United States. Statutory differences in patentable subject matter may
limit the protection the Company can obtain on some of its products outside of the United States.
These and other issues may prevent the Company from obtaining patent protection outside of the United
States. Failure to obtain patent protection outside the United States may have a material adverse
effect on the Company&#146;s business, financial condition and results of operations.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>14</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>No one has sued us for infringement and no third party has asserted their patents against us that we
believe are of any merit. However, there can be no assurances that such lawsuits have not been or
will not be filed and, if so filed, that we will prevail or be able to reach a mutually beneficial
settlement. We also intend to continue to rely upon trade secrets and improvements, unpatented proprietary
know-how, and continuing technological innovation to develop and maintain our competitive position
in research and diagnostic products. We typically place restrictions in our agreements with third
parties, which contractually restricts their right to use and disclose any of the Company&#146;s
proprietary technology with which they may be involved. In addition, we have internal non-disclosure
safeguards, including confidentiality agreements, with our employees. There can be no assurance,
however, that others may not independently develop similar technology or that the Company&#146;s
secrecy will not be breached. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Customer Concentration and Geographic Area Financial Information </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are currently in the research and development phase for all of our products and we have not generated
any product sales from any of our technologies under development. For financial information concerning
Avid&#146;s customer concentration and geographic areas of its customers, see Note&nbsp;12, &#147;Segment
Reporting&#148; to the consolidated financial statements. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Marketing Our Potential Products</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We intend to sell our products, if approved, in the United States and internationally in collaboration
with marketing partners or through an internal sales force. If the FDA approves Cotara&#174;&nbsp;or
Tarvacin&#153; or our other product candidates under development, the marketing of these product
candidates will be contingent upon us entering into an agreement with a company to market our products
or upon us recruiting, training and deploying our own sales force. We do not presently possess the
resources or experience necessary to market TNT (Cotara&#174;), Tarvacin&#153; or our other product
candidates and we currently have no arrangements for the distribution of our product candidates.
Development of an effective sales force requires significant financial resources, time, and expertise.
There can be no assurance that we will be able to obtain the financing necessary to establish such
a sales force in a timely or cost effective manner or that such a sales force will be capable of
generating demand for our product candidates. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Competition</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
pharmaceutical and biotechnology industry is intensely competitive and subject to rapid and significant
technological change. Many of the drugs that we are attempting to discover or develop will be competing
with existing therapies. In addition, we are aware of several pharmaceutical and biotechnology companies
actively engaged in research and development of antibody-based products that have commenced clinical
trials with, or have successfully commercialized, antibody products. Some or all of these companies
may have greater financial resources, larger technical staffs, and larger research budgets than we
have, as well as greater experience in developing products and running clinical trials. We expect
to continue to experience significant and increasing levels of competition in the future. In addition,
there may be other companies which are currently developing competitive technologies and products
or which may in the future develop technologies and products which are comparable or superior to
our technologies and products. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are conducting the initial part of our Cotara&#174; product registration trial for the treatment
of recurrent brain cancer as a stand-alone study in collaboration with New Approaches to Brain Tumor
Therapy (&#147;NABTT&#148;) consortium. Companies conducting late stage clinical trials in brain
cancer that may compete with us include, among others, Xenova Group plc, Allos Therapeutics, Inc.
and NeoPharm, Inc. Xenova has begun patient dosing in a phase III clinical trial of TransMID&#153;
for the treatment of progressive or recurrent non-operable glioblastoma multiforme. Allos is developing
RSR13 (efaproxiral) for the treatment of patients with brain metastases originating from breast cancer
in a phase III study. NeoPharm is developing IL13-PE38QQR for the treatment of recurrent glioblastoma
multiforme in a Phase III study. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>15</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tarvacin&#153;
for the treatment of advanced solid cancers is currently in Phase I clinical trials. As for Tarvacin&#153;,
there are a number of possible competitors with approved products or developing targeted agents in
combination with standard chemotherapy for the treatment of cancer,&nbsp;including but not limited
to, Avastin&#153; by Genentech, Gleevec&#174; by Novartis, Tarceva&#153; by OSI Pharmaceuticals and
Genentech, Erbitux&#153; by ImClone, and panitumumab by Abgenix. Due to the significant number of
companies attempting to develop cancer therapeutics combined with the fact that Tarvacin&#153; is
in Phase I development, we cannot provide an accurate listing of all possible competitors at this
stage of development. In addition, we received clearance from the FDA to commence a Phase I clinical
trial using Tarvacin&#153; for the treatment of HCV. There are a number of companies that have products
approved and on the market for the treatment of HCV, including but not limited to: Peg-Intron (pegylated
interferon-alpha-2b), Rebetol (ribavirin), and Intron-A (interferon-alpha-2a), which are marketed
by Schering-Plough, and Pegasys (pegylated interferon-alpha-2a), Copegus (ribavirin USP), and Roferon-A
(interferon-alpha-2a), which are marketed by Roche. In addition, a number of companies have products
in clinical trials for the treatment of HCV, such as Schering-Plough, Vertex Pharmaceuticals Incorporated,
Valeant Pharmaceuticals International, Anadys Pharmaceuticals, Inc., among others.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Research and Development</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A major
portion of our operating expenses to date is related to research and development. Research and development
expenses primarily include (i) payroll and related costs associated with research and development
personnel, (ii) costs related to clinical and pre-clinical testing of the Company&#146;s technologies
under development, (iii) the costs to manufacture the product candidates, including raw materials
and supplies, (iv) intellectual property filing and maintenance fees, (v) expenses for research and services rendered
under outside contracts, including sponsored research funding, and (vi) facility expenses. Research
and development expenses were $11,164,000 in fiscal year 2005, $9,673,000 in fiscal year 2004, and
$8,744,000 in fiscal year 2003. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Corporate Governance</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
Board is committed to legal and ethical conduct in fulfilling its responsibilities. The Board expects
all directors, as well as officers and employees, to act ethically at all times and to adhere to
the policies comprising the Company&#146;s Code of Business Conduct and Ethics. The Board of Directors
(the &#147;Board&#148;) of the Company adopted the corporate governance policies and charters. Copies
of the following corporate governance documents are posted on our website, and are available free
of charge, at <u><font color="#0000FF">www.peregrineinc.com</font></u>: (1)&nbsp;Peregrine Pharmaceuticals, Inc. Code of Business Conduct
and Ethics (2)&nbsp;Peregrine Pharmaceuticals, Inc. Charter of the Nominating Committee of the Board
of Directors, (3) Peregrine Pharmaceuticals, Inc. Charter of the Audit Committee of the Board of
Directors, and (4)&nbsp;Peregrine Pharmaceuticals, Inc. Charter of the Compensation Committee of
the Board of Directors. If you would like a printed copy of any of these corporate governance documents,
please send your request to Peregrine Pharmaceuticals, Inc., Attention: Corporate Secretary, 14272
Franklin Avenue, Tustin, California&nbsp;92780.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Human Resources</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2005, we employed 84 full-time employees and 6 part-time employees. Each of our employees
has signed a confidentiality agreement and none are covered by a collective bargaining agreement.
We have never experienced employment-related work stoppages and consider our employee relations to
be good. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>16</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>GLOSSARY OF TERMS</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>2C3 ANTIBODY </B>- Peregrine&#146;s mouse derived antibody that inhibits a key tumor blood vessel growth factor known
as Vascular Endothelial Growth Factor (&#147;VEGF&#148;) from inducing the formation of blood vessels in solid
tumors based on pre-clinical studies. The 2C3 antibody is part of Peregrine&#146;s anti-angiogenesis
compound family under development for the treatment of cancer and other diseases dependent on aberrant
blood vessel formation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>3G4 ANTIBODY</B> &nbsp;&#150; Peregrine&#146;s mouse derived antibody that preferentially binds to the aminophospholipids. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANGIOGENESIS </B>- The formation of new blood vessels.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTI-PHOSPHOLIPID THERAPY</B> &nbsp;- The study of phospholipids as targets for therapeutic and diagnostic intervention forms the
basis of our Anti-Phospholipid Therapy technology platform. We and our
collaborators have been studying the characteristics of phospholipids in a variety of different diseases.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTIBODY - </B>Protein formed by the body to help defend against infection and disease. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>ANTIGEN - </B>Any substance that antagonizes or stimulates the immune system to produce antibodies.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CELL LINES - </B>Specific cell types artificially maintained in the laboratory (in-vitro) for scientific purposes.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CHEMOTHERAPY</B> &nbsp;<B>- </B>Treatment of disease by means of chemical substances or drugs.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CHIMERIC -</B> &nbsp;A type of antibody that is mostly human and partially mouse.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>cGMP</B> &nbsp;<B>-</B> current Good Manufacturing Practices; regulations established by the FDA for the manufacture, processing,
packing, or holding of a drug to assure that such drug meets the requirements of the Federal Food,
Drug and Cosmetic Act as to safety, and has the identity and strength and meets the quality and purity
characteristics that it purports or is represented to possess.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>COTARA&#174; - </B>The tradename of our first Tumor Necrosis Therapy clinical compound. Cotara&#174; is a chimeric monoclonal
antibody combined with Iodine 131 (radioisotope) that targets dead and dying cells found primarily
at the core of a tumor.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>CYTOKINE - </B>A chemical messenger protein released by certain white blood cells. The cytokines include the interferons,
the interleukins, Tumor necrosis factor, and many others. Cytokines produced by lymphatic cells are
also called &#147;Lymphokines.&#148;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>DNA (DEOXYRIBONUCLEIC ACID) - </B>A complex protein that is the carrier of genetic information.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>ENDOTHELIAL CELLS</STRONG> &nbsp;<B>-</B> A layer of flat cells that line blood vessels.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>EPITOPE - </B>A unique shape or marker carried on an antigen&#146;s surface that triggers a corresponding antibody
response.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>FDA</STRONG> &nbsp;<B>-</B> the U.S. Food and Drug Administration; the government agency responsible for regulating the food,
drug and cosmetic industries, including the commercial approval of pharmaceuticals in the United
States.</FONT></P>
<P align=center><FONT size="2" face="Times New Roman, Times, serif">17</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>GLIOMA</STRONG> &nbsp;<B>-</B> A tumor derived from cells that form the glial cells of the brain.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>GLIOBLASTOMA MULTIFORME</B> &nbsp;- A type of brain tumor that forms from glial (supportive) tissue of the brain. Also called
grade IV astrocytoma. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>IN VIVO - </B>Studies conducted within a living organism, such as animal or human studies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>IN VITRO - </B>An artificial environment created outside a living organism, such as a test tube or culture plate,
used in experimental research to study a disease or process.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>IND</STRONG> &nbsp;- Investigational New Drug Application; the application submitted to the FDA requesting permission
to conduct human clinical trials.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>MAXIMUM TOLERATED DOSE</B> &nbsp;- The highest nontoxic dose that can be reasonably given to patients.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN - </B>The middle value such that for a series of numbers, one half are above the median, and one half are
below.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN SURVIVAL TIME</B> &nbsp;<B>-</B> The time at which half of the patients with a given disease are found to be, or are expected to be,
alive. In a clinical trial, the median survival time is a way to measure the effectiveness of a product.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MEDIAN TIME TO PROGRESSION - </B>The time in which half of the patients with a given disease show evidence of disease progression. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>MURINE</STRONG> &nbsp;- Derived from a mouse.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>MONOCLONAL ANTIBODY </B>- An antibody derived from a single clone of cells. Monoclonal antibodies bind to one unique epitope.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>NECROSIS</STRONG> &nbsp;<B>or NECROTIC</B> - The death and degradation of cells within a tissue. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>ONCOLOGY</STRONG> &nbsp;- The study and treatment of cancer.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PHARMACOKINETIC - </B>Concerning the study of how a drug is processed by the body, with emphasis on the time required for
absorption, distribution in the body metabolism and excretion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PHOSPHOLIPIDS</B> &nbsp;- Phospholipids are normal cellular structures that are present in all cells of the human body
and form the building blocks that make-up the outer and inner surface of cells responsible for maintaining
integrity and normal functions.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PRE-CLINICAL - </B>Generally refers to research that is performed in animals or tissues in the laboratory.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>PROTOCOL - </B>A detailed plan for studying a treatment for a specific condition.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>RADIOLABELING</STRONG> &nbsp;<B>or RADIOLABELED</B> - Process of attaching a radioactive isotope, such as Iodine 131. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>RECURRENCE - </B>The return or flare up of a condition thought to be cured or in remission.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>REGISTRATION TRIAL</B> - A clinical trial&nbsp;designed to provide clinical evidence of&nbsp;a drug&#146;s effectiveness,
to support product license registration.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>18</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>SOLID TUMORS</STRONG> &nbsp;- Cancer cells which grow as a solid mass. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TARVACIN&#153;</B> &nbsp;- The tradename of Peregrine&#146;s first Anti-Phospholipid Therapy clinical compound. Tarvacin&#153;
is a chimeric version of 3G4 in which most of the mouse portion of the antibody has been replaced
with a human antibody. This was performed in order to reduce the likelihood of the human body recognizing
the antibody as foreign and developing an immune response to 3G4. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TIME TO PROGRESSION - </B>The time from either diagnosis or treatment to the date that the disease shows progression. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>TOXICITY - </B>The extent, quality, or degree of being poisonous or harmful to the body.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>TOXICOLOGY STUDIES</B> &nbsp;- The study of a drug in animals designed to characterize possible toxic effects. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>TUMOR</STRONG> &nbsp;- An abnormal overgrowth of cells. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>TUMOR NECROSIS THERAPY (&#147;TNT&#148;)</STRONG> &nbsp;- Therapeutic agents that target dead and dying cells found primarily at the core of a tumor.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULATURE</STRONG> &nbsp;- Tubelike structures that deliver blood to tissues.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULAR TARGETING AGENTS (&#147;VTAs&#148;)</STRONG> &nbsp;- Monoclonal antibodies and other targeting agents that recognize markers found specifically
on tumor blood vessels. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASOPERMEATION ENHANCEMENT AGENTS (&#147;VEAs&#148;)</STRONG> &nbsp;- A new generation of drugs which increase the uptake of therapeutic agents to solid tumors.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><STRONG>VASCULAR ENDOTHELIAL GROWTH FACTOR (&#147;VEGF&#148;) </STRONG>-<STRONG> </STRONG>A growth factor that plays a role in a number of normal processes including blood vessel formation
(angiogenesis) and immune system regulation.</FONT></P><B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>19</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><U><B><I>RISK FACTORS AND FORWARD-LOOKING STATEMENTS</I></B></U></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>This Form 10-K contains forward-looking information based on our current expectations. Because our
actual results may differ materially from any forward-looking statements made by or on behalf of
Peregrine, this section includes a discussion of important factors that could affect our actual future
results, including, but not limited to, our product sales, royalties, contract manufacturing revenues,
expenses, net income and earnings per share.</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Cannot Obtain Additional Funding, Our Product Development And Commercialization Efforts May Be
Reduced Or Discontinued And We May Not Be Able To Continue Operations.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>At April 30, 2005, we had approximately $9.8 million in cash and cash equivalents. We have expended
substantial funds on (i) the research, development and clinical trials of our product candidates,
and (ii) funding the operations of our wholly-owned subsidiary, Avid Bioservices, Inc. As a result,
we have historically experienced negative cash flows from operations since our inception and we expect
the negative cash flows from operations to continue for the foreseeable future, unless and until
we are able to generate sufficient revenues from Avid&#146;s contract manufacturing services and/or
from the sale and/or licensing of our products under development. While we expect Avid to generate
revenues in the foreseeable future, we expect our monthly negative cash flow to continue for the
foreseeable future, due to our clinical trial activities using Cotara&#174;, our two Tarvacin&#153;
clinical trials (both solid cancer tumors and hepatitis C virus infection), our anticipated development
costs associated with Anti-Phospholipid Therapy, Vasopermeation Enhancement Agents (&#147;VEAs&#148;)
and Vascular Targeting Agents (&#147;VTAs&#148;), and possible expansion of our manufacturing capabilities.
We believe we have sufficient cash on hand to meet our obligations on a timely basis through at least
fiscal year 2006. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In addition to the operations of Avid, we plan to obtain any necessary financing through one or more
methods including either equity or debt financing and/or negotiating additional licensing or collaboration
agreements for our technology platforms. There can be no assurances that we will be successful in
raising such funds on terms acceptable to us, or at all, or that sufficient additional capital will
be raised to complete the research, development, and clinical testing of our product candidates.</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><I>Successful Development Of Our Products Is Uncertain. To Date, No Revenues Have Been Generated From
The Commercial Sale Of Our Products And Our Products May Not Generate Revenues In The Future.</I></B></FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Our development of current and future product candidates is subject to the risks of failure inherent
in the development of new pharmaceutical products and products based on new technologies. These risks
include:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>delays in product development, clinical testing or manufacturing;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>unplanned expenditures in product development, clinical testing or manufacturing;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>failure in clinical trials or failure to receive regulatory approvals;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>emergence of superior or equivalent products;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>inability to manufacture on our own, or through others, product candidates on a commercial scale;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>inability to market products due to third party proprietary rights;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>election by our partners not to pursue product development;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>failure by our partners to develop products successfully; and</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>failure to achieve market acceptance.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In certain instances, we have experienced delays in our product development and clinical testing as
a result of slower than anticipated patient recruitment. In addition, we determined not to continue
the further development of one product candidate, Oncolym&#174;, due to the failure by our partners
to develop products successfully and the emergence of superior or equivalent products, such as Bexxar&#153;,
Zevalin&#174;, and Rituxan&#174;. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>20</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>Because of these risks, our research and development efforts or those of our partners may not result
in any commercially viable products. If significant portions of these development efforts are not
successfully completed, required regulatory approvals are not obtained or any approved products are
not commercially successful, our business, financial condition and results of operations may be materially
harmed.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Because our licensing partners and we have not begun commercial sales of our products, our revenue
and profit potential are unproven and our limited operating history makes it difficult for an investor
to evaluate our business and prospects. Our technology may not result in any meaningful benefits
to our current or potential partners. No revenues have been generated from the commercial sale of
our products, and our products may not generate revenues in the future. Further, due to our limited
operating history, we have difficulty accurately forecasting our revenue. Our business and prospects
should be considered in light of the heightened risks and unexpected expenses and problems we may
face as a company in an early stage of development in a new and rapidly evolving industry.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We Have Had Significant Losses And We Anticipate Future Losses.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have incurred net losses in most fiscal years since we began operations in 1981. The following table
represents net losses incurred during the past three fiscal years:</FONT></P>
<TABLE width=40% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>Net Loss</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT size="2" face="Times New Roman, Times, serif">&nbsp; </FONT></TD>
<TD align=LEFT><FONT size="2" face="Times New Roman, Times, serif">&nbsp; </FONT></TD>
<TD colspan="2" align=RIGHT valign="top"><HR size=1  color=BLACK></TD>
<TD align=LEFT><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>Fiscal Year 2005</FONT></TD>
<TD width=9% align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, serif" size=2>$</FONT></TD>
<TD width=15% align=RIGHT><FONT face="Times New Roman, Times, serif" size=2> 15,452,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>Fiscal Year 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, serif" size=2> 14,345,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>Fiscal Year 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, serif" size=2> 11,559,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2005, we had an accumulated deficit of $169,803,000. While we expect to generate revenues
from Avid&#146;s contract manufacturing services, in an effort to achieve and sustain profitable
operations, we must successfully develop and obtain regulatory approval for our products, either
alone or with others, and must also manufacture, introduce, market and sell our products. The costs
associated with clinical trials and product manufacturing is very expensive and the time frame necessary
to achieve market success for our products is long and uncertain. We do not expect to generate product
or royalty revenues for at least the next 2 years, and we may never generate product revenues sufficient
to become profitable or to sustain profitability.</FONT></P>
<P align=left><i><FONT face="Times New Roman, Times, Serif" size=2><B>Our Product Development Efforts May Not Be Successful.</B></FONT></i></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Since inception, we have been engaged in the development of drugs and related therapies for the treatment
of people with cancer. We recently began exploring the use of one of our product candidates, Tarvacin&#153;,
for the treatment of viral infections (in particular enveloped viruses) and are in the process of
enrolling a clinical trial for the treatment of people with the hepatitis C virus. Our product candidates
have not received regulatory approval and are generally in research, clinical and pre-clinical stages
of development. If the results from any of the clinical trials are poor, those results may adversely
affect our ability to raise additional capital, which will affect our ability to continue full-scale
research and development for our antibody technologies. In addition, our product candidates may take
longer than anticipated to progress through clinical trials or patient enrollment in the clinical
trials may be delayed or prolonged significantly, thus delaying the clinical trials. Patient enrollment
is a function of many factors, including the size of the patient population, the nature of the protocol,
the proximity of patients to the clinical sites, the eligibility criteria for the study, and the
availability of insurance coverage. In addition, because our Cotara&#174; product currently in clinical
trials represents a departure from more commonly used methods for cancer treatment, potential patients
and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than
enroll patients in our clinical study.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>21</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><I>Clinical Trials Required For Our Product Candidates Are Expensive And Time Consuming, And Their Outcome
Is Uncertain.</I></B></FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In order to obtain FDA approval to market a new drug product, our partners or we must demonstrate proof
of safety and efficacy in humans. To meet these requirements, our partners or we will have to conduct
extensive pre-clinical testing and &#147;adequate and well-controlled&#148; clinical trials. Conducting
clinical trials is a lengthy, time consuming and expensive process. The length of time may vary substantially
according to the type, complexity, novelty and intended use of the product candidate, and often can
be several years or more per trial. Delays associated with products for which we are directly conducting
pre-clinical or clinical trials may cause us to incur additional operating expenses. Moreover, we
will continue to be affected by delays associated with the pre-clinical testing and clinical trials
of certain product candidates conducted by our partners over which we have no control. The commencement
and rate of completion of clinical trials may be delayed by many factors, including, for example:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the inability to manufacture sufficient quantities of qualified materials under current good <br>
&nbsp;&nbsp;&nbsp;  manufacturing
practices, or cGMPs, for use in clinical trials;</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the need or desire to modify our manufacturing processes;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>slower than expected rates of patient recruitment;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the inability to adequately observe patients after treatment;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>changes in regulatory requirements for clinical trials;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the lack of effectiveness during the clinical trials;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>unforeseen safety issues;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>delays, suspension, or termination of the clinical trials due to the institutional review board <br>
&nbsp;&nbsp;&nbsp;  responsible
for overseeing the study at a particular study site; and</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>government or regulatory delays or &#147;clinical holds&#148; requiring suspension or termination of
the <br>
&nbsp;&nbsp;&nbsp;trials.</FONT></TD>
</TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Even if we obtain positive results from pre-clinical or clinical trials, we may not achieve the same
success in future trials. Clinical trials may not demonstrate statistically sufficient safety and
effectiveness to obtain the requisite regulatory approvals for product candidates employing our technology.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Historically, we have experienced slower than expected rates of patient recruitment in certain of our
Cotara&#174; clinical trials. As a result, in certain instances, we have experienced delays in our
product development and clinical testing. Clinical trials that we conduct or that third-parties conduct
on our behalf may not demonstrate sufficient safety and efficacy to obtain the requisite regulatory
approvals for any of our product candidates. We expect to commence new clinical trials from time
to time in the course of our business as our product development work continues. The failure of clinical
trials to demonstrate safety and effectiveness for our desired indications could harm the development
of that product candidate as well as other product candidates. Any change in, or termination of,
our clinical trials could materially harm our business, financial condition and results of operations.</FONT></P><B><I></I></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>22</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Cannot License Or Sell Cotara&#174;, It May Be Delayed Or Never Be Further Developed.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have recently concluded our Phase I study with Cotara&#174; for colorectal cancer, and recently
entered into a collaboration with New Approaches to Brain Tumor Therapy Consortium (&#147;NABTT&#148;)
to initiate the first part of our FDA approved Phase II/III registration trial with Cotara&#174;
for the treatment of brain cancer. The Cotara&#174; Phase II/III registration study for brain cancer
is at the stage in development where substantial financial resources are needed to complete clinical
studies necessary for potential product approval. We do not presently have the financial resources
internally to complete the entire remaining portion of the Phase II/III registration trial. We therefore
intend to continue to seek a licensing or funding partner for Cotara&#174;, and hope that the data
from this collaboration with NABTT will enhance our chances of finding such partner. If a partner
is not found for this technology, we may not be able to advance the project past its current state
of development. Because there are a limited number of companies which have the financial resources,
the internal infrastructure, the technical capability and the marketing infrastructure to develop
and market a radiopharmaceutical based anti-cancer drug, we may not find a suitable partnering candidate
for Cotara&#174;. If we are not successful in licensing or funding Cotara&#174;, we may explore the
possibility of a spin-off of the technology into a separate entity whereby the Company will contribute
the technology and the other entity will fund future clinical development in exchange for a percentage
ownership of the new entity. We cannot assure you that we will be able to find a suitable licensing
or funding partner for this technology. Furthermore, we cannot assure you that if we do find a suitable
licensing partner, the financial terms that they propose will be acceptable to the Company.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Dependency On One Radiolabeling Supplier May Negatively Impact Our Ability To Complete Clinical
Trials And Market Our Products.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have procured our antibody radioactive isotope combination services (&#147;radiolabeling&#148;)
with Iso-tex Diagnostics, Inc. for all clinical trials using Cotara&#174;. If this supplier is unable
to continue to qualify its facility or label and supply our antibody in a timely manner, our current
clinical trial or potential licensing partner clinical trials using radiolabeling technology could
be adversely affected and delayed. While there are other suppliers for radioactive isotope combination
services, our clinical trial would be delayed for up to 12 to 18 months because it may take that
amount of time to certify a new facility under current Good Manufacturing Practices and qualify the
product, plus we would incur significant costs to transfer our technology to another vendor. Prior
to commercial distribution of any of our products, if approved, we will be required to identify and
contract with a company for commercial antibody manufacturing and radioactive isotope combination
services. An antibody that has been combined with a radioactive isotope, such as Iodine 131, cannot
be stored for long periods of time, as it must be used within one week of being radiolabeled to be
effective. Accordingly, any change in our existing or future contractual relationships with, or an
interruption in supply from, any such third-party service provider or antibody supplier could negatively
impact our ability to complete ongoing clinical trials conducted by us or a potential licensing partner. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Manufacturing Facilities May Not Continue To Meet Regulatory Requirements And Have Limited Capacity.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Before approving a new drug or biologic product, the FDA requires that the facilities at which the
product will be manufactured be in compliance with current good manufacturing practices, or cGMP
requirements. To be successful, our therapeutic products must be manufactured for development and,
following approval, in commercial quantities, in compliance with regulatory requirements and at acceptable
costs. Currently, we manufacture all pre-clinical and clinical material through Avid Bioservices,
our wholly-owned subsidiary. While we believe our current facilities are adequate for the limited
production of product candidates for clinical trials, our facilities may not be adequate to produce
sufficient quantities of any products for commercial sale.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>If we are unable to establish and maintain a manufacturing facility or secure third-party manufacturing
capacity within our planned time and cost parameters, the development and sales of our products and
our financial performance may be materially harmed.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>23</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P><FONT face="Times New Roman, Times, Serif" size=2>We may also encounter problems with the following:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>production yields;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>quality control and assurance;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>shortages of qualified personnel;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>compliance with FDA regulations, including the demonstration of purity and potency;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>changes in FDA requirements;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>production costs; and/or</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>development of advanced manufacturing techniques and process controls.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In addition, any third-party manufacturer and we will be required to register manufacturing facilities
with the FDA and other regulatory authorities. The facilities will be subject to inspections confirming
compliance with cGMP or other regulations. If any of our third-party manufacturers or we fail to
maintain regulatory compliance, the FDA can impose regulatory sanctions including, among other things,
refusal to approve a pending application for a new drug product or biologic product, or revocation
of a pre-existing approval. As a result, our business, financial condition and results of operations
may be materially harmed.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Manufacture Of Our Products And The Products Of Avid&#146;s Customers Is Subject To Government
Regulation.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Avid is generally required to maintain compliance with current Good Manufacturing Practice, or cGMP,
and is subject to inspections by the FDA or comparable agencies in other jurisdictions to confirm
this compliance. Any changes of suppliers or modifications of methods of manufacturing require amending
our application to the FDA. Our inability to demonstrate ongoing cGMP compliance could require us
to suspend or terminate the manufacture of our products or those of Avid&#146;s third party customers.
Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging, or
storage of our products or those of Avid&#146;s third party customers as a result of a failure of
our facilities to pass any regulatory agency inspection could significantly impair (i) our ability
to advance our products through clinical trials, and (ii) Avid&#146;s ability to generate revenue.
This could increase our costs, cause us to lose revenue or market share and damage our reputation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Have Significant Product Liability Exposure Because We Maintain Only Limited Product Liability
Insurance.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We face an inherent business risk of exposure to product liability claims in the event that the administration
of one of our drugs during a clinical trial adversely affects or causes the death of a patient. Although
we maintain product liability insurance for clinical studies in the amount of $1,000,000 per occurrence
or $1,000,000 in the aggregate on a claims-made basis, this coverage may not be adequate. Product
liability insurance is expensive, difficult to obtain and may not be available in the future on acceptable
terms, if at all. Our inability to obtain sufficient insurance coverage on reasonable terms or to
otherwise protect against potential product liability claims in excess of our insurance coverage,
if any, or a product recall, could negatively impact our financial position and results of operations.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In addition, the contract manufacturing services that we offer through Avid expose us to an inherent
risk of liability as the antibodies or other substances manufactured by Avid, at the request and
to the specifications of our customers, could possibly cause adverse effects or have product defects.
We obtain agreements from our customers indemnifying and defending us from any potential liability
arising from such risk. There can be no assurance that such indemnification agreements will adequately
protect us against potential claims relating to such contract manufacturing services or protect us
from being named in a possible lawsuit. Although Avid has procured insurance coverage, there is no
guarantee that we will be able to maintain our existing coverage or obtain additional coverage on
commercially reasonable terms, or at all, or that such insurance will provide adequate coverage against
all potential claims to which we might be exposed. A successful partially or completely uninsured
claim against Avid would have a material adverse effect on our consolidated operations<I>.</I></FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>24</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Liquidity Of Our Common Stock Will Be Adversely Affected If Our Common Stock Is Delisted from The
Nasdaq SmallCap Market.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Our common stock is presently traded on The Nasdaq SmallCap Market. To maintain inclusion on The Nasdaq
SmallCap Market, we must continue to meet the following six listing requirements:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>1.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Net tangible assets of at least $2,500,000 or market capitalization of at least $35,000,000 or net
income of at least $500,000 in either our latest fiscal year or in two of our last three fiscal years;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>2.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Public float of at least 500,000 shares;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>3.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Market value of our public float of at least $1,000,000;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>4.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>A minimum closing bid price of $1.00 per share of common stock, without falling below this minimum
bid price for a period of 30 consecutive trading days; </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>5.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>At least two market makers; and</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>6.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>At least 300 stockholders, each holding at least 100 shares of common stock.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We cannot guarantee that we will be able to maintain the minimum closing bid price requirement or maintain
any of the other requirements in the future. The market price of our common stock has generally been
highly volatile. During fiscal year 2005, the trading price of our common stock on the Nasdaq SmallCap
Market ranged from $0.88 per share to $1.96 per share. If we fail to meet any of the Nasdaq SmallCap
Market listing requirements, the market value of our common stock could fall and holders of common
stock would likely find it more difficult to dispose of the common stock.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>If our common stock is delisted, we would apply to have our common stock quoted on the over-the-counter
electronic bulletin board. Upon any such delisting, our common stock would become subject to the
regulations of the Securities and Exchange Commission relating to the market for penny stocks. A
penny stock, as defined by the Penny Stock Reform Act, is any equity security not traded on a national
securities exchange or quoted on the NASDAQ National or SmallCap Market, that has a market price
of less than $5.00 per share. The penny stock regulations generally require that a disclosure schedule
explaining the penny stock market and the risks associated therewith be delivered to purchasers of
penny stocks and impose various sales practice requirements on broker-dealers who sell penny stocks
to persons other than established customers and accredited investors. The broker-dealer must make
a suitability determination for each purchaser and receive the purchaser&#146;s written agreement
prior to the sale. In addition, the broker-dealer must make certain mandated disclosures, including
the actual sale or purchase price and actual bid offer quotations, as well as the compensation to
be received by the broker-dealer and certain associated persons. The regulations applicable to penny
stocks may severely affect the market liquidity for our common stock and could limit your ability
to sell your securities in the secondary market. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>The Sale Of Substantial Shares Of Our Common Stock May Depress Our Stock Price.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2005, we had approximately 152,983,000 shares of our common stock outstanding, and
the last reported sales price of our common stock was $1.21 per share on April 29, 2005. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>25</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>We could also issue up to approximately 24,724,000 additional shares of our common stock upon the exercise
of outstanding options and warrants as further described in the following table:</FONT></P>
<TABLE width=60% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH colspan=2 nowrap><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH align="center" nowrap><FONT face="Times New Roman, Times, Serif" size=1>Number of <BR>
Shares<BR>
Outstanding</FONT></TH>
<TH width="6%" nowrap>&nbsp;</TH>
<TH colspan=2 nowrap><FONT face="Times New Roman, Times, Serif" size=1>Weighted Average Per Share<BR>
Exercise Price</FONT></TH>
<TH nowrap>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD align="center"><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Common shares issuable upon <BR>
&nbsp;&nbsp;&nbsp;&nbsp;exercise of outstanding stock options</FONT></TD>
<TD width="4%" align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="12%" align=center><FONT face="Times New Roman, Times, Serif" size=2>11,182,000</FONT></TD>
<TD width="6%" align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="9%" align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> $ 1.61</FONT></TD>
<TD width="5%" align=LEFT>&nbsp;</TD>
<TD width="2%" align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Common shares issuable upon <BR>
&nbsp;&nbsp;&nbsp;&nbsp;exercise of outstanding warrants</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>13,542,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> $ 1.81</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD align=center><HR size=1  color=BLACK></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR size=1  color=BLACK></TD>
<TD></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Total</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2>24,724,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> $ 1.72</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD align=center><HR  color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR  color=#000000 size=2></TD>
<TD></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Of the total warrants and options outstanding as of April 30, 2005, approximately 10,778,000 option
and warrants would be considered dilutive to stockholders because we would receive an amount per
share which is less than the market price of our common stock at April 30, 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>Our Highly Volatile Stock Price And Trading Volume May Adversely Affect The Liquidity Of Our Common
Stock.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The market price of our common stock and the market prices of securities of companies in the biotechnology
sector have generally been highly volatile and are likely to continue to be highly volatile.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The following table shows the high and low sales price and trading volume of our common stock for each
quarter in the three years ended April 30, 2005: </FONT></P>
<TABLE width=90% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=3><FONT face="Times New Roman, Times, Serif" size=1>Common Stock<BR>
Sales Price</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=6><FONT face="Times New Roman, Times, Serif" size=1>Common Stock Daily <BR>
Trading Volume<BR>
(000&#146;s omitted)</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=3><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=6><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH align="center"><FONT face="Times New Roman, Times, Serif" size=1>High</FONT></TH>
<TH>&nbsp;</TH>
<TH align="center"><FONT face="Times New Roman, Times, Serif" size=1>Low</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>High</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=3><FONT face="Times New Roman, Times, Serif" size=1>Low</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH align="center"><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH align="center"><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=3><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>Fiscal Year 2005</FONT></B></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=7% align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=7% align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=4% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=2% align=LEFT>&nbsp;</TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=4% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=2% align=LEFT>&nbsp;</TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended April 30, 2005</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.64</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.11</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>5,945</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>223</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended January 31, 2005</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $1.45</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.99</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>6,128</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>160</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended October 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.96</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.95</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,141</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>148</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended July 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.92</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.88</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,749</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>131</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>Fiscal Year 2004</FONT></B></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended April 30, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.85</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.56</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,550</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>320</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended January 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 3.14</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.01</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>6,062</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>201</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended October 31, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.44</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.25</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>18,060</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>314</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended July 31, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.19</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.60</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>12,249</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>255</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>Fiscal Year 2003</FONT></B></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended April 30, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.85</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.44</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,239</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>94</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended January 31, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.20</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.50</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,619</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>59</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended October 31, 2002</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.93</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.35</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,696</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>104</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended July 31, 2002</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.29</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.66</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,686</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>113</FONT></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The market price of our common stock may be significantly impacted by many factors, including, but
not limited to:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Announcements of technological innovations or new commercial products by us or our <br>
&nbsp;&nbsp;&nbsp;competitors;</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>publicity regarding actual or potential clinical trial results relating to products under <br>
&nbsp;&nbsp;&nbsp;development
by us or our competitors;</FONT></TD>
</TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>26</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<p></p>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>our financial results or that of our competitors;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>published reports by securities analysts;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>announcements of licensing agreements, joint ventures, strategic alliances, and any other <br>
&nbsp;&nbsp;&nbsp;transaction
that involves the sale or use of our technologies or competitive technologies;</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>developments and/or disputes concerning our patent or proprietary rights;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>regulatory developments and product safety concerns;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>general stock trends in the biotechnology and pharmaceutical industry sectors;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>public concerns as to the safety and effectiveness of our products;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>economic trends and other external factors, including but not limited to, interest rate <br>
&nbsp;&nbsp;&nbsp;fluctuations,
economic recession, inflation, foreign market trends, national crisis, and <br>
&nbsp;&nbsp;&nbsp;disasters; and</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>health care reimbursement reform and cost-containment measures implemented by <br>
&nbsp;&nbsp;&nbsp;government agencies.
</FONT></TD>
</TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>These and other external factors have caused and may continue to cause the market price and demand
for our common stock to fluctuate substantially, which may limit or prevent investors from readily
selling their shares of common stock and may otherwise negatively affect the liquidity of our common
stock.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Are Unable To Obtain, Protect And Enforce Our Patent Rights, We May Be Unable To Effectively
Protect Or Exploit Our Proprietary Technology, Inventions And Improvements.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Our success depends in part on our ability to obtain, protect and enforce commercially valuable patents.
We try to protect our proprietary positions by filing United States and foreign patent applications
related to our proprietary technology, inventions and improvements that are important to developing
our business. However, if we fail to obtain and maintain patent protection for our proprietary technology,
inventions and improvements, our competitors could develop and commercialize products that would
otherwise infringe our patents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Our patent position is generally uncertain and involves complex legal and factual questions. Legal
standards relating to the validity and scope of claims in the biotechnology and biopharmaceutical
fields are still evolving. Accordingly, the degree of future protection for our patent rights is
uncertain. The risks and uncertainties that we face with respect to our patents include the following:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the pending patent applications we have filed or to which we have exclusive rights may not <br>
&nbsp;&nbsp;&nbsp;result in
issued patents or may take longer than we expect to result in issued patents;</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the claims of any patents that issue may not provide meaningful protection;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>we may be unable to develop additional proprietary technologies that are patentable;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the patents licensed or issued to us may not provide a competitive advantage;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>other parties may challenge patents licensed or issued to us;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>disputes may arise regarding the invention and corresponding ownership rights in inventions <br>
&nbsp;&nbsp;&nbsp;and know-how
resulting from the joint creation or use of intellectual property by us, our <br>
&nbsp;&nbsp;&nbsp;licensors, corporate
partners and other scientific collaborators; and</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>other parties may design around out patented technologies.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Become Involved In Lawsuits To Protect Or Enforce Our Patents That Would Be Expensive And Time
Consuming.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In order to protect or enforce our patent rights, we may initiate patent litigation against third parties.
In addition, we may become subject to interference or opposition proceedings conducted in patent
and trademark offices to determine the priority of inventions. The defense of intellectual property
rights, including patent rights through lawsuits, interference or opposition proceedings, and other
legal and administrative proceedings, would be costly and divert our technical and management personnel
from their normal responsibilities. An adverse determination of any litigation or defense proceedings
could put our patent application at risk of not being issued.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>27</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised
by disclosure during this type of litigation. For example, during the course of this kind of litigation,
confidential information may be inadvertently disclosed in the form of documents or testimony in
connection with discovery requests, depositions or trial testimony. This disclosure could materially
adversely affect our business and financial results.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>We May Not Be Able To Compete With Our Competitors In The Biotechnology Industry Because Many Of Them
Have Greater Resources Than We Do And They Are Further Along In Their Development Efforts.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The biotechnology industry is intensely competitive. We face competition from pharmaceutical companies,
pharmaceutical divisions of chemical companies, and biotechnology companies of various sizes. Some
or all of these companies may have greater financial resources, larger technical staffs, and larger
research budgets than we have, as well as greater experience in developing products and running clinical
trials. We expect to continue to experience significant and increasing levels of competition in the
future. In addition, there may be other companies which are currently developing competitive technologies
and products or which may in the future develop technologies and products which are comparable or
superior to our technologies and products. We are conducting the initial part of our Cotara&#174;
product registration trial for the treatment of recurrent brain cancer as a stand-alone study in
collaboration with New Approaches to Brain Tumor Therapies (&#147;NABTT&#148;) consortium. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Companies conducting late stage clinical trials in brain cancer that may complete with us include,
among others, Xenova Group plc, Allos Therapeutics, Inc. and NeoPharm. Xenova has begun patient dosing
in a phase III clinical trial of TransMID&#153; for the treatment of progressive or recurrent non-operable
glioblastoma multiforme. Allos Therapeutics, Inc. is developing RSR13 (efaproxiral) for the treatment
of patients with brain metastases originating from breast cancer in a phase III study. NeoPharm is
developing IL13-PE38QQR for the treatment of recurrent glioblastoma multiforme in a Phase III study.
Most of our other products are in early stages of development or clinical trials, including Tarvacin&#153;.
Tarvacin&#153; for the treatment of advanced solid cancers is currently in Phase I clinical trials.
As for Tarvacin&#153;, there are a number of possible competitors with approved products or developing
targeted agents in combination with standard chemotherapy,&nbsp;including but not limited to, Avastin&#153;
by Genentech, Iressa&#174; by AstraZeneca, Gleevec&#174; by Novartis, Tarceva&#153; by OSI Pharmaceuticals
and Genentech, Erbitux&#153; by ImClone, and panitumumab by Abgenix. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Due to the significant number of companies attempting to develop cancer therapeutics combined with
the fact that our other products are generally in early stages of development, we cannot provide
an accurate listing of all possible competitors at this stage of development. In addition, we received
clearance from the FDA to commence a Phase I clinical trial using Tarvacin&#153; for the treatment
of hepatitis C virus (&#147;HCV&#148;). There are a number of companies that have products approved
and on the market for the treatment of HCV, including but not limited to: Peg-Intron (pegylated interferon-alpha-2b),
Rebetol (ribavirin), and Intron-A (interferon-alpha-2a), which are marketed by Schering-Plough, and
Pegasys (pegylated interferon-alpha-2a), Copegus (ribavirin USP), and Roferon-A (interferon-alpha-2a),
which are marketed by Roche. In addition, a number of companies have products in clinical trials
for the treatment of HCV, such as Schering-Plough, Vertex Pharmaceuticals Incorporated, Valeant Pharmaceuticals
International, Anadys Pharmaceuticals, Inc., among others.</FONT></P><B><I></I></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>28</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>New And Potential New Accounting Pronouncements May Impact Our Future Financial Position And Results
Of Operations</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>There may be potential new accounting pronouncements or regulatory rulings, which may have an impact
on our future financial position and results of operations. In particular, there are a number of
rule changes and proposed legislative initiatives following the recent corporate bankruptcies and
failures which could result in changes in accounting rules, including the accounting for employee
stock options as an expense. These and other potential changes could materially impact our assets
and liabilities, and the expenses we report under generally accepted accounting principles, and could
adversely affect our operating results or financial condition. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>If We Lose Qualified Management And Scientific Personnel Or Are Unable To Attract And Retain Such Personnel,
We May Be Unable To Successfully Develop Our Products Or We May Be Significantly Delayed In Developing
Our Products.</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Our success is dependent, in part, upon a limited number of key executive officers, each of whom is
an at-will employee, and also upon our scientific researchers. For example, because of his extensive
understanding of our technologies and product development programs, the loss of Mr. Steven King,
our President and Chief Executive Officer, would adversely affect our development efforts and clinical
trial programs during the 6 to 12 month period we estimate it would take to find and train a qualified
replacement.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We also believe that our future success will depend largely upon our ability to attract and retain
highly-skilled research and development and technical personnel. We face intense competition in our
recruiting activities, including competition from larger companies with greater resources. We do
not know if we will be successful in attracting or retaining skilled personnel. The loss of certain
key employees or our inability to attract and retain other qualified employees could negatively affect
our operations and financial performance.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a2"></A>ITEM 2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>PROPERTIES</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The Company&#146;s corporate, research and development, and clinical trial operations are located in
two Company-leased office and laboratory buildings with aggregate square footage of approximately
47,770 feet. The facilities are adjacent to one another and are located at 14272 and 14282 Franklin
Avenue, Tustin, California 92780-7017. The Company currently makes combined monthly lease payments
of approximately $62,000 for these facilities with a 3.35% rental increase every two years. The next
rental increase is scheduled for December 2006. The lease, which commenced in December 1998, has
an initial twelve-year term with two five-year term extensions. The Company believes its facilities
are adequate for its current needs and that suitable additional substitute space would be available
if needed. </FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>29</FONT></P>
<HR noshade size=5>
<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a3"></A>ITEM 3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<U>LEGAL PROCEEDINGS</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are a party to various legal proceedings, including licensing and contract disputes and other matters.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
December 16, 2004, we filed a lawsuit against the University of Southern California (&#147;USC&#148;)
and Alan Epstein, M.D. The lawsuit was filed in the Superior Court of the State of California for
the County of Los Angeles, Central District. The lawsuit alleges that USC has breached various agreements
with the Company by (i) failing to protect the Company&#146;s patent rights in Japan with respect
to certain technology exclusively licensed from USC due to non-payment of annuities, (ii) failing
to provide accounting documentation for research expenditures, and (iii) misusing certain antibodies
the Company provided to USC and Dr. Epstein for research. The claims against Dr. Epstein, who was
a scientific advisor and former consultant to the Company, involve breach of contract for misusing
certain antibodies and breach of fiduciary duties. The Company is seeking unspecified damages, declaratory
relief with respect to its rights under the option and license agreement pursuant to which it acquired
the rights to the technology, and an accounting of research expenditures. Because the lawsuit is
ongoing, the final outcome of this matter cannot be determined at this time.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
September 30, 2004, we filed a lawsuit against Knobbe, Martens, Olson &amp; Bear, LLP and Joseph
Reisman, of the law firm Knobbe, Martens, Olson &amp; Bear, LLP, in San Diego Superior Court. This
suit is related to the above-mentioned USC&#146;s failure to protect patent rights in Japan. Accordingly,
the case against the Knobbe firm was dismissed in connection with receiving a tolling agreement extending
the statute of limitations on our claims against the firm while USC pursues those claims. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we are currently investigating whether certain technologies developed at USC and subsequently
licensed to&nbsp;a private company, Pivotal BioSciences, Inc., an entity we believe is partially
owned by the principal investigator and others at USC, were developed&nbsp;using&nbsp;resources under
our sponsored research agreement with USC and/or funding provided from another source for which we
have geographic technology rights. We are in active discussions with Pivotal BioSciences, Inc. to
resolve the matter in an amicable manner. The current investigation does not affect our current rights
to our technologies under development nor should it have any effect, regardless of the outcome of
the investigation, on the development of any of our existing technologies.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a4"></A>ITEM 4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
were no matters submitted to a vote of security holders during the quarter ended April 30, 2005. </FONT></P><B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>30</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">

<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART II</U></B></FONT></P>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a5"></A>ITEM 5. &nbsp;</B></FONT><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><B><U>MARKET FOR REGISTRANT&#146;S COMMON EQUITY AND RELATED STOCKHOLDERS&#146; </U></B></FONT></td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><B><U>MATTERS</U></B></FONT></td>
  </tr>
</table>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(a)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I>Market Information.</I> &nbsp;The Company is listed on the SmallCap market of the Nasdaq Stock Market under the stock trading
symbol &#147;PPHM&#148;. The following table shows the high and low sales price of the Company&#146;s
common stock for each quarter in the two years ended April 30, 2005: </FONT></P>
<TABLE width=70% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH colspan=2 nowrap><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=3><FONT face="Times New Roman, Times, Serif" size=1>Common Stock Sales Price</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH nowrap>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=3><HR size=1 color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH align="center"><FONT face="Times New Roman, Times, Serif" size=1>High</FONT></TH>
<TH>&nbsp;</TH>
<TH align="center"><FONT face="Times New Roman, Times, Serif" size=1>Low</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH align="center"><HR size=1 color=BLACK></TH>
<TH>&nbsp;</TH>
<TH align="center"><HR size=1 color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><I><FONT face="Times New Roman, Times, Serif" size=2>Fiscal Year 2005</FONT></I></B></TD>
<TD width=5% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=10% align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=10% align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended April 30, 2005</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.64</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.11</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended January 31, 2005</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.45</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.99</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended October 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.96</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.95</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended July 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.92</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.88</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><B><I><FONT face="Times New Roman, Times, Serif" size=2>Fiscal Year 2004</FONT></I></B></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended April 30, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.85</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.56</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended January 31, 2004</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 3.14</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.01</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended October 31, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.44</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 1.25</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Quarter Ended July 31, 2003</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 2.19</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=center><FONT face="Times New Roman, Times, Serif" size=2> $ 0.60</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(b)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I>Holders.</I> &nbsp;As of June 30, 2005, the number of stockholders of record of the Company&#146;s common stock
was 5,885.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>(c)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I></I><I>Dividends.</I> &nbsp;No dividends on common stock have been declared or paid by the Company. The Company intends
to employ all available funds for the development of its business and, accordingly, does not intend
to pay any cash dividends in the foreseeable future.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> <I></I><I>Recent sales of unregistered securities.</I> &nbsp;During March 2005, the Company issued an unregistered three-year warrant to a consultant for
business development services to purchase up to 350,000 shares of the Company&#146;s common stock
at an exercise price of $1.47 per share. </FONT></P>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>31</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a6"></A>ITEM 6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <U></U><U>SELECTED FINANCIAL DATA</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> The following selected financial data has been derived from audited consolidated financial statements
of the Company for each of the five years in the period ended April 30, 2005. These selected financial
summaries should be read in conjunction with the financial information contained for each of the
three years in the period ended April 30, 2005, included in the consolidated financial statements
and notes thereto, Management&#146;s Discussion and Analysis of Results of Operations and Financial
Condition, and other information provided elsewhere herein.</FONT></P>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH colspan=16><FONT face="Times New Roman, Times, serif" size=2>CONSOLIDATED STATEMENTS OF OPERATIONS<BR>
FIVE YEARS ENDED APRIL 30, </FONT><FONT face="Times New Roman, Times, serif" size=2></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=16><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2005</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2003</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2002</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2001</FONT></TH>
<TH>&nbsp;</TH>
</TR>

<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Revenues</FONT></TD>
<TD width=1% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 4,959,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,314,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,921,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,766,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 979,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Net loss</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (15,452,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (14,345,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (11,559,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (11,718,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (9,535,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Basic and diluted loss per
common share</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (0.11</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (0.11</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (0.10</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (0.11</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (0.10</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Weighted average
shares outstanding</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>144,812,001</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>134,299,407</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>116,468,353</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>104,540,204</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>95,212,423</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH colspan=16><FONT face="Times New Roman, Times, Serif" size=2>CONSOLIDATED BALANCE SHEET DATA<BR>
AS OF APRIL 30,</FONT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=16><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2005</FONT>
<HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT>
<HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2003</FONT>
<HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2002</FONT>
<HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2001</FONT>
<HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Cash and cash equivalents</FONT></TD>
<TD width=1% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 9,816,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 14,884,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,137,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 6,072,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 6,327,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Working capital</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 7,975,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 13,631,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,949,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 4,007,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,446,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Total assets</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 14,245,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 19,137,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 5,399,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 7,866,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 7,900,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>

<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Long-term debt</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 434,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> &#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 760,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> &#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Accumulated deficit</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (169,803,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (154,351,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (140,006,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (128,447,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (116,729,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Stockholders&#146; equity</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 9,610,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 14,759,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,131,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 5,083,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,686,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>32</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a7"></A>ITEM 7. </B></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>&nbsp;MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</U></B></FONT></TD>
</TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following discussion is included to describe the Company&#146;s financial position and results
of operations for each of the three years in the period ended April 30, 2005. The consolidated financial
statements and notes thereto contain detailed information that should be referred to in conjunction
with this discussion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Overview</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Peregrine Pharmaceuticals, Inc., (&#147;Peregrine&#148;) located in Tustin, California, is a biopharmaceutical
company primarily engaged in the research, development, manufacture and commercialization of biotherapeutics
directed towards the treatment of cancer, viruses and other diseases using targeted monoclonal antibodies.
We are organized into two reportable operating segments: (i) Peregrine, the parent company, is engaged
in the research and development of targeted biotherapeutics and (ii) Avid Bioservices, Inc., (&#147;Avid&#148;)
a wholly-owned subsidiary, is engaged in providing an array of contract manufacturing services, including
contract manufacturing of antibodies and proteins, cell culture development, process development,
and testing of biologics for biopharmaceutical and biotechnology companies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Results of Operations</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following table compares the statement of operations for the fiscal years ended April 30, 2005, April
30, 2004 and April 30, 2003. This table provides you with an overview of the changes in the statement
of operations for the comparative periods, which changes are further discussed below. </FONT></P>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=8><FONT face="Times New Roman, Times, Serif" size=1>Years Ended April 30,</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=8><FONT face="Times New Roman, Times, Serif" size=1>Years Ended April 30,</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=8><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=8><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2005</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>$ Change</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2003</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>$ Change</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=8><I><FONT face="Times New Roman, Times, Serif" size=1>(in thousands)</FONT></I></TH>
<TH>&nbsp;</TH>
<TH colspan=8><I><FONT face="Times New Roman, Times, Serif" size=1>(in thousands)</FONT></I></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>REVENUES:</FONT></B></TD>
<TD width=1% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=6% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2></FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Contract manufacturing</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 4,684</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,039</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,645</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,039</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,346</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (307</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>License revenue</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>275</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>275</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>275</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>575</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(300</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Total revenues</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,959</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,314</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,645</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,314</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,921</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(607</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>COST AND EXPENSES:</FONT></B></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Cost of contract manufacturing</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,401</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,212</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,189</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,212</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,860</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(648</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Research and development</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>11,164</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>9,673</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,491</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>9,673</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>8,744</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>929</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Selling, general and administrative</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>5,098</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,225</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>873</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,225</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,987</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,238</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;Total cost and expenses</FONT></TD>

<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>20,663</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>16,110</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,553</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>16,110</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>14,591</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,519</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>LOSS FROM OPERATIONS</FONT></B></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(15,704</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(12,796</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(2,908</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(12,796</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(10,670</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(2,126</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>OTHER INCOME</FONT></B></TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Interest and other income</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>265</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>291</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(26</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>291</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>291</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Interest and other expense</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(13</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(1,840</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,827</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(1,840</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(1,180</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(660</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=8><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><B><FONT face="Times New Roman, Times, Serif" size=2>NET LOSS</FONT></B></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (15,452</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(14,345</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(1,107</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(14,345</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(11,559</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(2,786</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=8><HR size=2  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=8><HR size=2  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>33</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Total Revenues</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2005 Compared to the Year Ended April 30, 2004:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in revenues of $1,645,000 during the year ended April 30, 2005 compared to the prior year
was due to an increase in contract manufacturing revenue of the same amount. The current year increase
in contract manufacturing revenue was primarily due to an increase in the number of manufacturing
runs completed in fiscal year 2005 compared to the prior year. Although Avid currently has a number
of active projects and outstanding project proposals with various potential customers, we cannot
estimate nor can we determine the likelihood that we will be successful in completing these ongoing
projects or converting any of these proposals into definitive agreements during fiscal year 2006. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:</I> &nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in revenues of $607,000 during the year ended April 30, 2004 compared to the prior year
was primarily due to a reduction in contract manufacturing revenue of $307,000 combined with a decrease
in license revenue of $300,000. The decrease in contract manufacturing revenue was primarily due
to fewer equivalent manufacturing days billed in fiscal year 2004 compared to fiscal year 2003. The
decrease in license revenue was primarily due to the fiscal year 2003 recognition of $350,000 in
license revenue associated with certain TNT rights licensed to Merck KGaA while we had no corresponding
revenue recognized during fiscal year 2004. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Cost of Contract Manufacturing</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2005 Compared to the Year Ended April 30, 2004:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in cost of contract manufacturing of $2,189,000 during the year ended April 30, 2005 compared
to the prior year was primarily due to the current year increase in contract manufacturing revenue.
In addition, the increase was further supplemented by costs associated with the write-off of unusable
work-in-process inventory generated during the quarter ended April 30, 2005 in the amount of $605,000.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in cost of contract manufacturing of $648,000 during the year ended April 30, 2004 compared
to the prior year was primarily due to Peregrine&#146;s increased use of the manufacturing facility
for its products under development and the related costs being allocated to research and development
expenses combined with a related decrease in contract manufacturing revenue. During the current year,
we increased our antibody process development efforts associated with the Anti-Phospholipid Therapy
program and the manufacturing of Tarvacin&#153; for research and toxicology studies required for
the anticipated commencement of Phase I clinical studies.</FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><B>Research and Development Expenses</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2005 Compared to the Year Ended April 30, 2004:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in research and development expenses of $1,491,000 during the year ended April 30, 2005
compared to the prior year was primarily due to a net increase in expenses associated with our following
platform technologies under development:&nbsp;</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>34</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=48>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><I>Anti-Phospholipid Therapy (Tarvacin&#153;)</I> &nbsp;&#150; During fiscal year 2005, Anti-Phospholipid Therapy (Tarvacin&#153;) program expenses
increased $1,728,000 to $4,805,000 compared to $3,077,000 in fiscal year 2004. The increase in Anti-Phospholipid
Therapy (Tarvacin&#153;) program expenses of $1,728,000 is primarily due to increases in payroll
and related expenses, various clinical trial start-up expenses, and allocated manufacturing expenses
to support two separate Investigational New Drug (&#147;IND&#148;) applications that were filed with
the U.S. Food &amp; Drug Administration (&#147;FDA&#148;) during the current fiscal year using Tarvacin&#153;,
our lead Anti-Phospholipid Therapy agent, for the treatment of solid cancer tumors and chronic hepatitis
C virus infection, in addition to supporting the related upcoming Tarvacin&#153; Phase I clinical
studies associated with these IND&#146;s, both of which received clearance from the FDA to initiate
Phase I patient enrollment. In addition, intellectual property access fees increased during the current
fiscal year as we expanded our coverage under the Anti-Phospholipid Therapy platform. These increases
were offset by a decrease in antibody development and access fees associated with the timing of various
payments due under our licensing agreements to support Tarvacin&#153; and other related antibodies under development.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><I>TNT (Cotara&#174;)</I> &nbsp;&#150; During fiscal year 2005, TNT (Cotara&#174;) program expenses increased $833,000 to $3,183,000
compared to $2,350,000 in fiscal year 2004. The increase in TNT (Cotara&#174;) program expenses of
$833,000 is primarily due to an increase in manufacturing expenses, payroll and related expenses,
and radiolabeling process expenses to support the planned initiation of a clinical study representing
the first part of the Cotara&#174; Phase II/III registration trial for the treatment of brain cancer
in collaboration with the New Approaches to Brain Tumor Therapy consortium, and to support the increase
in research and development programs associated with our TNT technology platform. These increases
were further supplemented by an increase in technology access fees, which was primarily due to an
up-front license fee to obtain certain worldwide non-exclusive rights used in the manufacturing process
for the Cotara&#174; antibody. </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><I>VEA </I>&#150; During fiscal year 2005, VEA program expenses decreased $624,000 to $567,000 compared to $1,191,000
in fiscal year 2004. The decrease in VEA program expenses of $624,000 is primarily due to a decrease
in sponsored research fees paid to University of Southern California and stock-based compensation
expense associated with the amortization of the fair value of options granted to non-employee consultants
performing research and development activities that were fully amortized in the prior fiscal year.
These decreases were further supplemented by a decrease in allocated manufacturing expenses as we
increased our efforts associated with the manufacturing of Tarvacin&#153; and Cotara&#174; during
the current fiscal year and a decrease in technology access fees. In January 2005, we entered into
an agreement with Merck KGaA of Darmstadt, Germany, that will provide us access to Merck&#146;s technology
and expertise in protein expression to advance the development of our VEA technology.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><I>LYM (Oncolym&#174;)</I> &nbsp;&#150; During fiscal year 2005, LYM (Oncolym&#174;) program expenses decreased $229,000 to $7,000
compared to $236,000 in fiscal year 2004. The decrease in LYM (Oncolym&#174;) program expenses of
$229,000 is primarily due to allocated expenses incurred in the prior fiscal year to manufacture
LYM materials for research purposes only. </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><I>VTA and Anti-Angiogenesis</I> &nbsp;&#150; During fiscal year 2005, VTA and Anti-angiogenesis program expenses decreased $217,000 to
$2,602,000 compared to $2,819,000 in fiscal year 2004. The decrease in VTA and Anti-Angiogenesis
program expenses of $217,000 is primarily due to a decrease intellectual property access fees, antibody
development fees and manufacturing expenses, offset with an increase in payroll and related fees
to support our increase in active VTA and Anti-Angiogenesis pre-clinical research programs. </FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>35</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We expect research and development expenses to increase over the near term primarily under the following
ongoing research and development programs:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>1.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Anti-Phospholipid Therapy clinical programs associated with the commencement of two separate Phase
I clinical trials to evaluate Tarvacin&#153; for the treatment of solid tumors and chronic hepatitis
C virus infection;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>2.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Cotara&#174; clinical study for the treatment of brain cancer in collaboration with New Approaches
to Brain Tumor Therapy, a brain tumor treatment consortium, representing the first part of our Phase
II/III registration trial;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>3.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Anti-Phospholipid Therapy research and development program;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>4.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>2C3 (anti-angiogenesis antibody) research and development program;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>5.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Vascular Targeting Agent research and development program; and</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=60></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>6.<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Vasopermeation Enhancement Agent research and development program.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Due to the number of ongoing research programs, if we fail to obtain additional funding during fiscal
year 2006, we may be forced to scale back our product development efforts, or our operations, in
a manner that will ensure we can pay our obligations as they come due in the ordinary course of business
beyond fiscal year 2006.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in research and development expenses of $929,000 during the year ended April 30, 2004
compared to the prior year was primarily due to an increase in i) Anti-Phospholipid Therapy pre-clinical
development expenses, ii) manufacturing expenses, iii) intellectual property access and maintenance
fees, and iv) antibody development fees associated with our VTA and Anti-Angiogenesis technologies.
These amounts were primarily offset by a decrease in clinical trial expenses. During fiscal year
2004, we expended an aggregate of $1,557,000 for antibody license and development fees and toxicology
studies associated with our Tarvacin&#153; pre-clinical program, which amount was not incurred in
fiscal year 2003. Manufacturing expenses increased $599,000 to $2,825,000 in fiscal year 2004 compared
to $2,226,000 in fiscal year 2003 primarily due to our increased use of Avid&#146;s manufacturing
facility to manufacture Tarvacin&#153; for pre-clinical and clinical studies. Intellectual property
access fees increased $403,000 to $1,335,000 in fiscal year 2004 compared to $933,000 in fiscal year
2003 primarily due to increase filing fees related to our VTA and Anti-Phospholipid Therapy technologies.
In addition, antibody development fees associated with our VTA, Anti-Angiogenesis, and VEA technologies
increased $352,000 to $432,000 in fiscal year 2004 from $80,000 in fiscal year 2003 primarily due
to an increase in outside antibody development fees associated with the respective technologies. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The fiscal year 2004 increases in research and development expenses were offset by a decrease in clinical
trial program expenses and stock-based compensation expense. During fiscal year 2004, clinical trial
program expenses decreased $1,394,000 to $476,000 compared to $1,871,000 in fiscal year 2003. The
decrease was primarily due to costs incurred in the prior year of $762,000 related to clinical trial
start-up activities associated with seeking protocol approval for the Cotara&#174; Phase II/III registration
trial, which amount was not incurred in fiscal year 2004. This was supplemented by a decrease in
patient fees of $245,000 due to the treatment of fewer patients in the current year since we only
enrolled patients in our Phase I Cotara&#174; study at Stanford during fiscal year 2004. Moreover,
stock-based compensation expense decreased $330,000 to $199,000 in fiscal year 2004 compared to $529,000
in fiscal year 2003 due to a decrease in amortization expenses associated with the fair value of
options granted to non-employee consultants performing research and development activities that were
fully amortized in the prior year period. The options were valued using the Black-Scholes valuation
model and are being amortized over the estimated period of service or related vesting period.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>36</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
&nbsp;
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following represents the research and development expenses (&#147;R&amp;D Expenses&#148;) we incurred
by each major technology platform under development:</FONT></P>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH><FONT face="Times New Roman, Times, Serif" size=1>Technology Platform</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>R&amp;D Expenses- <BR>
Year Ended<BR>
April 30, 2003</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>R&amp;D Expenses-<BR>
Year Ended<BR>
April 30, 2004</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>R&amp;D Expenses-<BR>
Year Ended<BR>
April 30, 2005</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>R&amp;D Expenses-<BR>
May 1, 1998 to<BR>
April 30, 2005</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>TNT (Cotara&#174;)</FONT></TD>
<TD width=8% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 4,913,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,350,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 3,183,000</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=10% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 28,816,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Anti-Phospholipid Therapy (Tarvacin&#153;)</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>3,077,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>4,805,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>7,882,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>VTA and anti-angiogenesis</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,325,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,819,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>2,602,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>10,755,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>VEA</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,187,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,191,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>567,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>5,368,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>LYM (Oncolym&#174;)</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>319,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>236,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>7,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>13,441,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Total research and development</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 8,744,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 9,673,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 11,164,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 66,262,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>From inception to April 1998, we have expensed $20,898,000 on research and development of our product
candidates, with the costs primarily being closely split between the TNT and Oncolym&#174; technologies.
In addition to the above costs, we have expensed an aggregate of $32,004,000 for the acquisition
of our TNT and VTA technologies, which were acquired during fiscal years 1995 and 1997, respectively.
</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Looking beyond the next twelve months, it is extremely difficult for us to reasonably estimate all
future research and development costs associated with each of our technologies due to the number
of unknowns and uncertainties associated with pre-clinical and clinical trial development. These
unknown variables and uncertainties include, but are not limited to:</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of our capital resources to fund research, development and clinical studies beyond
the current fiscal year; </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of future costs associated with our pre-clinical candidates, including Vascular Targeting
Agents, Anti-angiogenesis agents, and Vasopermeation Enhancement Agents, which costs are dependent
on the success of pre-clinical development. We are uncertain whether or not these product candidates
will be successful and we are uncertain whether or not we will incur any additional costs beyond
pre-clinical development; </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of future clinical trial results; </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of the number of patients to be treated in any clinical trial;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of the Food and Drug Administration allowing our studies to move forward from Phase
I clinical studies to Phase II and Phase III clinical studies; </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of the rate at which patients are enrolled into any current or future study. Any delays
in clinical trials could significantly increase the cost of the study and would extend the estimated
completion dates;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of terms related to potential future partnering or licensing arrangements; and</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>the uncertainty of protocol changes and modifications in the design of our clinical trial studies,
which may increase or decrease our future costs.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We or our potential partners will need to do additional development and clinical testing prior to seeking
any regulatory approval for commercialization of our product candidates as all of our products are
in discovery, pre-clinical or clinical development. Testing, manufacturing, commercialization, advertising,
promotion, exporting and marketing, among other things, of our proposed products are subject to extensive
regulation by governmental authorities in the United States and other countries. The testing and
approval process requires substantial time, effort and financial resources, and we cannot guarantee
that any approval will be granted on a timely basis, if at all. Companies in the pharmaceutical and
biotechnology industries have suffered significant setbacks in conducting advanced human clinical
trials, even after obtaining promising results in earlier trials. Furthermore, the United States
Food and Drug Administration may suspend clinical trials at any time on various grounds, including
a finding that the subjects or patients are being exposed to an unacceptable health risk. Even if
regulatory approval of a product is granted, such approval may entail limitations on the indicated
uses for which it may be marketed. Accordingly, our potential partners or we may experience difficulties
and delays in obtaining necessary governmental clearances and approvals to market our products, and
we or our potential partners may not be able to obtain all necessary governmental clearances and
approvals to market our products.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>37</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Selling, General and Administrative Expenses</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2005 Compared to the Year Ended April 30, 2004:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Selling, general and administrative expenses consist primarily of payroll and related expenses, director
fees, legal and accounting fees, investor and public relation fees, insurance, and other expenses
relating to our general management, administration, and business development activities of the Company.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in selling, general and administrative expenses of $873,000 during the year ended April
30, 2005 compared to the prior year is primarily due to an increase in (i) payroll and related expenses
of $173,000 from $2,184,000 in fiscal year 2004 to $2,357,000 in fiscal year 2005 primarily due to
an increase in headcount across most corporate functions to support the increased operations primarily
pertaining to Avid and the expansion of the our pre-clinical and clinical development plans, which
were offset by a decrease in consulting fees associated with the prior year business development
efforts of Avid, (ii) audit and accounting fees of $253,000 from $164,000 in fiscal year 2004 to
$417,000 in fiscal year 2005 primarily related to the implementation of Section 404 of the Sarbanes-Oxley
Act of 2002, (iii) legal fees of $345,000 from $196,000 in fiscal year 2004 to $541,000 in fiscal
year 2005 primarily pertaining to the lawsuits described in this Annual Report on Form 10-K under
Part I, Item 3, Legal Proceedings and other patent and corporate matters, (iv) public relation fees
of $141,000 from $107,000 in fiscal year 2004 to $248,000 in fiscal year 2005 primarily due to the
addition of a new public relations firm assisting the Company with its public relations activities,
and (v) facility and related expenses of $114,000 from $204,000 in fiscal year 2004 to $318,000 in
fiscal year 2005 primarily related to an increased allocation of lease expense resulting from the
termination of a sub-lease arrangement combined with an increase in other facility related expenses
associated with the increase in employee headcount in the general and administrative departments.
These increases were offset by an $188,000 decrease in director fees from $464,000 in fiscal year
2004 to $276,000 in fiscal year 2005 primarily due to a one-time aggregate director fee of $180,000
incurred in the prior year associated with our director&#146;s increased oversight responsibilities
mandated by the Sarbanes-Oxley Act of 2002. Prior to fiscal year 2004, directors did not receive
any cash compensation other than the reimbursement of expenses.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003: </I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in selling, general and administrative expenses of $1,238,000 during the year ended April
30, 2004 compared to the prior year is primarily due to an increase in i) payroll and related expenses,
ii) director fees, and iii) legal fees. During fiscal year 2004, payroll and related expenses increased
$584,000 to $2,184,000 compared to $1,600,000 in fiscal year 2003 primarily due to business development
efforts of Avid and Peregrine. We incurred aggregate director fees of $464,000 in fiscal year 2004
associated with increased oversight responsibilities mandated by the Sarbanes-Oxley Act of 2002.
These fees were not incurred in the prior year as directors did not receive any cash compensation
other than the reimbursement of expenses prior to fiscal year 2004. In addition during fiscal year
2004, legal fees increased $120,000 to $196,000 compared to $76,000 in fiscal year 2003 primarily
due to an increase in business development activities.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>38</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P><FONT face="Times New Roman, Times, Serif" size=2><B>Interest and Other Expense</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2005 Compared to the Year Ended April 30, 2004:&nbsp;</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The decrease in interest and other expense of $1,827,000 during the year ended April 30, 2005 compared
to the prior year is primarily due to a decrease in non-cash interest expense of $1,811,000 associated
with the amortization of the convertible debt discount and debt issuance costs in fiscal year 2004.
We did not incur any interest expense associated with convertible debt discount and debt issuance
costs during fiscal year 2005 as all outstanding convertible debt was converted into common stock
and associated discount and issuance costs were fully amortized in the prior year. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Year Ended April 30, 2004 Compared to the Year Ended April 30, 2003: </I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The increase in interest and other expense of $660,000 during the year ended April 30, 2004 compared
to the prior year is primarily due to an increase in non-cash interest expense associated with the
amortization of the convertible debt discount and debt issuance costs related to an increase in convertible
debt conversions in the current year compared to the prior year. As of April 30, 2004, all outstanding
convertible debt was converted into common stock and the associated discount and debt issuance costs
were fully amortized. </FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=0 ><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following non-cash interest expense was included in Interest and other expense in the accompanying
consolidated statements of operations for fiscal years 2005, 2004 and 2003:</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR></TABLE>
<TABLE width=70% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2005</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2003</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Interest and other expense, as reported</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=11% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 13,000</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=11% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,840,000</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=11% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,180,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Less interest and other expenses paid in cash</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(13,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(29,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(163,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=1  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Interest, non-cash expense</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> &#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,811,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,017,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=2  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=2  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
<TD colspan="2" align=RIGHT><HR size=2  color=BLACK></TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Critical Accounting Policies </B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The methods, estimates and judgments we use in applying our most critical accounting policies have
a significant impact on the results we report in our consolidated financial statements. We evaluate
our estimates and judgments on an on-going basis. We base our estimates on historical experience
and on assumptions that we believe to be reasonable under the circumstances. Our experience and assumptions
form the basis for our judgments about the carrying value of assets and liabilities that are not
readily apparent from other sources. Actual results may vary from what we anticipate and different
assumptions or estimates about the future could change our reported results. We believe the following
accounting policies are the most critical to us, in that they are important to the portrayal of our
financial statements and they require our most difficult, subjective or complex judgments in the
preparation of our consolidated financial statements:&nbsp;</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenue
Recognition </I>- We currently derive revenues primarily from licensing agreements associated with Peregrine&#146;s
technologies under development and from contract manufacturing services provided by Avid. We recognize
revenues pursuant to Staff Accounting Bulletin No. 101 (&#147;SAB No. 101&#148;), <I>Revenue Recognition in Financial Statements </I>and Staff Accounting Bulletin No. 104 (&#147;SAB No. 104&#148;), <I>Revenue Recognition</I>. These bulletins draw on existing accounting rules and provides specific guidance on how those accounting
rules should be applied. Revenue is generally realized or realizable and earned when (i) persuasive
evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii)
the seller&#146;s price to the buyer is fixed or determinable, and (iv) collectibility is reasonably
assured. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>39</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
addition, we comply with Financial Accounting Standards Board&#146;s Emerging Issues Task Force No.
00-21 (&#147;EITF 00-21&#148;), <I>Revenue Arrangements with Multiple Deliverables</I>. In accordance with EITF 00-21, we recognize revenue for delivered elements only when the delivered
element has stand-alone value and we have objective and reliable evidence of fair value for each
undelivered element. If the fair value of any undelivered element included in a multiple element
arrangement cannot be objectively determined, revenue is deferred until all elements are delivered
and services have been performed, or until fair value can objectively be determined for any remaining
undelivered elements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues
associated with licensing agreements primarily consist of nonrefundable up-front license fees and
milestones payments. Revenues under licensing agreements are recognized based on the performance
requirements of the agreement. Nonrefundable up-front license fees received under license agreements,
whereby continued performance or future obligations are considered inconsequential to the relevant
licensed technology, are generally recognized as revenue upon delivery of the technology. Nonrefundable
up-front license fees, whereby ongoing involvement or performance obligations exist, are generally
recorded as deferred revenue and generally recognized as revenue over the term of the performance
obligation or relevant agreement. Milestone payments are recognized as revenue upon the achievement
of mutually agreed milestones, provided that (i)&nbsp;the milestone event is substantive and its
achievement is not reasonably assured at the inception of the agreement, and (ii)&nbsp;there are
no continuing performance obligations associated with the milestone payment. Under some license agreements,
the obligation period may not be contractually defined. Under these circumstances, we must exercise
judgment in estimating the period of time over which certain deliverables will be provided to enable
the licensee to practice the license. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract
manufacturing revenues are generally recognized once the service has been provided and/or upon shipment
of the product to the customer. We also record a provision for estimated contract losses, if any,
in the period in which they are determined. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2000, the Emerging Issues Task Force (&#147;EITF&#148;) released Issue 99-19 (&#147;EITF 99-19&#148;),
<I>Reporting Revenue Gross as a Principal versus Net as an Agent</I>. EITF 99-19 summarized the EITF&#146;s views on when revenue should be recorded at the gross amount
billed to a customer because it has earned revenue from the sale of goods or services, or the net
amount retained (the amount billed to the customer less the amount paid to a supplier) because it
has earned a fee or commission. In addition, the EITF released Issue 00-10 (&#147;EITF 00-10&#148;), <I>Accounting for Shipping and Handling Fees and Costs</I>, and Issue 01-14 (&#147;EITF 01-14&#148;), <I>Income Statement Characterization of Reimbursements Received for &#147;Out-of-Pocket&#148; Expenses
Incurred</I>. EITF 00-10 summarized the EITF&#146;s views on how the seller of goods should classify in the income
statement amounts billed to a customer for shipping and handling and the costs associated with shipping
and handling. EITF 01-14 summarized the EITF&#146;s views on when the reimbursement of out-of-pocket
expenses should be characterized as revenue or as a reduction of expenses incurred. Our revenue recognition
policies are in compliance with EITF 99-19, EITF 00-10 and EITF 01-14 whereby we recorded revenue
for the gross amount billed to customers (the cost of raw materials, supplies, and shipping, plus
the related handling mark-up fee) and we recorded the cost of the amounts billed as cost of sales
as we act as a principal in these transactions. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allowance
for Doubtful Accounts</I>. We continually monitor our allowance for doubtful accounts for all receivables. A considerable amount
of judgment is required in assessing the ultimate realization of these receivables and we estimate
an allowance for doubtful accounts based on factors that appear reasonable under the circumstances.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>40</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Liquidity and Capital Resources</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We had $9,816,000 in cash and cash equivalents at April 30, 2005 compared to $14,884,000 at April 30,
2004. From May 1, 2005 through July 5, 2005, we received an additional $11,302,000 in net proceeds
from the sale of shares of our common stock and we have $16,898,000 in cash and cash equivalents
at July 6, 2005. Although we have sufficient cash on hand to meet our current planned obligations
through at least fiscal year 2006, our development efforts are dependent on our ability to
raise additional capital to support our future operations. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have expended substantial funds on the development of our product candidates and we have incurred
negative cash flows from operations for the majority of our years since inception. Since inception,
we have generally financed our operations primarily through the sale of our common stock and issuance
of convertible debt, which has been supplemented with payments received from various licensing collaborations
and through the revenues generated by Avid. We expect negative cash flows from operations to continue
until we are able to generate sufficient revenue from the contract manufacturing services provided
by Avid and/or from the sale and/or licensing of our products under development. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Revenues earned by Avid during fiscal years ended April 30, 2005, 2004 and 2003 amounted to $4,684,000,
$3,039,000 and $3,346,000, respectively. We expect that Avid will continue to generate revenues which
should lower consolidated cash flows used in operations, although we expect those near term revenues
will be insufficient to cover anticipated cash flows used in operations. In addition, revenues from
the sale and/or licensing of our products under development are always uncertain. Therefore, we expect
we will continue to need to raise additional capital to continue the development of our product candidates,
including the anticipated development and clinical costs of Tarvacin&#153; and Cotara&#174;, the
anticipated research and development costs associated with our other platform technologies and the
potential expansion of our manufacturing capabilities.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We plan to raise additional capital through the offer and sale of shares of our common stock. However,
given uncertain market conditions and the volatility of our stock price and trading volume, we may
not be able to sell our securities at prices or on terms that are favorable to us, if at all. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to equity financing, we are actively exploring various other sources of funding, including
possible debt financing and leveraging our many assets, including our intellectual property portfolio
and the operations of Avid. Our broad intellectual property portfolio allows us to develop products
internally while at the same time we are able to out-license certain areas of the technology, which
would not interfere with our internal product development efforts. We also have the facilities of
Avid that we may leverage in a strategic transaction if the right opportunity and financial terms
are presented to us, provided that the manufacturing needs of our customers and Peregrine are not
jeopardized. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>There can be no assurances that we will be successful in raising sufficient capital on terms acceptable
to us, or at all (from either debt, equity or the licensing, partnering or sale of technology assets
and/or the sale of all or a portion of Avid), or that sufficient additional revenues will be generated
from Avid or under potential licensing agreements to complete the research, development, and clinical
testing of our product candidates beyond fiscal year 2006. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Significant
components of the changes in cash flows from operating, investing, and financing activities for the
year ended April 30, 2005 compared to the prior year are as follows:</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>41</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B> <I>Cash Used In Operating Activities</I>. Cash used in operating activities is primarily driven by changes in our net loss. However, cash used
in operating activities generally differs from our reported net loss as a result of non-cash operating
expenses or differences in the timing of cash flows as reflected in the changes in operating assets
and liabilities. During the year ended April 30, 2005, cash used in operating activities increased
$1,917,000 to $13,168,000 compared to $11,251,000 for the year ended April 30, 2004. The increase
in cash used in operating activities was primarily related to an increase of $3,138,000 in net cash
used in operating activities after deducting non-cash operating expenses and before considering the
changes in operating assets and liabilities. This increase was primarily due to an increase in research
and development expenses primarily associated with Tarvacin&#153; and Cotara&#174; planned clinical
trials, an increase in cost of manufacturing associated with a direct increase in related revenues,
combined with an increase in general and administrative expenses primarily related to the implementation
of Section 404 of the Sarbanes-Oxley Act of 2002 and increased investor and public relations activities.
This current year increase of $3,138,000 as described above was partially offset by the timing of
cash flows as reflected in the changes in operating assets and liabilities in the amount of $1,221,000.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
changes in operating activities as a result of non-cash operating expenses or differences in the
timing of cash flows as reflected in the changes in operating assets and liabilities are as follows:</FONT></P>
<TABLE width=70% border=0 align="center" cellpadding=0 cellspacing=0>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=5><FONT face="Times New Roman, Times, Serif" size=1>Year Ended April 30,</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=5><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2005</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>2004</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
<TH colspan=2><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Net loss, as reported</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=14% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (15,452,000</FONT></TD>
<TD width=5% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=14% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (14,345,000</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Less non-cash operating expenses:</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Depreciation</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>325,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>374,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Stock-based compensation expense</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>231,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>271,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Stock issued for research services</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>485,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>616,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;Amortization of discount on convertible<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;debt and debt issuance costs</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>1,811,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=1></TD>
<TD></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Net cash used in operating activities before<BR>
&nbsp;&nbsp;changes in operating assets and liabilities</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>(14,411,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (11,273,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Net change in operating assets and liabilities</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,243,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 22,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Net cash used in operating activities</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (13,168,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> (11,251,000</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>)</FONT></TD>
</TR>
<TR>
<TD colspan=2></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
<TD colspan=2 align=RIGHT><HR color=#000000 size=2></TD>
<TD></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Cash Used In Investing Activities.</I> &nbsp;Net cash used in investing activities increased $530,000 to $1,191,000 for the year ended April
30, 2005 compared to $661,000 for the same prior year period. This increase was primarily due to
the purchase of laboratory equipment to support the expanded research efforts of Peregrine and the
expanded services of Avid combined with an increase in other assets related to security deposits
paid to GE Capital Corporation on notes payable to finance certain laboratory equipment. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></B> <I>Cash Provided By Financing Activities. </I>Net cash provided by financing activities decreased $14,368,000 to $9,291,000 for the year ended April
30, 2005 compared to net cash provided of $23,659,000 for the same prior year period. The decrease
in financing activities during the current year is primarily due to a lower amount of capital raised
during the current period from the sale of our shares of common stock compared to the prior year.
This was partially offset by an increase in proceeds received from notes payable of $733,000 during
the current year to finance certain laboratory equipment.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>42</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>Contractual Obligations</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> Contractual obligations represent future cash commitments and liabilities under agreements with third
parties, and exclude contingent liabilities for which we cannot reasonably predict future payments.
The following chart represents our contractual obligations as of April 30, 2005, aggregated by type:</FONT></P>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=14><FONT face="Times New Roman, Times, Serif" size=1>Payments Due by Period (in thousands)</FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2>&nbsp;</TH>
<TH colspan=14><HR size=1  color=BLACK></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>Total</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1> &#139; 1 year </FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>1-3 years</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>4-5 years</FONT></TH>
<TH>&nbsp;</TH>
<TH colspan=2><FONT face="Times New Roman, Times, Serif" size=1>After 5 years</FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Operating leases, net (1)</FONT></TD>
<TD width=3% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=7% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 4,532</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=7% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 794</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=7% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,412</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=7% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,326</FONT></TD>
<TD width=4% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=1% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD width=7% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> &#151;</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Notes payable (2)</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>668</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 234</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 434</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Purchase obligations (3)</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>86</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>86</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT><P><FONT face="Times New Roman, Times, Serif" size=2>Other long-term liabilities -</FONT><BR>
<FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;minimum license obligations (4)</FONT></P></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>425</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>425</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>&#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
<TR valign=Bottom bgcolor="#EAF9E8">
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>Total contractual obligations</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 5,711</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,539</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 2,846</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> 1,326</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>$</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2> &#151;</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD colspan=2>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
<TD colspan=2><HR size=1  color=BLACK></TD>
<TD>&nbsp;</TD>
</TR>
</TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD colspan="3" valign=top></TD>
</TR>
<TR>
<TD colspan="3" valign=top></TD>
</TR>
<TR>
<TD colspan="3" valign=top></TD>
</TR>
<TR>
<TD colspan="3" valign=top>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
</TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(1)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Represents our (i) facility operating lease in Tustin, California under a non-cancelable lease agreement,
(ii) facility operating lease in Houston, Texas, which has a three year lease term, and (iii) various
office equipment leases, which generally have a five year lease term. </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(2)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Represents our two note payable agreements entered into with General Electric Capital Corporation during
fiscal year 2005, which are collateralized by certain laboratory equipment.</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(3)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Represents purchase obligation for the acquisition of laboratory equipment which is planned to be delivered
and installed during fiscal year 2006. </FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=48></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>(4)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>We periodically enter into licensing agreements with third parties to obtain exclusive or non-exclusive
licenses for certain technologies. The terms of certain of these agreements require us to pay future
milestone payments based on product development success. We anticipate we may make milestone payments
in the amount of $425,000 during fiscal year 2006 under two licensing agreements pertaining to the Tarvacin&#153; clinical trial, which
milestones we anticipate may occur during fiscal year 2006. Other milestones
fees under these and other licensing agreements cannot be predicted due to the uncertainty of future
clinical trial results and development milestones and therefore, cannot be reasonably predicted or
estimated at the present time. </FONT></TD></TR></TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a8"></A>ITEM 7A.</B></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</U></B></FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Changes in United States interest rates would affect the interest earned on our cash and cash equivalents.
Based on our overall interest rate exposure at April 30, 2005, a near-term change in interest rates,
based on historical movements, would not materially affect the fair value of interest rate sensitive
instruments. </FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a9"></A>ITEM 8.</B></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</U></B></FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Reference is made to the financial statements included in this Report at pages F-1 through&nbsp;F-33.</FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a10"></A>ITEM 9.</B></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURES</U></B></FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Not applicable.</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>43</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
&nbsp;<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=96><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a11"></A>ITEM 9A.</B> &nbsp;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>CONTROLS AND PROCEDURES</U></B></FONT></TD>
</TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2><I>(a) Evaluation of Disclosure Controls and Procedures</I> <I>.</I> &nbsp;The term &#147;disclosure controls and procedures&#148; (defined in Rule&nbsp;13a-15(e) under
the Securities and Exchange Act of 1934 (the &#147;Exchange Act&#148;) refers to the controls and
other procedures of a company that are designed to ensure that information required to be disclosed
by a company in the reports that it files under the Exchange Act is recorded, processed, summarized
and reported within the required time periods. Under the supervision and with the participation of
our management, including our chief executive officer and chief financial officer, we have conducted
an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures,
as of April 30, 2005. Based on this evaluation, our president and chief executive office and our
chief financial officer concluded that our disclosure controls and procedures were effective as of
April 30, 2005 to ensure the timely disclosure of required information in our Securities and Exchange
Commission filings. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>Because of inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. In addition, the design of any system of control is based upon certain assumptions
about the likelihood of future events, and there can be no assurance that any design will succeed
in achieving its stated goals under all future events, no matter how remote. Accordingly, even effective
internal control over financial reporting can only provide reasonable assurance of achieving their
control objectives. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><I>(b)&nbsp;&nbsp;Management&#146;s Report on Internal Control Over Financial Reporting</I> <I>.</I> &nbsp;Management&#146;s Report on Internal Control Over Financial Reporting, which appears on the
following page, is incorporated herein by this reference. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>Our management&#146;s assessment of the effectiveness of our internal control over financial reporting
as of April 30, 2005 has been audited by Ernst &amp; Young LLP, an independent registered public
accounting firm, as stated in its report which appears on page 46 of this Annual Report, and which
is incorporated herein by this reference. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2><I>(c) Changes in Internal Control over Financial Reporting.</I> &nbsp;There have been no changes in our internal control over financial reporting during the fourth
quarter of the fiscal year ended April 30, 2005 that have materially affected, or are reasonably
likely to materially affect, our internal control over financial reporting. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>44</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.<BR>MANAGEMENT&#146;S REPORT ON<BR>INTERNAL CONTROL OVER FINANCIAL REPORTING</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The management of the Company is responsible for establishing and maintaining effective internal control
over financial reporting and for the assessment of the effectiveness of internal control over financial
reporting. The Company&#146;s internal control over financial reporting is a process designed, as
defined in Rule&nbsp;13a-15(f) under the Securities and Exchange Act of 1934, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of consolidated financial
statements for external purposes in accordance with generally accepted accounting principles. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The Company&#146;s internal control over financial reporting is supported by written policies and procedures
that: </FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the
transactions and dispositions of the Company&#146;s assets;</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated
financial statements in accordance with generally accepted accounting principles, and that receipts
and expenditures of the Company are being made only in accordance with authorizations of the Company&#146;s
management and directors; and</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR>
<TR>
<TD valign=top width=24></TD>
<TD valign=top width=24><FONT face="Times New Roman, Times, Serif" size=2>&#149;</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition,
use or disposition of the Company&#146;s assets that could have a material effect on the consolidated
financial statements.</FONT></TD></TR></TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Projections of any evaluation of effectiveness to future periods are subject to the
risk that controls may become inadequate because of changes in conditions, or that the degree of
compliance with the policies or procedures may deteriorate. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In connection with the preparation of the Company&#146;s annual consolidated financial statements,
management of the Company has undertaken an assessment of the effectiveness of the Company&#146;s
internal control over financial reporting based on criteria established in Internal Control - Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (&#147;the
COSO Framework&#148;). Management&#146;s assessment included an evaluation of the design of the Company&#146;s
internal control over financial reporting and testing of the operational effectiveness of the Company&#146;s
internal control over financial reporting. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Based on this assessment, management has concluded that the Company&#146;s internal control over financial
reporting was effective as of April 30, 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Ernst &amp; Young LLP, the independent registered public accounting firm that audited the company&#146;s
consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation
report on management&#146;s assessment of internal control over financial reporting which appears
on the following page. </FONT></P>
<TABLE width="100%" border="0" cellspacing="0" cellpadding="0">
<TR>
<TD width="3%"><FONT size="2" face="Times New Roman, Times, serif">By: </FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="20%"><FONT size="2" face="Times New Roman, Times, serif">/s/STEVEN W. KING </FONT></TD>
<TD width="40%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="3%"><FONT size="2" face="Times New Roman, Times, serif">By: </FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="20%"><FONT size="2" face="Times New Roman, Times, serif">/s/PAUL J. LYTLE</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD>&nbsp;</TD>
</TR>
<TR>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Steven W. King, </FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Paul J. Lytle</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">President and Chief </FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Chief Financial Officer</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Executive Officer</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2>July 8, 2005</FONT></P><B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>45</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The Board of Directors and Stockholders<BR>Peregrine Pharmaceuticals, Inc.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have audited management&#146;s assessment, included in the accompanying Management&#146;s Annual
Report on Internal Control Over Financial Reporting included in Item 9A, that Peregrine Pharmaceuticals,
Inc. maintained effective internal control over financial reporting as of April 30, 2005, based on
criteria established in Internal Control--Integrated Framework issued by the Committee of Sponsoring
Organizations of the Treadway Commission (the COSO criteria). Peregrine Pharmaceuticals, Inc.&#146;s
management is responsible for maintaining effective internal control over financial reporting and
for its assessment of the effectiveness of internal control over financial reporting. Our responsibility
is to express an opinion on management&#146;s assessment and an opinion on the effectiveness of Peregrine
Pharmaceuticals, Inc.&#146;s internal control over financial reporting based on our audit.
</FONT><FONT face="Times New Roman, Times, Serif" size=2>We conducted our audit in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether effective internal control over financial reporting was maintained in all
material respects. Our audit included obtaining an understanding of internal control over financial
reporting, evaluating management&#146;s assessment, testing and evaluating the design and operating
effectiveness of internal control, and performing such other procedures as we considered necessary
in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>A company&#146;s internal control over financial reporting is a process designed to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements
for external purposes in accordance with generally accepted accounting principles. A company&#146;s
internal control over financial reporting includes those policies and procedures that (1) pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions
and dispositions of the assets of the company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial statements in accordance with generally
accepted accounting principles, and that receipts and expenditures of the company are being made
only in accordance with authorizations of management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or
disposition of the company&#146;s assets that could have a material effect on the financial statements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Also, projections of any evaluation of effectiveness to future periods are subject
to the risk that controls may become inadequate because of changes in conditions, or that the degree
of compliance with the policies or procedures may deteriorate.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In our opinion, management&#146;s assessment that Peregrine Pharmaceuticals, Inc. maintained effective
internal control over financial reporting as of April 30, 2005 is fairly stated, in all material
respects, based on the COSO criteria. Also, in our opinion, Peregrine Pharmaceuticals, Inc. maintained,
in all material respects, effective internal control over financial reporting as of April 30, 2005,
based on the COSO criteria.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the consolidated balance sheets of Peregrine Pharmaceuticals, Inc. as of April 30,
2005 and 2004, and the related consolidated statements of operations, stockholders&#146; equity and
cash flows for each of the three years in the period ended April 30, 2005 and our report dated July
8, 2005 expressed an unqualified opinion thereon. </FONT></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR>
<TD width="50%">&nbsp;</TD>
<TD width="10%">&nbsp;</TD>
<TD><FONT face="Times New Roman, Times, Serif" size=2><B>/s/ ERNST &amp; YOUNG LLP</B></FONT></TD>
</TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Orange County, California<BR>July 8, 2005&nbsp; </FONT></P>
<B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>46</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART III</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a12"></A>ITEM 10. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT </U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information required by this item, including, without limitation, disclosure regarding our Code of
Ethics, is incorporated by reference to the information set forth under the caption &#147;Directors
and Executive Officers&#148; in our 2005 Proxy Statement to be filed within 120&nbsp;days after the
end of our fiscal year ended April 30, 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a13"></A>ITEM 11. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>EXECUTIVE COMPENSATION</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information required by this item is incorporated by reference to the information set forth under
the caption &#147;Executive Compensation&#148; in our 2005 Proxy Statement to be filed within 120&nbsp;days
after the end of our fiscal year ended April 30, 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a14"></A>ITEM 12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>SECURITY STOCK OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information required by this item is incorporated by reference to the information set forth under
the caption &#147;Common Stock Ownership of Certain Beneficial Owners and Management&#148; in our
2005 Proxy Statement to be filed within 120&nbsp;days after the end of our fiscal year ended April
30, 2005.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a15"></A>ITEM 13. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information required by this item is incorporated by reference to the information set forth under
the caption &#147;Certain Relationships and Related Transactions&#148; in our 2005 Proxy Statement
to be filed within 120&nbsp;days after the end of our fiscal year ended April 30, 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a16"></A>ITEM 14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>PRINCIPAL ACCOUNTING FEES AND SERVICES</U></B></FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
information required by this item is incorporated by reference to the information set forth under
the caption &#147;Independent Auditors&#148; in our 2005 Proxy Statement to be filed within 120&nbsp;days
after the end of our fiscal year ended April 30, 2005.</FONT></P>
<P align=center><FONT size="2" face="Times New Roman, Times, serif">47</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U>PART IV</U></B></FONT></P>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=8%><FONT face="Times New Roman, Times, Serif" size=2><B><A name="a17"></A>ITEM 15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><B><U>EXHIBITS, CONSOLIDATED FINANCIAL STATEMENTS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K</U></B></FONT></TD></TR></TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=8%><FONT face="Times New Roman, Times, Serif" size=2>(a)</FONT></TD>
<TD width="6%" valign=top><FONT face="Times New Roman, Times, Serif" size=2>(1) </FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><U>Consolidated Financial Statements</U></FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=8%>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Index to consolidated financial statements:</FONT></TD></TR></TABLE>
<P align=right><FONT face="Times New Roman, Times, Serif" size=2></FONT></P>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TH>&nbsp;</TH>
<TH>&nbsp;</TH>
<TH><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
<TH align="right"><FONT face="Times New Roman, Times, Serif" size=1><U>Page</U></FONT><FONT face="Times New Roman, Times, Serif" size=1></FONT></TH>
<TH>&nbsp;</TH>
</TR>
<TR valign=Bottom>
<TD width="8%" align=LEFT>&nbsp;</TD>
<TD width="6%" align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b1"><FONT face="Times New Roman, Times, Serif" size=2>Report of Independent Registered Public Accounting Firm</FONT></A></TD>
<TD width=5% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width=5% align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-1</FONT></TD>
<TD width=2% align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b2"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Balance Sheets as of April 30, 2005 and 2004</FONT></A></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-2</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b3"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Operations for each of the three years in the period ended April 30, 2005</FONT></A></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-4</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b4"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Stockholders&#146; Equity for each of the three years in the period ended April 30, 2005</FONT></A></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-5</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b5"><FONT face="Times New Roman, Times, Serif" size=2>Consolidated Statements of Cash Flows for each of the three years in the period ended April 30, 2005</FONT></A></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-6</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=RIGHT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
</TR>
<TR valign=Bottom>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b6"><FONT face="Times New Roman, Times, Serif" size=2>Notes to Consolidated Financial Statements</FONT></A></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-8</FONT></TD>
<TD align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=8%>&nbsp;</TD>
<TD width="6%" valign=top><FONT face="Times New Roman, Times, Serif" size=2>(2) </FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><U>Financial Statement Schedules</U></FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=8%>&nbsp;</TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>The following schedule is filed as part of this Form 10-K:</FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellpadding=0 cellspacing=0 border=0 width=100%>
<TR valign=Bottom>
<TD width="8%" align=LEFT>&nbsp;</TD>
<TD width="6%" align=LEFT>&nbsp;</TD>
<TD align=LEFT><A href="#b7"><FONT face="Times New Roman, Times, Serif" size=2>Schedule II- Valuation
of Qualifying Accounts for each of the three years in the period ended April 30,
2005&nbsp;</FONT></A></TD>
<TD width="5%" align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD width="5%" align=RIGHT><FONT face="Times New Roman, Times, Serif" size=2>F-33</FONT></TD>
<TD width="2%" align=LEFT><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
</TR>
</TABLE>
<BR>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>All other schedules for which provision is made in the applicable accounting regulations of the Securities
and Exchange Commission are not required under the related instructions or are inapplicable and therefore
have been omitted.</FONT></TD></TR></TABLE>
<P align=center><FONT size="2" face="Times New Roman, Times, serif">48</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
&nbsp;<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top width=8%>&nbsp;</TD>
<TD width="6%" valign=top><FONT face="Times New Roman, Times, Serif" size=2>(3)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><U>Exhibits</U></FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD colspan="2" valign=top>&nbsp;</TD></TR></TABLE>
<BR>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<TR valign="top">
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">3.1</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certificate of Incorporation of Techniclone Corporation, a Delaware corporation (Incorporated by reference to Exhibit B to the Company&#146;s 1996 Proxy Statement as filed with the Commission on or about August 20, 1996).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">3.2</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Amended and Restated Bylaws of Peregrine Pharmaceuticals, Inc. (formerly Techniclone Corporation), a Delaware corporation (Incorporated by reference to Exhibit 3.1 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">3.3 </FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certificate of Designation of 5% Adjustable Convertible Class C Preferred Stock as filed with the Delaware Secretary of State on April 23, 1997. (Incorporated by reference to Exhibit 3.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">3.4</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certificate of Amendment to Certificate of Incorporation of Techniclone Corporation to effect the name change to Peregrine Pharmaceuticals, Inc., a Delaware corporation. </FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">3.5</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certificate of Amendment to Certificate of Incorporation of Peregrine Pharmaceuticals, Inc. to increase the number of authorized shares of the Company&#146;s common stock to two hundred million shares (Incorporated by reference to Exhibit 3.5 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003). </FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.1</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Certificate for Common Stock (Incorporated by reference to the exhibit of the same number contained in Registrant&#146;s Annual Report on Form 10-K for the year end April 30, 1988).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.7</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">5% Preferred Stock Investment Agreement between Registrant and the Investors (Incorporated by reference to Exhibit 4.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.13</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Stock Purchase Warrant to be issued to the Equity Line Subscribers pursuant to the Regulation D Common Stock Equity Subscription Agreement (Incorporated by reference to Exhibit 4.7 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about June 29, 1998).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.16</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Non-qualified Stock Option Agreement by and between Registrant, Director and certain consultants dated December 22, 1999 (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716)).*</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.17</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Peregrine Pharmaceuticals, Inc. 2002 Non-Qualified Stock Option Plan (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in Form S-8 (File No. 333-106385)).*</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">4.18</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of 2002 Non-Qualified Stock Option Agreement (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in Form S-8 (File No. 333-106385)).*</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>49</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.40</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">1996 Stock Incentive Plan (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in form S-8 (File No. 333-17513)).*</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.41</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Stock Exchange Agreement dated as of January 15, 1997 among the stockholders of Peregrine Pharmaceuticals, Inc. and Registrant (Incorporated by reference to Exhibit 2.1 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1997).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.42</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">First Amendment to Stock Exchange Agreement among the Stockholders of Peregrine Pharmaceuticals, Inc. and Registrant (Incorporated by reference to Exhibit 2.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the Commission on or about May 12, 1997).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.43</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Termination and Transfer Agreement dated as of November&nbsp;14, 1997 by and between Registrant and Alpha Therapeutic Corporation (Incorporated by reference to Exhibit 10.1 contained in Registrant&#146;s Current Report on Form 8-K as filed with the commission on or about November 24, 1997).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.47</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Real Estate Purchase Agreement by and between Techniclone Corporation and 14282 Franklin Avenue Associates, LLC dated December 24, 1998 (Incorporated by reference to Exhibit 10.47 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.48</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Lease and Agreement of Lease between TNCA, LLC, as Landlord, and Techniclone Corporation, as Tenant, dated as of December 24, 1998 (Incorporated by reference to Exhibit 10.48 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.49</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Promissory Note dated as of December 24, 1998 between&nbsp;Techniclone Corporation (Payee) and TNCA Holding, LLC (Maker) for $1,925,000 (Incorporated by reference to Exhibit 10.49 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.50</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Pledge and Security Agreement dated as of December 24, 1998 for $1,925,000 Promissory Note between Grantors and Techniclone Corporation (Secured Party) (Incorporated by reference to Exhibit 10.50 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.56</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">License Agreement dated as of March 8, 1999 by and between Registrant and Schering A.G. (Incorporated by reference to Exhibit 10.56 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 1999).**</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.57</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Patent License Agreement dated October 8, 1998 between Registrant and the Board of Regents of the University of Texas System for patents related to Targeting the Vasculature of Solid Tumors (Vascular Targeting Agent patents) (Incorporated by reference to Exhibit 10.57 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.58</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Patent License Agreement dated October 8, 1998 between Registrant and the Board of Regents of the University of Texas System for patents related to the Coagulation of the Tumor Vasculature (Vascular Targeting Agent patents) (Incorporated by reference to Exhibit 10.58 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>50</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.59</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">License Agreement between Northwestern University and Registrant dated August 4, 1999 covering the LYM-1 and LYM-2 antibodies (Oncolym) (Incorporated by reference to Exhibit 10.59 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 1999).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.64</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Regulation D Subscription Agreement dated January 6, 2000 between Registrant and Subscribers, Swartz Investments, LLC and Biotechnology Development, LTD. (Incorporated by reference to Exhibit 10.64 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.65</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Registration Right Agreement dated January 6, 2000 between Registrant and Subscribers of the Regulation D Subscription Agreement dated January 6, 2000 (Incorporated by reference to Exhibit 10.65 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.66</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Subscribers pursuant to the Regulation D Subscription Agreement dated January 6, 2000 (Incorporated by reference to Exhibit 10.66 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.67</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Warrant to purchase 750,000 shares of Common Stock of Registrant issued to Swartz Private Equity, LLC dated November 19, 1999 (Incorporated by reference to Exhibit 10.67 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2000).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.68</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Amendment Agreement dated June 14, 2000 to the License Agreement dated March 8, 1999 by and between Registrant and Schering A.G. (Incorporated by reference to Exhibit 10.68 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.69</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Waiver Agreement effective December 29, 1999 by and between Registrant and Biotechnology Development Ltd. (Incorporated by reference to Exhibit 10.69 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.70</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Joint Venture Agreement dated May 11, 2000 by and between Registrant and Oxigene, Inc. (Incorporated by reference to Exhibit 10.70 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-40716).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.73</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement to purchase up to 6,000,000 shares of Common Stock of Registrant issued to ZLP Master Fund, LTD, ZLP Master Technology Fund, LTD, Eric Swartz, Michael C. Kendrick, Vertical Ventures LLC and Triton West Group, Inc. dated November 16, 2001 (Incorporated by reference to Exhibit 10.73 to Registrant&#146;s Current Report on Form 8-K dated November 19, 2001, as filed with the Commission on November 19, 2001).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.74</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Investors pursuant to the Common Stock Purchase Agreement dated November 16, 2001 (Incorporated by reference to Exhibit 10.74 to Registrant&#146;s Current Report on Form 8-K dated November 19, 2001, as filed with the Commission on November 19, 2001).</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>51</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.75</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement to purchase 1,100,000 shares of Common Stock of Registrant issued to ZLP Master Fund, LTD and Vertical Capital Holdings, Ltd. dated January 28, 2002 (Incorporated by reference to Exhibit 10.75 to Registrant&#146;s Current Report on Form 8-K dated January 31, 2002, as filed with the Commission on February 5, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.76</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Investors pursuant to the Common Stock Purchase Agreement dated January 28, 2002 (Incorporated by reference to Exhibit 10.76 to Registrant&#146;s Current Report on Form 8-K dated January 31, 2002, as filed with the Commission on February 5, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.77</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Securities Purchase Agreement dated as of August 9, 2002 between Registrant and Purchasers (Incorporated by reference to Exhibit 10.77 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.78</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Convertible Debentures issued to Purchasers pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.78 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.79</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Registration Rights Agreement dated August 9, 2002 between Registrant and Purchasers of Securities Purchase Agreements dated August 9, 2002 (Incorporated by reference to Exhibit 10.79 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.80</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to Purchasers pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.80 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.81</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant issued to Debenture holders pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.81 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.82</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Adjustment Warrant issued to Investors pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.82 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.83</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Securities Purchase Agreement dated as of August 9, 2002 between Registrant and ZLP Master Fund, Ltd. (Incorporated by reference to Exhibit 10.83 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.84</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Registration Rights Agreement dated August 9, 2002 between Registrant and ZLP Master Fund, Ltd. (Incorporated by reference to Exhibit 10.84 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>52</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.85</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Warrant to be issued to ZLP Master Fund, Ltd. pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.85 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.86</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Form of Adjustment Warrant issued to ZLP Master Fund, Ltd. pursuant to Securities Purchase Agreement dated August 9, 2002 (Incorporated by reference to Exhibit 10.86 to Registrant&#146;s Registration Statement on Form S-3 (File No. 333-99157), as filed with the Commission on September 4, 2002).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.87</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 6, 2003 between Registrant and eight institutional investors (Incorporated by reference to Exhibit 10.87 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.88</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 6, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.88 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.89</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated June 26, 2003 between Registrant and seven institutional investors (Incorporated by reference to Exhibit 10.89 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.90</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated July 24, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.90 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended July 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.91</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated September 18, 2003 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.91 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended October 31, 2003).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.92</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated January 22, 2004 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.92 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2004).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.93</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated March 31, 2004 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.93 to Registrant&#146;s Annual Report on Form 10-K for the year ended April 30, 2005).</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.95</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">2003 Stock Incentive Plan Non-qualified Stock Option Agreement (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in form S-8 (File No. 333-121334).*</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.96</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">2003 Stock Incentive Plan Incentive Stock Option Agreement (Incorporated by reference to the exhibit contained in Registrant&#146;s Registration Statement in form S-8 (File No. 333-121334)).*</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">10.97</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Common Stock Purchase Agreement dated January 31, 2005 between Registrant and one institutional investor (Incorporated by reference to Exhibit 10.97 to Registrant&#146;s Quarterly Report on Form 10-Q for the quarter ended January 31, 2005).</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>53</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
&nbsp;<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD colspan="3" align="center"><FONT size="2" face="Times New Roman, Times, serif"><B>Exhibit<BR>
Number</B></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><B>Description</B></FONT></TD>
</TR>
<TR valign="top">
<TD colspan="3"><HR size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR size=1  color=BLACK></TD>
</TR>
<tr>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">21</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Subsidiaries of Registrant ***</FONT></TD>
</tr>
<tr>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</tr>
<tr>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">23.1</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Consent of Independent Registered Public Accounting Firm ***</FONT></TD>
</tr>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">31.1 </FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">31.2</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.***</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">32</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.***</FONT></TD>
</TR>
</TABLE>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="top">
<TD>&nbsp;</TD>
<TD align="center">&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
<TD>&nbsp;</TD>
</TR>
<TR valign="top">
<TD colspan="5">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD align="center"><FONT size="2" face="Times New Roman, Times, serif"><I>*</I></FONT></TD>
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><I>This Exhibit is a management contract or a compensation plan or arrangement.</I></FONT></TD>
</TR>
<TR valign="top">
<TD width="1%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="4%" align="center"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="2%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD align="center"><FONT size="2" face="Times New Roman, Times, serif"><I>**</I></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><I>Portions omitted pursuant to a request of confidentiality filed separately with the Commission.</I></FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD align="center"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="top">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD align="center"><FONT size="2" face="Times New Roman, Times, serif"><I>***</I></FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif"><I>Filed herewith.</I></FONT></TD>
</TR>
</TABLE>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">

<TR>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD valign=top width=3%></TD>
<TD valign=top width=5%><FONT face="Times New Roman, Times, Serif" size=2>(b)<FONT face="Times New Roman, Times, Serif" size=2></FONT></FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2><FONT face="Times New Roman, Times, Serif" size=2></FONT>Reports on Form 8-K:</FONT></TD></TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD></TR></TABLE>
<TABLE cellspacing="0" cellpadding="0" width="100%" border="0">
<TR>
<TD valign=top width=8%></TD>
<TD valign=top width=3%><FONT face="Times New Roman, Times, Serif" size=2>(i)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Current report on Form 8-K as filed with the Commission on February 2, 2005 reporting the Registrant entered into a Common Stock Purchase Agreement with Melton Management, Ltd., an institutional investor.</FONT></TD>
</TR>
<TR>
<TD valign=top></TD>
<TD valign=top></TD>
<TD valign=top>&nbsp;</TD>
</TR>
<TR>
<TD valign=top width=8%></TD>
<TD valign=top width=3%><FONT face="Times New Roman, Times, Serif" size=2>(ii)</FONT></TD>
<TD valign=top><FONT face="Times New Roman, Times, Serif" size=2>Current report on Form 8-K as filed with the Commission on March 14, 2005 reporting the Company&#146;s financial results for the quarter ended January 31, 2005.</FONT></TD>
</TR>
</TABLE>
<B><U></U></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>54</FONT></P>
<HR noshade size=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><U><A name="a18"></A>SIGNATURES</U></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant
has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD colspan="2" valign="bottom"><FONT face="Times New Roman, Times, serif" size=2>PEREGRINE PHARMACEUTICALS, INC.</FONT></TD>
<TD>&nbsp;</TD>
</TR>
<TR>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD>&nbsp;</TD>
</TR>
<TR>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD>&nbsp;</TD>
</TR>
<TR>
<TD width="45%" valign="bottom"><FONT face="Times New Roman, Times, serif" size=2>Dated:&nbsp;&nbsp;July 12, 2005</FONT></TD>
<TD width="5%" valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="3%" valign="bottom"><FONT face="Times New Roman, Times, serif" size=2>By:</FONT></TD>
<TD valign="bottom"><FONT face="Times New Roman, Times, serif" size=2>/s/ STEVEN W. KING&nbsp;</FONT></TD>
<TD width="5%">&nbsp;</TD>
</TR>
<TR>
<TD colspan="3" valign="bottom"><FONT size="1" face="Times New Roman, Times, serif">&nbsp;</FONT><FONT size="1" face="Times New Roman, Times, serif">&nbsp;</FONT><FONT size="1" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD valign="top" nowrap><font size="1">&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</font></TD>
<TD><font size="1">&nbsp;</font></TD>
</TR>
<TR>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp; </FONT></TD>
<TD valign="bottom"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;  </FONT></TD>
<TD valign="top">&nbsp;</TD>
<TD valign="top"><FONT face="Times New Roman, Times, serif" size=2>Steven W. King, <br>
  President and Chief Executive Officer</FONT></TD>
<TD>&nbsp;</TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><B>POWER OF ATTORNEY</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and
appoints Steven W. King, President and Chief Executive Officer, and Paul J. Lytle, Chief Financial
Officer and Corporate Secretary, and each of them, his true and lawful attorneys-in-fact and agents,
with the full power of substitution and re-substitution, for him and in his name, place and stead,
in any and all capacities, to sign any amendments to this report, and to file the same, with exhibits
thereto and other documents in connection therewith, with the Securities and Exchange Commission,
granting unto each said attorney-in-fact and agent full power and authority to do and perform each
and every act in person, hereby ratifying and confirming all that said attorney-in-fact and agent,
or either of them, or their or his substitute or substitutes, may lawfully do or cause to be done
by virtue hereof.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below
by the following persons on behalf of the Registrant and in the capacities and on the dates indicated:</FONT></P>
<TABLE width="100%"  border="0" cellspacing="0" cellpadding="0">
<TR valign="bottom">
<TD><FONT face="Times New Roman, Times, serif" size=2>Signature</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Capacity</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Date</FONT></TD>
</TR>
<TR valign="bottom">
<TD><HR align="left" width="50" size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR align="left" width="50" size=1  color=BLACK></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><HR align="left" width="30" size=1  color=BLACK></TD>
</TR>
<TR valign="bottom">
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD width="30%"><FONT face="Times New Roman, Times, serif" size=2>/s/ Steven W. King</FONT></TD>
<TD width="5%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="30%"><FONT face="Times New Roman, Times, serif" size=2>President &amp; Chief Executive</FONT></TD>
<TD width="5%"><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD width="30%"><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Officer (Principal Executive</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>Steven W. King</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Officer) </FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>/s/ Paul J. Lytle</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Chief Financial Officer</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>(Principal Financial and</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>Paul J. Lytle</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Principal Accounting Officer)</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>/s/ Carlton M. Johnson</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Director</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>Carlton M. Johnson</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>/s/ David H. Pohl</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Director</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>David H. Pohl</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>/s/ Eric S. Swartz</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Director</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>Eric S. Swartz</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>/s/ Dr. Thomas A. Waltz</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>Director</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT face="Times New Roman, Times, serif" size=2>July 12, 2005</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap>&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;&#151;</TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
<TR valign="bottom">
<TD nowrap><FONT face="Times New Roman, Times, serif" size=2>Thomas A. Waltz, M.D.</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
<TD><FONT size="2" face="Times New Roman, Times, serif">&nbsp;</FONT></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>55</FONT></P>
<HR noshade size=5>
<P style="PAGE-BREAK-BEFORE: always">


<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a><P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b1"></a>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>The Board of Directors and Stockholders<br>
</FONT><FONT face="Times New Roman, Times, Serif" size=2>Peregrine Pharmaceuticals, Inc.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We have audited the accompanying consolidated balance sheets of Peregrine Pharmaceuticals, Inc. as
of April 30, 2005 and 2004, and the related consolidated statements of operations, stockholders&#146;
equity, and cash flows for each of the three years in the period ended April 30, 2005. Our audits
also included the financial statement schedule listed in the Index at Item&nbsp;15&nbsp;(a)(2). These
financial statements and schedule are the responsibility of the Company&#146;s management. Our responsibility
is to express an opinion on these financial statements and schedule based on our audits. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We conducted our audits in accordance with the standards of the Public Company Accounting Oversight
Board (United States). Those standards require that we plan and perform the audit to obtain reasonable
assurance about whether the financial statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements.
An audit also includes assessing the accounting principles used and significant estimates made by
management, as well as evaluating the overall financial statement presentation. We believe that our
audits provide a reasonable basis for our opinion.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>In our opinion, the financial statements referred to above present fairly, in all material respects,
the consolidated financial position of Peregrine Pharmaceuticals, Inc. at April&nbsp;30, 2005 and
2004, and the consolidated results of its operations and its cash flows for each of the three years
in the period ended April 30, 2005, in conformity with U.S. generally accepted accounting principles.
Also, in our opinion, the related financial statement schedule, when considered in relation to the
basic financial statements taken as a whole, presents fairly in all material respects the information
set forth therein.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board
(United States), the effectiveness of Peregrine Pharmaceuticals, Inc.&#146;s internal control over
financial reporting as of April 30, 2005, based on criteria established in Internal Control&#151;Integrated
Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and our
report dated July 8, 2005 expressed an unqualified opinion thereon.</FONT></P>
<table width="100%" border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td width="60%">&nbsp;</td>
    <td><font face="Times New Roman, Times, Serif" size=2><b>/s/ ERNST &amp; YOUNG LLP</b></font></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>Orange County, California<br>
</FONT><FONT face="Times New Roman, Times, Serif" size=2>July 8, 2005<B>&nbsp; </B></FONT></P>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-1</FONT></P>
<HR noShade SIZE=5>
<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
&nbsp;<table width="100%" border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td>
      <P><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b2"></a>CONSOLIDATED BALANCE SHEETS</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>AS OF APRIL 30, 2005 AND 2004</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><hr color="black" size="1"></td>
    <td>&nbsp;</td>
  </tr>
</table>

<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>ASSETS</b></FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT ASSETS:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Cash and cash equivalents</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 9,816,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,884,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Trade and other receivables, net of allowance for doubtful accounts of <br>
    $69,000 and $64,000, respectively</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>486,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,520,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Inventories</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>627,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Prepaid expenses and other current assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,197,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12,126,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>17,884,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>PROPERTY:</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Leasehold improvements</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>494,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>389,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Laboratory equipment</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,029,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,211,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Furniture, fixtures and computer equipment</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>647,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>646,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,170,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,246,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Less accumulated depreciation and amortization</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,532,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,373,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property, net</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,638,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>873,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>OTHER ASSETS:</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=left><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Note receivable, net of allowance of
    $1,512,000 and $1,581,000, respectively</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=right><font size="2">&nbsp;</font></TD>
    <TD ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
	    <TD ALIGN=right><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>481,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>380,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#EAF9E8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total other assets</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>481,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>380,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TOTAL ASSETS</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,245,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>

<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-2</FONT></P>
<HR noShade SIZE=5>
<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<table width="100%" border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td>
      <P><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
    <td width="2%">&nbsp;</td>

  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>CONSOLIDATED BALANCE SHEETS</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>AS OF APRIL 30, 2005 AND 2004 (continued) </B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><hr color="black" size="1"></td>
    <td>&nbsp;</td>
  </tr>
</table>
<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</b></FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>CURRENT LIABILITIES:</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accounts payable</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,325,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,331,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued clinical trial site fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>54,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued legal and accounting fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>549,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>407,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued royalties and license fees</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>149,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>149,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accrued payroll and related costs</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>806,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>503,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Notes payable, current portion</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>234,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Other current liabilities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>563,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>285,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred revenue</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>517,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,524,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,151,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,253,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>NOTES PAYABLE</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>434,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>DEFERRED LICENSE REVENUE</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>50,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>125,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>COMMITMENTS AND CONTINGENCIES</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>STOCKHOLDERS&#146; EQUITY:</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Preferred stock - $.001 par value; authorized 5,000,000 shares; non-voting; <br>
    nil shares outstanding</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock-$.001 par value; authorized 200,000,000 shares; <br>
outstanding &#150; 152,983,460 and 141,268,182, respectively</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>153,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>141,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Additional paid-in-capital</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>180,011,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>168,969,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Deferred stock compensation</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(751,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Accumulated deficit</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(169,803,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(154,351,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total stockholders&#146; equity</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,610,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>14,759,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>TOTAL LIABILITIES AND STOCKHOLDERS&#146; EQUITY</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 14,245,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 19,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-3</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<table width="100%" border="0" cellpadding="0" cellspacing="0">
  <tr>
    <td>
      <P><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></P></td>
    <td width="2%">&nbsp;</td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b3"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005</B></FONT></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td><hr color="black" size="1"></td>
    <td>&nbsp;</td>
  </tr>
</table>
<br>
<table cellpadding=0 cellspacing=0 border=0 width=100%>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2005</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2004</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2003</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>REVENUES:</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2></font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Contract manufacturing revenue</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 4,684,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,039,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,346,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>License revenue</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>575,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Total revenues</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>4,959,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,314,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,921,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>COSTS AND EXPENSES:</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Cost of contract manufacturing</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>4,401,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,212,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,860,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Research and development</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>11,164,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>9,673,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>8,744,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Selling, general and administrative</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>5,098,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>4,225,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>2,987,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Total costs and expenses</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>20,663,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>16,110,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>14,591,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>LOSS FROM OPERATIONS</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(15,704,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(12,796,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(10,670,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>OTHER INCOME (EXPENSE):</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Interest and other income</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>265,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>291,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>291,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Interest and other expense</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(13,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,840,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,180,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><b><font face="Times New Roman, Times, Serif" size=2>NET LOSS</font></b></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (15,452,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (14,345,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,559,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><b><font face="Times New Roman, Times, Serif" size=2>WEIGHTED AVERAGE SHARES OUTSTANDING</font></b></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>144,812,001</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>134,299,407</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>116,468,353</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><b><font face="Times New Roman, Times, Serif" size=2>BASIC AND DILUTED LOSS PER COMMON SHARE</font></b></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (0.11</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (0.11</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (0.10</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
</table>
<table width="100%"  border="0" cellspacing="0" cellpadding="0">
  <tr>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td align="center"><font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-4</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
<TD width="2%" vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top>&nbsp;</TD>
<TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b4"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#146; EQUITY</B></FONT></TD>
<TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005</B></FONT></TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><hr color="black" size="1"></TD>
  <TD vAlign=top>&nbsp;</TD>
</TR>
</TABLE>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=5 ALIGN=center valign="bottom">&nbsp;</TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 rowspan="3" ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Additional<br>
      Paid-In<br>
      Captital</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 rowspan="3" ALIGN=center valign="bottom" nowrap><b><font size="1" face="Times New Roman, Times, serif">Deferred<br>
      Stock<br>
      Compensation</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 rowspan="3" ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Accumulated<br>
      (Deficit)</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 rowspan="3" ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Total <br>
      Stockholders&#146;<br>
      Equity</font></b></TD>
    <TD></TD>
  </TR>
  <TR>
    <TD COLSPAN=2 rowspan="2"></TD>
    <TD COLSPAN=5 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Common Stock</font></b><b></b></TD>
    <TD rowspan="2" align="center" valign="bottom"></TD>
    <TD rowspan="2" align="center" valign="bottom"></TD>
    <TD rowspan="2" align="center" valign="bottom"></TD>
    <TD rowspan="2" align="center" valign="bottom"></TD>
    <TD rowspan="2"></TD>
  </TR>
  <TR>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Shares</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Amount</font></b></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>BALANCES, April 30, 2002</FONT></b></TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD WIDTH=6% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>110,275,209</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD WIDTH=1% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD WIDTH=6% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 110,000</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD WIDTH=1% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD WIDTH=6% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 134,221,000</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD WIDTH=1% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD WIDTH=6% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> (801,000</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD WIDTH=1% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD WIDTH=6% ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> (128,447,000</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD WIDTH=1% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD WIDTH=6% ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 5,083,000</FONT></b></TD>
    <TD WIDTH=2% ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under Securities Purchase Agreement, net of issuance costs of $341,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,221,540</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,858,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,863,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under Shelf File No. 333-71086, net of issuance costs of $190,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,900,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,853,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,856,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued upon conversion of convertible debt, net of issuance cost of $17,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,594,119</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,336,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,338,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash upon exercise of options</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>109,633</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>38,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>38,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Rescind prior sale of common stock to related party</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(500,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(500,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(500,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Intrinsic value of embedded conversion feature related to convertible debt</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,143,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,143,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Fair market value of detachable warrants issued with convertible debt</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,321,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,321,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Deferred stock compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>4,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(4,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Stock-based compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>548,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>548,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Net loss</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(11,559,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>BALANCES, April 30, 2003</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>119,600,501</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>120,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>142,274,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>(257,000</FONT></b></TD>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>(140,006,000</FONT></b></TD>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,131,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under June 6, 2003 Financing, net of issuance costs of $104,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,412,448</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,969,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,971,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under June 26, 2003 Financing, net of issuance costs of $101,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,599,997</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,737,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,739,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under option granted under June 26, 2003 Financing, net of issuance <br>
costs of $54,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,599,997</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,784,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,786,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under July 24, 2003 Financing, net of issuance costs of $13,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,885,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,887,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under September 18, 2003 Financing, net of issuance costs of $19,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,800,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,271,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,273,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under November 17, 2003 Financing, net of issuance costs of $1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>4,254,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>4,256,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under January 22, 2004 Financing, net of issuance costs of $1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,274,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,275,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued to
    an unrelated entity for research services under a research collaboration <br>
agreement, net of issuance costs of under $1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>243,101</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>648,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>648,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued upon conversion of convertible debt</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,817,645</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,392,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,395,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued upon exercise of options and warrants, net of issuance costs of $134,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,194,493</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,467,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,472,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Reversal of deferred stock compensation associated with the cancellation of unvested options</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(52,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>28,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(24,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Deferred stock compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>66,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(66,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Stock-based compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>295,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>295,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Net loss</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(14,345,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>BALANCES, April 30, 2004</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>141,268,182</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>141,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>168,969,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>(154,351,000</FONT></b></TD>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>14,759,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under March 31, 2004 Financing, net of issuance costs of $43,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,204,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,207,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued for cash under January 31, 2005 Financing, net of issuance costs of $1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,276,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>3,279,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued to various unrelated entities for research services</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,174,682</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,448,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>1,449,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Common stock issued upon exercise of options and warrants, net of issuance costs of $5,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>4,540,596</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>5,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,132,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>2,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Deferred stock compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>982,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(982,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Stock-based compensation</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>231,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>231,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>Net loss</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(15,452,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=1>(15,452,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>BALANCES, April 30, 2005</FONT></b></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>152,983,460</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 153,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 180,011,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> (751,000</FONT></b></TD>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD ALIGN=RIGHT nowrap><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> (169,803,000</FONT></b></TD>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>)</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1>$</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, serif" SIZE=1> 9,610,000</FONT></b></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD COLSPAN=19><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR>
    <TD COLSPAN=2></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT>&nbsp;</TD>
    <TD></TD>
  </TR>
  <TR align="center" valign="bottom">
    <TD COLSPAN=20><p><font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font></p></TD>
  </TR>
</TABLE>
<br>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-5</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b5"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<br>
<table cellpadding=0 cellspacing=0 border=0 width=100%>
  <tr>
    <td></td>
    <th colspan=2 align=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">2005</font></b></th>
    <td></td>
    <th colspan=2 align=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">2004</font></b></th>
    <td></td>
    <th colspan=2 align=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">2003</font></b></th>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font size="2" face="Times New Roman, Times, serif">CASH FLOWS FROM OPERATING ACTIVITIES:</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Net loss</font></td>
    <td width="1%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width="10%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (15,452,000</font></td>
    <td width="3%" align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td width="1%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width="10%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (14,345,000</font></td>
    <td width="3%" align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td width="1%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width="10%" align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,559,000</font></td>
    <td width="2%" align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT bgcolor="#eaf9e8"><font face="Times New Roman, Times, Serif" size=2>Adjustments to reconcile net loss to net cash used in operating activities:</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Depreciation</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>325,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>374,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>364,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Stock-based compensation expense</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>231,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>271,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>548,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Amortization of discount on convertible debt and debt issuance costs</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,811,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,017,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Stock issued for research services</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>485,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>616,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Changes in operating assets and liabilities:</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Trade and other receivables</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,034,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>83,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Short-term investments</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>242,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(242,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Inventories</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>613,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(864,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(370,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Prepaid expenses and other current assets</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>7,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>49,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>127,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Accounts payable</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(6,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>771,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(510,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Accrued clinical trial site fees</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(46,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(206,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(347,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Deferred revenue</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,082,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>918,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>701,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Accrued payroll and related expenses</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>303,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>189,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(60,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Other accrued expenses and current liabilities</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>420,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>198,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(57,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in operating activities</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(13,168,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(11,251,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(10,305,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>CASH FLOWS FROM INVESTING ACTIVITIES:</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Proceeds from sale of property</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>11,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Property acquisitions</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,090,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(411,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(184,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Increase in other assets</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(101,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(250,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash used in investing activities</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,191,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(661,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(173,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>CASH FLOWS FROM FINANCING ACTIVITIES:</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=RIGHT><font size="2">&nbsp;</font></td>
    <td align=LEFT><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Proceeds from issuance of common stock, net of issuance costs of<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$49,000, $428,000, and $548,000, respectively </font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>8,623,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>23,659,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>4,740,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Rescind prior sale of common stock to related party</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(500,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Proceeds from issuance of convertible debt, net of issuance costs of<br>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;$363,000 (2003) </font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,387,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Proceeds from issuance of notes payable</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>733,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Principal payments on notes payable</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(65,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(84,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td><font size="2">&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net cash provided by financing activities</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>9,291,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>23,659,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>7,543,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-6</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>CONSOLIDATED STATEMENTS OF CASH FLOWS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<br>
<table cellpadding=0 cellspacing=0 border=0 width=100%>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2005</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2004</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2003</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT>&nbsp;</td>
    <td></td>
    <td colspan=2 align=RIGHT>&nbsp;</td>
    <td></td>
    <td colspan=2 align=RIGHT>&nbsp;</td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (5,068,000</font></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 11,747,000</font></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=10% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (2,935,000</font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>CASH AND CASH EQUIVALENTS, Beginning of year</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>14,884,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>3,137,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>6,072,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>CASH AND CASH EQUIVALENTS, End of year</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 9,816,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 14,884,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,137,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>SUPPLEMENTAL INFORMATION:</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Interest paid</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 13,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 78,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 104,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Property acquired in exchange for note payable</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 82,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Conversion of Convertible Debt into common stock</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 2,395,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 1,355,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock issued for research fees and prepayments for future research services</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 1,449,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 648,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
</table>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;For
supplemental information relating to conversion of convertible debentures into common stock, common
stock issued in exchange for services, and property acquired in exchange for note payable, see Notes&nbsp;5,
7 and 9.</FONT></TD>
</TR>
<TR>
  <TD vAlign=top>&nbsp;</TD>
</TR>
<TR>
  <TD vAlign=top><div align="center"><font size="2" face="Times New Roman, Times, serif">See accompanying notes to consolidated financial statements.</font></div></TD>
</TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-7</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b6"></a>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2>1. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ORGANIZATION AND BUSINESS DESCRIPTION </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Organization</I> &nbsp;&#150; In this Annual Report, &#147;Peregrine,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148;
and &#147;our,&#148; refer to Peregrine Pharmaceuticals, Inc. We were incorporated in the state of
Delaware on September 25, 1996. We were originally incorporated in California in June 1981 under
the name Techniclone International Corporation and subsequently merged into Techniclone Corporation
in March 1997. We changed our name to Peregrine Pharmaceuticals, Inc. in October 2000. In January
2002, we formed our wholly-owned subsidiary, Avid Bioservices, Inc. (&#147;Avid&#148;). </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Business Description &#150;</I> &nbsp;We are a biopharmaceutical company primarily engaged in the research, development, manufacture
and commercialization of biotherapeutics directed towards the treatment of cancer, viruses and other
diseases using targeted monoclonal antibodies. We are organized into two reportable operating segments:
(i) Peregrine, the parent company, is engaged in the research and development of targeted biotherapeutics
and (ii) Avid, our wholly-owned subsidiary, is engaged to providing an array of contract manufacturing
services, including contract manufacturing of antibodies and proteins, cell culture development,
process development, and testing of biologics for biopharmaceutical and biotechnology companies under
current Good Manufacturing Practices (&#147;cGMP&#148;).</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>We plan to enroll patients in three (3) separate clinical trials in the U.S. These clinical trials
include (i) a Phase I clinical trial for the treatment of all solid cancers using Tarvacin&#153;,
a potential broad spectrum anti-cancer agent, (ii) a collaborative clinical study with NABTT representing
the first part of the Phase II/III registration trial for the treatment of brain
cancer using Cotara&#174;,
a tumor targeting agent combined with a radioisotope, and (iii) a Phase I clinical trial for the
treatment of hepatitis C virus infection using Tarvacin&#153;, a potential broad spectrum anti-viral
agent. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>We had $9,816,000 in cash and cash equivalents at April 30, 2005 compared to $14,884,000 at April 30,
2004. From May 1, 2005 through July 5, 2005, we received an additional $11,302,000 in net proceeds
from the sale of shares of our common stock (Note 9). Although we have sufficient cash on hand to
meet our current planned obligations through at least fiscal year 2006, our development efforts and
ability to continue operations beyond fiscal year 2006 are dependent on our ability to raise additional
capital to support our future operations. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>We
have expended substantial funds on the development of our product candidates and we have incurred
negative cash flows from operations for the majority of our years since inception. Since inception,
we generally financed our operations primarily through the sale of our common stock and issuance
of convertible debt, which has been supplemented with payments received from various licensing collaborations
and through the revenues generated by Avid. We expect negative cash flows from operations to continue
until we are able to generate sufficient revenue from the contract manufacturing services provided
by Avid and/or from the sale and/or licensing of our products under development. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>Revenues earned by Avid during fiscal years ended April 30, 2005, 2004 and 2003 amounted to $4,684,000,
$3,039,000 and $3,346,000, respectively. We expect that Avid will continue to generate revenues which
should lower consolidated cash flows used in operations, although we expect those near term revenues
will be insufficient to cover anticipated cash flows used in operations. In addition, revenues from
the sale and/or licensing of our products under development are always uncertain. Therefore, we expect
we will continue to need to raise additional capital to continue the development of our product candidates,
including the anticipated development and clinical costs of Tarvacin&#153; and Cotara&#174;, the
anticipated research and development costs associated with our other platform technologies and the
potential expansion of our manufacturing capabilities.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-8</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>We plan to raise additional capital through the offer and sale of shares of our common stock. However,
given uncertain market conditions and the volatility of our stock price and trading volume, we may
not be able to sell our securities at prices or on terms that are favorable to us, if at all. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to equity financing, we are actively exploring various other sources of funding, including
possible debt financing and leveraging our many assets, including our intellectual property portfolio
and the operations of Avid. Our broad intellectual property portfolio allows us to develop products
internally while at the same time we are able to out-license certain areas of the technology which
would not interfere with our internal product development efforts. We also have the facilities of
Avid that we may leverage in a strategic transaction if the right opportunity and financial terms
are presented to us, provided that the manufacturing needs of our customers and Peregrine are not
jeopardized. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>There can be no assurances that we will be successful in raising sufficient capital on terms acceptable
to us, or at all (from either debt, equity or the licensing, partnering or sale of technology assets
and/or the sale of all or a portion of Avid), or that sufficient additional revenues will be generated
from Avid or under potential licensing agreements to complete the research, development, and clinical
testing of our product candidates beyond fiscal year 2006. </FONT></P>
<P><FONT face="Times New Roman, Times, Serif" size=2>2. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Basis
of Presentation - </I>The accompanying consolidated financial statements include the accounts of the Company and its wholly-owned
subsidiaries, Avid Bioservices, Inc. and Vascular Targeting Technologies, Inc. All intercompany balances
and transactions have been eliminated.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash
and Cash Equivalents</I> &nbsp;<I>-</I> We consider all highly liquid, short-term investments with an initial maturity of three months or
less to be cash equivalents. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Allowance
for Doubtful Accounts -</I> &nbsp;We continually monitor our allowance for doubtful accounts for all receivables. A considerable
amount of judgment is required in assessing the ultimate realization of these receivables and we
estimate an allowance for doubtful accounts based on factors that appear reasonable under the circumstances.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid
Expenses &#150; </I>Our prepaid expenses primarily represent pre-payments made to secure the receipt of services at a future
date. During fiscal year 2005, we prepaid various research and development related services through
the issuance of our shares of common stock with unrelated entities, which are expensed once the services
have been provided under the terms of the arrangement. As of April 30, 2005, prepaid research and
development services of $1,028,000 paid in shares of our common stock is included in prepaid expenses
and other current assets in the accompanying consolidated financial statements. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Short-term Investments</I> <I>-</I> We classify our short-term investments as trading securities under the requirements of Statement of
Financial Accounting Standards No. 115 (&#147;SFAS No. 115&#148;), <I>Accounting for Certain Investments in Debt and Equity Securities</I>. SFAS No. 115 considers trading securities as securities that are bought with the intention of being
sold in the near term for the general purpose of realizing profits. Trading securities are recorded
at fair market value and unrealized holding gains and losses on trading securities are included in
other income in the accompanying consolidated financial statements.</FONT></P><I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-9</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> <I>Inventories</I>&nbsp;<I>-</I> Inventories are stated at the lower of cost or market and primarily includes raw materials, direct
  labor, and overhead costs associated with our wholly-owned subsidiary, Avid. Inventories consist
  of the following at April 30, 2005 and April 30, 2004:</FONT></P>
<table width=60% border=0 align="center" cellpadding=0 cellspacing=0>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2005</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2004</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Raw materials</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=15% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 445,000</font></td>
    <td width=5% align=LEFT bgcolor="#eaf9e8"><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=15% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 411,000</font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Work-in-process</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>182,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>829,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=1></td>
    <td></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Total inventories</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 627,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 1,240,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
    <td colspan=2 align=RIGHT><hr color=black size=2></td>
    <td></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><B></B> <I>Concentrations of Credit Risk</I>&nbsp;- The majority of trade and other receivables as of April 30, 2005, are from customers in the
United States. Most contracts require up-front payments and installment payments as the project progresses.
We perform periodic credit evaluations of our ongoing customers and generally do not require collateral,
but we can terminate any contract if a material default occurs. Reserves are maintained for potential
credit losses and such losses have been within our estimates. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><B></B> <I>Comprehensive Loss</I>&nbsp;- Comprehensive loss is equal to net loss for all periods presented.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Property</I>&nbsp;- Property is recorded at cost. Depreciation and amortization are computed using the straight-line
method over the estimated useful lives of the related asset, generally ranging from three to ten
years. Amortization of leasehold improvements is calculated using the straight-line method over the
shorter of the estimated useful life of the asset or the remaining lease term.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Impairment</I>&nbsp;&#150; Long-lived assets are reviewed for impairment when events or changes in circumstances
indicate that the carrying amount of such assets may not be recoverable. We assess recoverability
of our long-term assets by comparing the remaining carrying value to the value of the underlying
collateral or the fair market value of the related long-term asset based on undiscounted cash flows.
Long-lived assets are reported at the lower of carrying amount or fair value less cost to sell.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
Revenue </I>- Deferred revenue primarily consists of up-front contract fees and installment payments received prior
to the recognition of revenues under contract manufacturing and development agreements and up-front
license fees received under technology licensing agreements. Deferred revenue is generally recognized
once the service has been provided, all obligations have been met and/or upon shipment of the product
to the customer.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Revenue Recognition </I>- We currently derive revenues primarily from licensing agreements associated with Peregrine&#146;s
technologies under development and from contract manufacturing services provided by Avid.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>We recognize revenues pursuant to Staff Accounting Bulletin No. 101 (&#147;SAB No. 101&#148;), <I>Revenue Recognition in Financial Statements </I>and Staff Accounting Bulletin No. 104 (&#147;SAB No. 104&#148;), <I>Revenue Recognition</I>. These bulletins draw on existing accounting rules and provide specific guidance on how those accounting
rules should be applied. Revenue is generally realized or realizable and earned when (i) persuasive
evidence of an arrangement exists, (ii) delivery has occurred or services have been rendered, (iii)
the seller&#146;s price to the buyer is fixed or determinable, and (iv) collectibility is reasonably
assured. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-10</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>In
addition, we comply with Financial Accounting Standards Board&#146;s Emerging Issues Task Force No.
00-21 (&#147;EITF 00-21&#148;), <I>Revenue Arrangements with Multiple Deliverables</I>. In accordance with EITF 00-21, we recognize revenue for delivered elements only when the delivered
element has stand-alone value and we have objective and reliable evidence of fair value for each
undelivered element. If the fair value of any undelivered element included in a multiple element
arrangement cannot be objectively determined, revenue is deferred until all elements are delivered
and services have been performed, or until fair value can objectively be determined for any remaining
undelivered elements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Revenues
associated with licensing agreements primarily consist of nonrefundable up-front license fees and
milestones payments. Revenues under licensing agreements are recognized based on the performance
requirements of the agreement. Nonrefundable up-front license fees received under license agreements,
whereby continued performance or future obligations are considered inconsequential to the relevant
licensed technology, are generally recognized as revenue upon delivery of the technology. Nonrefundable
up-front license fees, whereby ongoing involvement or performance obligations exist, are generally
recorded as deferred revenue and generally recognized as revenue over the term of the performance
obligation or relevant agreement. Milestone payments are recognized as revenue upon the achievement
of mutually agreed milestones, provided that (i)&nbsp;the milestone event is substantive and its
achievement is not reasonably assured at the inception of the agreement, and (ii)&nbsp;there are
no continuing performance obligations associated with the milestone payment. Under a license agreement
with Schering A.G. (Note 8), the obligation period was not contractually defined in relation to a
$300,000 upfront fee. Under this circumstance, we exercised judgment in estimating the period of
time over which certain deliverables will be provided to enable the licensee to practice the license,
which was determined to be 48 months. The estimated period of 48 months was primarily determined
based on the historical experience with Schering A.G. under a separate license agreement. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract
manufacturing revenues are generally recognized once the service has been provided and/or upon shipment
of the product to the customer. We also record a provision for estimated contract losses, if any,
in the period in which they are determined. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
July 2000, the Emerging Issues Task Force (&#147;EITF&#148;) released Issue 99-19 (&#147;EITF 99-19&#148;),
<I>Reporting Revenue Gross as a Principal versus Net as an Agent</I>. EITF 99-19 summarized the EITF&#146;s views on when revenue should be recorded at the gross amount
billed to a customer because it has earned revenue from the sale of goods or services, or the net
amount retained (the amount billed to the customer less the amount paid to a supplier) because it
has earned a fee or commission. In addition, the EITF released Issue 00-10 (&#147;EITF 00-10&#148;), <I>Accounting for Shipping and Handling Fees and Costs</I>, and Issue 01-14 (&#147;EITF 01-14&#148;), <I>Income Statement Characterization of Reimbursements Received for &#147;Out-of-Pocket&#148; Expenses
Incurred</I>. EITF 00-10 summarized the EITF&#146;s views on how the seller of goods should classify in the income
statement amounts billed to a customer for shipping and handling and the costs associated with shipping
and handling. EITF 01-14 summarized the EITF&#146;s views on when the reimbursement of out-of-pocket
expenses should be characterized as revenue or as a reduction of expenses incurred. Our revenue recognition
policies are in compliance with EITF 99-19, EITF 00-10 and EITF 01-14 whereby we recorded revenue
for the gross amount billed to customers (the cost of raw materials, supplies, and shipping, plus
the related handling mark-up fee) and we recorded the cost of the amounts billed as cost of sales
as we act as a principal in these transactions. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Fair Value of Financial Instruments </I>- Our financial instruments consist principally of cash and cash equivalents, receivables, inventories,
accounts payable, and accrued liabilities. We believe all of the financial instruments&#146; recorded
values approximate current values due to the short-term nature of these instruments.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Use of Estimates</I>&nbsp;- The preparation of our financial statements in conformity with U.S. generally accepted accounting
principles requires management to make estimates and assumptions that affect the amounts reported
in the consolidated financial statements and accompanying notes. Actual results could differ from
these estimates.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-11</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2> <I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Net Loss Per Common Share</I> &nbsp;- Basic and diluted net loss per common share is calculated in accordance with Statement of
  Financial Accounting Standards No. 128, <I>Earnings per Share</I>. Basic net loss per common share is computed by dividing our net loss by the weighted average number
  of common shares outstanding during the period excluding the dilutive effects of options, warrants,
  and convertible instruments. Diluted net loss per common share is computed by dividing our net loss
  by the sum of the weighted average number of common shares outstanding during the period plus the
  potential dilutive effects of options, warrants, and convertible debt outstanding during the period.
  Potentially dilutive common shares consist of stock options and warrants calculated in accordance
  with the treasury stock method, but are excluded if their effect is antidilutive. The potential dilutive
  effect of convertible debt was calculated using the if-converted method assuming the conversion of
  the convertible debt as of the earliest period reported or at the date of issuance, if later. Because
  the impact of options, warrants, and other convertible instruments are antidilutive during periods
  of net loss, there was no difference between basic and diluted loss per share amounts for the three
  years ended April 30, 2005. The dilutive effect of the following shares issuable upon the exercise
  of options, warrants, and convertible debt outstanding during the period were excluded from dilutive
  net loss per common share because their effect is antidilutive since we reported a net loss in the periods presented:</FONT></P>
<table width="90%" align="center" cellpadding="0" cellspacing="0">
  <tr valign="middle">
    <td><div align="center"><font size="1" face="Times New Roman, Times, serif"><i> &nbsp;</i></font></div></td>
    <td colspan="2"><div align="center"><b><font size="1" face="Times New Roman, Times, serif"> 2005 </font></b></div></td>
    <td>&nbsp;</td>
    <td colspan="2"><div align="center"><b><font size="1" face="Times New Roman, Times, serif"> 2004 </font></b></div></td>
    <td>&nbsp;</td>
    <td colspan="2"><div align="center"><b><font size="1" face="Times New Roman, Times, serif"> 2003 </font></b></div></td>
    <td>&nbsp;</td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
  </tr>
  <tr bgcolor="#eaf9e8">
    <td valign="top" nowrap><font size="2" face="Times New Roman, Times, serif"> Common stock equivalent shares&nbsp;assuming issuance of shares<br>
&nbsp;&nbsp;&nbsp;&nbsp;represented by outstanding&nbsp;stock options and warrants<br>
&nbsp;&nbsp;&nbsp;&nbsp;utilizing the treasury stock&nbsp;method</font></td>
    <td width="1%" valign="top">&nbsp;</td>
    <td width="10%" align="right" valign="bottom" bgcolor="#eaf9e8"><font size="2" face="Times New Roman, Times, serif">6,485,168</font></td>
    <td width="4%" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="1%" valign="bottom">&nbsp;</td>
    <td width="10%" align="right" valign="bottom" bgcolor="#eaf9e8"><font size="2" face="Times New Roman, Times, serif">11,462,682</font></td>
    <td width="4%" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td width="1%" valign="bottom">&nbsp;</td>
    <td width="10%" align="right" valign="bottom" bgcolor="#eaf9e8"><font size="2" face="Times New Roman, Times, serif">4,354,442</font></td>
    <td width="2%" valign="bottom">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top" nowrap><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="top"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></td>
  </tr>
  <tr>
    <td valign="top" nowrap><font size="2" face="Times New Roman, Times, serif"> Common stock equivalent shares  assuming issuance of shares<br>
&nbsp;&nbsp;&nbsp;&nbsp;upon conversion of convertible&nbsp;debt utilizing the if-converted<br>
&nbsp;&nbsp;&nbsp;&nbsp;method</font></td>
    <td valign="top">&nbsp;</td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&#151;</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom">&nbsp;</td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">563,054</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom">&nbsp;</td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&#151;</font></td>
    <td align="right" valign="bottom">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top" nowrap>&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=1></td>
    <td valign="top">&nbsp;</td>
  </tr>
  <tr bgcolor="#eaf9e8">
    <td valign="top"><font size="2" face="Times New Roman, Times, serif"> Total </font></td>
    <td valign="top">&nbsp;</td>
    <td align="right" valign="top"><font size="2" face="Times New Roman, Times, serif">6,485,168 </font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="top">&nbsp;</td>
    <td align="right" valign="top"><font size="2" face="Times New Roman, Times, serif">12,025,736</font></td>
    <td valign="top"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td valign="top">&nbsp;</td>
    <td align="right" valign="top"><font size="2" face="Times New Roman, Times, serif">4,354,442 </font></td>
    <td valign="top">&nbsp;</td>
  </tr>
  <tr>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=2></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=2></td>
    <td valign="top">&nbsp;</td>
    <td colspan="2" valign="top"><hr color=black size=2></td>
    <td valign="top">&nbsp;</td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>Weighted average outstanding options and warrants to purchase up to 11,946,248, 8,393,083 and 13,845,742
shares of common stock for the fiscal years ended April 30, 2005, 2004 and 2003, respectively, were
also excluded from the calculation of diluted earnings per common share because their exercise prices
were greater than the average market price during the period. In addition, weighted average shares
of 2,581,547, assuming issuance of shares upon conversion of convertible debt for fiscal year 2003,
were also excluded from the calculation of diluted earnings per common share because the conversion
price was greater than the average market price during the period.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>From May 1, 2005 through June 30, 2005, we issued an aggregate 12,707,217 shares of our common stock
under various financing transactions (Note 9) in exchange for aggregate net proceeds of $11,302,000,
which additional shares have been excluded from basic and dilutive net loss per common share for
the year ended April 30, 2005.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-12</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Income Taxes</I> - &nbsp;We utilize the liability method of accounting for income taxes as set forth in Statement of
Financial Accounting Standards No. 109, <I>Accounting for Income Taxes</I>. Under the liability method, deferred taxes are determined based on the differences between the consolidated
financial statements and tax basis of assets and liabilities using enacted tax rates. A valuation
allowance is provided when it is more likely than not that some portion or the entire deferred tax
asset will not be realized.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Reclassification</I>&nbsp;- Certain amounts in fiscal years 2004 and 2003 consolidated financial statements have been
reclassified to conform to the current year presentation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research
and Development</I>&nbsp;- Research and development costs are charged to expense when incurred in accordance with Statement
of Financial Accounting Standards No. 2, <I>Accounting for Research and Development Costs</I>. Research and development expenses primarily include (i) payroll and related costs associated with
research and development personnel, (ii) costs related to clinical and pre-clinical testing of our
technologies under development, (iii) the costs to manufacture the product candidates, including
raw materials and supplies, (iv) technology access and maintenance fees, including amounts incurred
under licensing agreements and intellectual property access fees, (v) expenses for research and services
rendered under outside contracts, including sponsored research funding, and (vi) facility and other
research and development expenses. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I><I>Stock-based Compensation</I> &#150; In December 2002, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Statement
of Financial Accounting Standards No. 148 (&#147;SFAS No. 148&#148;), <I>Accounting for Stock-Based Compensation-Transition and Disclosure</I>. SFAS No. 148 amends SFAS No. 123 (&#147;SFAS No. 123&#148;), <I>Accounting for Stock-Based Compensation, </I>and provides alternative methods of transition for a voluntary change to the fair value based method
of accounting for stock-based employee compensation. In addition, SFAS No. 148 amends the disclosure
requirements of SFAS No. 123 to require prominent disclosures in both annual and interim financial
statements about the method of accounting for stock-based employee compensation, and the effect of
the method used on reported results.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
have not adopted a method under SFAS No. 148 to expense stock options but rather we continue to apply
the provisions of SFAS No. 123; however, we have adopted the additional disclosure provisions of
the statement. As SFAS No. 123 permits, we elected to continue accounting for our employee stock
options in accordance with Accounting Principles Board Opinion No. 25 (&#147;APB No. 25&#148;), <I>Accounting for Stock Issued to Employees</I> <I>and Related Interpretations</I>. APB No. 25 requires compensation expense to be recognized for stock options when the market price
of the underlying stock exceeds the exercise price of the stock option on the date of the grant.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
utilize the guidelines in APB No. 25 for measurement of stock-based transactions for employees and,
accordingly, no compensation expense has been recognized for the options in the accompanying consolidated
financial statements for the three years ended April 30, 2005.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-13</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Had we used a fair value model for measurement of stock-based transactions for employees under SFAS
No. 123 and amortized the expense over the vesting period, pro forma information would be as follows:</FONT></P>
<table width="90%" align="center" cellpadding="0" cellspacing="0">
  <tr align="center">
    <td><font size="1">&nbsp;</font></td>
    <td colspan="2"><b><font size="1" face="Times New Roman, Times, serif">2005</font></b></td>
    <td><font size="1">&nbsp;</font></td>
    <td colspan="2"><b><font size="1" face="Times New Roman, Times, serif">2004</font></b></td>
    <td><font size="1">&nbsp;</font></td>
    <td colspan="2"><b><font size="1" face="Times New Roman, Times, serif">2003</font></b></td>
    <td><font size="1">&nbsp;</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom">&nbsp;</td>
  </tr>
  <tr bgcolor="#eaf9e8">
    <td><font size="2" face="Times New Roman, Times, serif">Net loss, as reported</font></td>
    <td width="1%" align="right"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td width="12%" align="right"><font size="2" face="Times New Roman, Times, serif">(15,452,000</font></td>
    <td width="3%" align="left"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td width="1%" align="right"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td width="12%" align="right"><font size="2" face="Times New Roman, Times, serif">(14,345,000</font></td>
    <td width="3%" align="left"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td width="1%" align="right"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td width="12%" align="right"><font size="2" face="Times New Roman, Times, serif">(11,559,000</font></td>
    <td width="2%" align="left"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Stock-based employee compensation cost that <br>
      &nbsp;&nbsp;&nbsp;would have been included in the determination<br>
      &nbsp;&nbsp;&nbsp;of net loss if the fair value based method had<br>
      &nbsp;&nbsp;&nbsp;been applied to all awards</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(2,828,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif"> (2,541,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif"> (2,003,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=1></td>
    <td align="left" valign="bottom">&nbsp;</td>
  </tr>
  <tr bgcolor="#eaf9e8">
    <td><font size="2" face="Times New Roman, Times, serif">Pro forma net loss as if the fair value based <br>
      &nbsp;&nbsp;&nbsp;method had been applied to all awards</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(18,280,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(16,886,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(13,562,000</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td><font size="2" face="Times New Roman, Times, serif">Basic and diluted loss per
    common share, as reported</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(0.11</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(0.11</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif"> (0.10</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom">&nbsp;</td>
  </tr>
  <tr bgcolor="#eaf9e8">
    <td><font size="2" face="Times New Roman, Times, serif">Basic and diluted loss per
    common share, pro forma</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(0.13</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(0.13</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">$</font></td>
    <td align="right" valign="bottom"><font size="2" face="Times New Roman, Times, serif">(0.12</font></td>
    <td align="left" valign="bottom"><font size="2" face="Times New Roman, Times, serif">)</font></td>
  </tr>
  <tr>
    <td>&nbsp;</td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom"></td>
    <td colspan="2" align="right" valign="bottom"><hr color=black size=2></td>
    <td align="left" valign="bottom">&nbsp;</td>
  </tr>
  <tr>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
    <td></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
fair value of stock options on the date of grant and the assumptions used to estimate the fair value
of the stock options using the Black-Scholes option valuation model, were as follows:</FONT></P>
<TABLE WIDTH=90% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">2005</font></b></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">2004</font></b></TD>
    <TD ALIGN=left>&nbsp;</TD>
    <TD colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">2003</font></b></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr color=black size=1></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr color=black size=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT><hr color=black size=1></TD>
    <TD ALIGN=left>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Weighted average fair value of stock options granted</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.80</FONT></TD>
    <TD WIDTH=3% ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD WIDTH=1% ALIGN=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1.59</FONT></TD>
    <TD WIDTH=3% ALIGN=left><font size="2">&nbsp;</font></TD>
    <TD WIDTH=1% ALIGN=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 0.64</FONT></TD>
    <TD WIDTH=2% ALIGN=left><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Risk-free interest rate</FONT></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3.38</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.31</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2.31</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected life (in years)</FONT></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=left><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=left><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=left><font size="2">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected volatility factor</FONT></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>115</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>124</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>122</FONT></TD>
    <TD ALIGN=left><font face="Times New Roman, Times, Serif" size=2>%</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Expected dividend yield</FONT></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=left><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><font size="2">&nbsp;</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=left><font size="2">&nbsp;</font></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Black-Scholes option valuation model was developed for use in estimating the fair value of traded
options that have no vesting restrictions and are fully transferable. Option valuation models require
the input of highly subjective assumptions, including the expected stock volatility. Because our
options have characteristics significantly different from those of traded options and because changes
in the subjective input assumptions can materially affect the fair values estimated, in the opinion
of management, the existing models do not necessarily provide a reliable measure of the fair value
of our options. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Stock-based compensation expense recorded during each of the three years in the periods ended April
30, 2005 primarily relates to stock option grants made to consultants and has been measured utilizing
the Black-Scholes option valuation model. Stock-based compensation expense recorded during fiscal
years 2005, 2004 and 2003 amounted to $231,000, $271,000, and $548,000, respectively, and is being
amortized over the estimated period of service or related vesting period. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In December 2004, the FASB issued Statement of Financial Accounting Standards No. 123R (&#147;SFAS No. 123R&#148;),
<I>Share-Based Payment (Revised 2004)</I>, which requires companies to recognize in the income statement the fair value of all employee share-based
payments, including grants of employee stock options as well as compensatory employee stock purchase
plans, for interim periods beginning after June 15, 2005. In April 2005, the Securities and Exchange
Commission adopted a rule amendment that delayed the compliance dates of FAS 123R such that we are
now allowed to adopt the new standard no later than May 1, 2006. SFAS No. 123R eliminates the ability
to account for share-based compensation using APB No. 25, and the pro forma disclosures previously
permitted under SFAS No. 123 no longer will be an alternative to financial statement recognition.
Although we have not yet determined whether the adoption of SFAS No. 123R will result in amounts
that are similar to the current pro forma disclosures under SFAS No. 123 (as shown above), we are
evaluating the requirements under SFAS No. 123R including the valuation methods and support for the
assumptions that underlie the valuation of the awards, as well as the transition methods (modified
prospective transition method or the modified retrospective transition method) and expect the adoption
to have a significant impact on our consolidated statements of operations and net loss per share
and minimal impact on our consolidated statement of financial position.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-14</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, during August 2003, a member of our Board of Directors voluntarily cancelled an option
  to purchase shares of our common stock due to an insufficient number of stock options available in
  our stock option plans for new employee grants. During October 2003, we received stockholder approval
  for our 2003 Stock Incentive Plan (&#147;2003 Plan&#148;) and the director was re-granted an option
  to purchase shares under the 2003 Plan. In accordance with FASB Interpretation No. 44 (&#147;FIN
  No. 44&#148;), <I>Accounting for Certain Transactions Involving Stock Compensation</I>, the option granted to the director under the 2003 Plan is subject to variable accounting, which could
  result in increases or decreases to compensation expense in subsequent periods based on movements
  in the intrinsic value of the option until the date the option is exercised, forfeited or expires
  unexercised. Decreases in compensation expense are limited to the net expense previously reported.
  During the fiscal years 2004 and 2005, as a result of movements in the intrinsic value of the option,
  we did not record compensation expense with respect to such option in accordance with FIN No. 44.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>Recent
Accounting Pronouncements</I>&nbsp;- In November 2004, the FASB issued Statement of Financial Accounting Standards No. 151 (&#147;SFAS
No. 151&#148;), <I>Inventory Costs</I>. SFAS No. 151 amends the guidance in ARB No. 43, Chapter 4, Inventory Pricing, to improve financial
reporting by clarifying that abnormal amounts of idle facility expense, freight, handling costs,
and wasted materials (spoilage) should be recognized as current-period charges and by requiring the
allocation of fixed production overheads to inventory based on the normal capacity of the production
facilities. The standard is effective for inventory costs incurred during fiscal years beginning
after June 15, 2005. We would be required to implement this standard no later than May 1, 2006, unless
earlier adopted. We are currently evaluating the impact of SFAS No. 151 on our financial position
and results of operations. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SHORT-TERM INVESTMENTS </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
March 2003, we received 61,653 shares of SuperGen, Inc. common stock under a license agreement dated
February 13, 2001 (Note 8). We account for our short-term investments at fair value as trading securities
in accordance with SFAS No. 115. The cost basis of the common stock was $200,000. During the quarter
ended July 31, 2003, we sold all 61,653 shares of common stock of SuperGen, Inc. for gross proceeds
of $271,000. The realized gain of $71,000 relating to the short-term investment is included in interest
and other income in the accompanying consolidated financial statements for the year ended April 30, 2004.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-15</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>4. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES RECEIVABLE</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 1998, we completed the sale and subsequent leaseback of our two facilities and recorded
an initial note receivable from the buyer of $1,925,000. The note receivable bears interest at 7.5%
per annum and payments are due monthly based on a 20-year amortization period. The note receivable
is due on the earlier to occur of (i) December 1, 2010 or (ii) upon the sale of the facility and
the transfer of title. In addition, if we default under the lease agreement, including but not limited
to, filing a petition for bankruptcy or failure to pay the basic rent, the note receivable shall
be deemed to be immediately satisfied in full and the buyer shall have no further obligation to us
for such note receivable, as defined in the note agreement. Although we have made all payments under
the lease agreement and we have not filed for protection under the laws of bankruptcy, during the
quarter ended October 31, 1999, we did not have sufficient cash on hand to meet our obligations on
a timely basis and we were operating at significantly reduced levels. In addition, at that time,
if we could not raise additional cash by December 31, 1999, we may have had to file for protection
under the laws of bankruptcy. Due to the uncertainty of our ability to pay our lease obligations
on a timely basis, we established a 100% reserve for the note receivable in the amount of $1,887,000
as of October 31, 1999. We reduce the reserve as payments are received and we record the reduction
as interest and other income in the accompanying consolidated statement of operations. Due to the
uncertainty of our ability to fund our operations beyond fiscal year 2006, the carrying value of
the note receivable approximates its fair value at April 30, 2005. We have received all payments
to date under the note receivable. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following represents a rollforward of the allowance of the note receivable for the two years ended
April 30, 2005:</FONT></P>
<TABLE WIDTH=60% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Allowance balance, beginning</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=13% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,645,000</FONT></TD>
    <TD WIDTH=4% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=13% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,705,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Principal payments received</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(64,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(60,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Allowance balance, ending</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,581,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,645,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR COLOR=#000000 SIZE=2></TD>
    <TD></TD>
  </TR>
</TABLE>

<P align=left><FONT face="Times New Roman, Times, Serif" size=2>5. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; NOTES PAYABLE</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
May 2002, we entered into two separate note payable agreements with an aggregate original amount
due of $134,000 to finance laboratory equipment. The notes, which were unsecured, bore interest at
10% per annum and were paid in full during March 2003. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
November 2004, we entered into a note agreement with General Electric Capital Corporation (&#147;GE&#148;)
in the amount of $350,000 collateralized by certain laboratory equipment. The note bears interest
at a rate of 5.78% per annum with payments due monthly in the amount of approximately $11,000 over
36 months commencing January 1, 2005. Under the terms of the agreement, we paid to GE a security
deposit of 25%, or approximately $88,000, which is due and payable to us at the end of the note term.
The deposit is included in other long term assets in the accompanying consolidated financial statements.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 2004, we entered into an additional note agreement with GE in the amount of $383,000 collateralized
by certain laboratory equipment. The note bears interest at a rate of 5.85% per annum with payments
due monthly in the amount of approximately $12,000 over 36 months commencing February 1, 2005. Under
the terms of the agreement, we paid to GE a security deposit of 25%, or approximately $96,000, which
is due and payable to us at the end of the note term. The deposit is included in other long term
assets in the accompanying consolidated financial statements.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-16</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B> </B><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>As of April 30, 2005, we owed GE an aggregate amount of $668,000 under both note payable agreements.
  Minimum future principal payments on notes payable as of April 30, 2005 are as follows:</FONT></P>
<TABLE WIDTH=60% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=4><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD WIDTH=10% ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Year ending April 30: </FONT></TD>
    <TD WIDTH=1% ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD WIDTH=2% ALIGN=LEFT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD WIDTH=10% ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2006</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>234,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2007</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>248,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2008</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>186,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 668,000</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#eaf9e8">&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
    <TD></TD>
  </TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2>6. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; COMMITMENTS AND CONTINGENCIES</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating
Lease</I> &nbsp;- In December 1998, we sold and subsequently leased back our two facilities in Tustin, California.
The lease has an original lease term of 12 years with two 5-year renewal options and includes scheduled
rental increases of 3.35% every two years. We record rent expense on a straight-line basis and the
differences between the amounts paid and the amounts expensed are included in other accrued liabilities
in the accompanying consolidated financial statements. Annual rent expense under the lease agreement
totaled $735,000 during fiscal year 2005, 2004 and 2003. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
fiscal year 2004, we entered into an operating lease agreement to lease certain office equipment.
The lease has a 5-year term and annual minimum lease payments are $29,000. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
February 2005, we entered into an operating lease agreement to lease certain office space in Houston,
Texas. The lease has a 3-year term and annual minimum lease payments are $20,000. Rent expense under
the lease agreement totaled $4,000 during fiscal year 2005. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>At
April 30, 2005, future minimum lease payments and sublease income under all non-cancelable operating
leases are as follows: </FONT></P>
<TABLE WIDTH=70% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR>
    <TD COLSPAN=3 align="left" valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Year ending<br>
      April 30: </font></b></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom" nowrap><b><font size="1" face="Times New Roman, Times, serif">Minimum Lease<br>
    Payments</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Sublease Income</font></b></TD>
    <TD align="center" valign="bottom"></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">Net Lease Payments</font></b></TD>
    <TD></TD>
  </TR>
  <TR>
    <TD><HR align="left" width="100" SIZE=1 NOSHADE COLOR=#000000></TD>
    <TD></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2006</FONT></TD>
    <TD WIDTH=4% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 794,000</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (59,000</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 735,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2007</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>804,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(40,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>764,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2008</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>815,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>815,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2009</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>793,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>793,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2010</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>796,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>796,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Thereafter</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>530,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>530,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,532,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (99,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 4,433,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Rental Income</I> &#150; We currently sublease portions of our unused space. Sublease rental income totaled $99,000,
$179,000 and $216,000 for fiscal years 2005, 2004 and 2003, respectively.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Legal
Proceedings</I> &#150; From time to time, we are subject to legal proceedings
and disputes during the ordinary course of business. We currently are not aware
of any such legal proceeding or claim that we believe will have, individually or
in the aggregate, a material adverse effect on our business, prospects,
operating results or cash flows.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-17</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>7. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CONVERTIBLE DEBT</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
August 9, 2002, we entered into a private placement with four investors under a Debenture Securities
Purchase Agreement (&#147;Debt SPA&#148;), whereby we issued Convertible Debentures (&#147;Convertible
Debt&#148;) for gross proceeds of $3,750,000. The Convertible Debt was fully converted into 4,411,764
shares of common stock, of which, 1,594,119 shares of our common stock were issued during fiscal
year 2003 and 2,817,645 shares of our common stock were issued during fiscal year 2004. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In accordance with EITF 00-27, <I>Application of Issue No. 98-5 to Certain Convertible Instruments</I>, we initially recorded the convertible debt net of discount of (i) the relative fair value of the
warrants issued in the amount of $1,321,000 and (ii) the intrinsic value of the embedded conversion
feature in the amount of $1,143,000. The relative fair value of the warrants was determined in accordance
with the Black-Scholes valuation model based on the warrant terms. The debt discount, along with
the debt issuance costs, were amortized as non-cash interest expense on a straight-line basis over
the term of the Convertible Debt, which approximates the effective interest method. Upon conversion
of the Convertible Debt, the entire unamortized debt discount and debt issuance costs remaining at
the date of conversion that was attributed to the converted Convertible Debt were immediately recognized
as interest expense in the accompanying consolidated statements of operations. During fiscal years
2004 and 2003, we recognized $1,635,000 and $829,000, respectively, in non-cash interest expense
associated with the Convertible Debt, which amount was included in interest and other expense in
the accompanying consolidated statements of operations. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of April 30, 2004, all outstanding Convertible Debt was converted into common stock and the associated
discount was fully amortized as non-cash interest expense in the accompanying financial statements
as follows:</FONT></P>
<TABLE WIDTH=80% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=3><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">2004</font></b></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=center valign="bottom"><b><font size="1" face="Times New Roman, Times, serif">2003</font></b></TD>
    <TD></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2><u>Principal Balance of Convertible Debt</u></FONT></b></TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=12% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Convertible Debt, beginning</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 2,395,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Convertible Debt issued</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,750,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Convertible Debt conversions</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,395,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,355,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Convertible Debt, ending</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,395,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2><u>Discount on Convertible Debt</u></FONT></b></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Convertible debt discount, beginning</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,635,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,464,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Amount amortized as non-cash interest expense</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,635,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(829,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;Convertible debt discount, ending</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,635,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;Convertible Debt, net of discount</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 760,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
    <TD COLSPAN=2 ALIGN=RIGHT><HR NOSHADE COLOR=#000000 SIZE=2></TD>
    <TD></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>Under the Debt SPA, each Debenture holder was granted a detachable warrant equal to 75% of the quotient
obtained by dividing the principal amount of the Convertible Debt by the Conversion Price or an aggregate
of 3,308,827 warrants. The detachable warrants have a 4-year term with an exercise price of $0.75
per share. During fiscal year 2004, Debenture holders exercised 2,244,120 warrants under the Debt
SPA for gross proceeds of $1,683,000 at the exercise price of $0.75 per share. As of April 30, 2005,
1,064,707 warrants were outstanding under the Debt SPA (Note 11).</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-18</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B> In connection with the Convertible Debt, we incurred approximately $363,000 in debt issuance costs,
including placement agent fees of $318,000, which was amortized as interest expense on a straight-line
basis over the life of the Convertible Debt, which approximates the effective interest method. Upon
conversion of the Convertible Debt, the entire unamortized debt issuance costs remaining at the date
of conversion that was attributed to the converted Convertible Debt was immediately recognized as
interest expense in the accompanying consolidated statements of operations. During fiscal years 2004
and 2003, we expensed $175,000 and $188,000, respectively, in debt issuance costs included in interest
and other expense in the accompanying consolidated statements of operations. As of April 30, 2004,
the debt issuance costs were completely amortized. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>8. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;LICENSE, RESEARCH AND DEVELOPMENT
AGREEMENTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
following represents our significant licensing arrangements for the development and commercialization
of our five (5) platform technologies:&nbsp;Tumor Necrosis Therapy (&#147;TNT&#148;), Anti-Phospholipid
Therapy, Vascular Targeting Agents (&#147;VTAs&#148;), Anti-Angiogenesis Agents, and Vasopermeation
Enhancement Agents (&#147;VEAs&#148;). In addition, we do not perform any research and development
activities for any unrelated entities. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Tumor Necrosis Therapy</I> <I>&nbsp;(Cotara&#174;)</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We acquired the rights to the TNT technology in July 1994 after the merger between Peregrine and Cancer
Biologics, Inc. was approved by our stockholders. The assets acquired from Cancer Biologics, Inc.
primarily consisted of patent rights to the TNT technology. To date, no product revenues have been
generated from our TNT technology.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In
October 2004, we entered into a worldwide non-exclusive license agreement with Lonza Biologics for
intellectual property and materials relating to the expression of recombinant monoclonal antibodies
for use in the manufacture of Cotara&#174;. Under the terms of the agreement, we paid an upfront
fee of 75,000 pounds sterling ($141,000 U.S.) which amount is included in research and development expense in the
accompanying consolidated financial statements in fiscal year 2005, and we will pay a royalty on
net sales of any products that we market that utilize the underlying technology. In the event we
or Lonza do not manufacture Cotara&#174;, we would owe 300,000 pounds sterling per year in addition
to an increased royalty on net sales. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
October 2000, we entered into a licensing agreement with Merck KGaA to license a segment of our TNT
technology for use in the application of cytokine fusion proteins. During January 2003, we entered
into an amendment to the license agreement, whereby we received an extension to the royalty period
from six years to ten years from the date of the first commercial sale. Under the terms of the amendment,
we received the remaining up-front fee of $350,000 which is included in license revenue in the accompanying
consolidated statements of operations for the year ended April 30, 2003 in accordance with SAB No.
101 and SAB No. 104. Under the terms of agreement, we would receive a royalty on net sales if a product
is approved under the agreement. Merck KGaA has not publicly disclosed the development status of its program.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In February 1996, we entered into a joint venture agreement with Cambridge Antibody Technology, Inc.
(&#147;CAT&#148;), which provided for the co-sponsorship of development and clinical testing of the
TNT antibodies. In May 1998, we mutually elected to discontinue the joint venture of the TNT antibodies
and we assumed full responsibility to fund development and clinical trials of the TNT antibody. During
October 2002, we entered into an assignment agreement whereby CAT assigned us the worldwide rights
to the human TNT antibody. In exchange, we agreed to pay a royalty on net sales to CAT if a product
is approved, as defined in the agreement, and we agreed to forgive any amounts owed to us under the
joint venture. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-19</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During September 1995, we entered into an agreement with Cancer Therapeutics, Inc. whereby we granted
to Cancer Therapeutics, Inc. the exclusive right to sublicense TNT to a major pharmaceutical company
solely in the People&#146;s Republic of China. In addition, we are entitled to receive 50% of the
distributed profits received by Cancer Therapeutics, Inc. from the Chinese pharmaceutical company.
Cancer Therapeutics, Inc. has the right to 20% of the distributed profits under the agreement with
the Chinese pharmaceutical company. During March 2001, we extended the exclusive licensing period
granted to Cancer Therapeutics, which now expires on December 31, 2016. In exchange for this extension,
Cancer Therapeutics, Inc. agreed to pay us ten percent (10%) of all other consideration received
by Cancer Therapeutics, Inc., excluding research funding. Through fiscal year ended April 30, 2005,
we have not received any amounts under the agreement. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Anti-Phospholipid Therapy</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In August 2001, we exclusively licensed a new technology platform from the University of Texas Southwestern
Medical Center at Dallas which we named Anti-Phospholipid Therapy. Under the license agreement, we
paid an up-front license fee, annual maintenance fees, and are obligated to pay future milestone
payments based on development progress, plus a royalty on net sales or a percentage of sublease income.
Our aggregate future milestone payments under this agreement are $450,000 assuming the achievement
of all development&nbsp;milestones under the agreement through commercialization of the product,
of which, we expect to pay $25,000 during fiscal year 2006. Tarvacin&#153; is our first Anti-Phospholipid
Therapy product under this agreement. We have initiated two separate Phase I clinical trials for
the treatment of solid cancers and hepatitis C virus using Tarvacin&#153;. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I></FONT><FONT face="Times New Roman, Times, Serif" size=2>During November 2003 and October 2004, we entered into two non-exclusive license agreements with Genentech,
Inc. to license certain intellectual property rights covering the methods and processes for producing
antibodies used in connection with the development of our Anti-Phospholipid
Therapy program. Under the terms of the non-exclusive license agreements, we
paid a non-refundable license fee of $100,000, and we are required to pay future
development milestone fees based on the achievement of development milestones
and a royalty on net sales. During fiscal year 2004, we expensed $100,000 under this
agreement which is included in research and development expense in the accompanying consolidated
financial statements. Our aggregate future milestone payments under this agreement are $5,600,000
assuming the achievement of all development milestones under the agreement through commercialization
of the product, of which, we expect to incur $400,000 during fiscal year 2006. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2><I>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</I>In
March 2005, we entered into a worldwide non-exclusive license agreement with Lonza Biologics for
intellectual property and materials relating to the expression of recombinant monoclonal antibodies
for use in the manufacture of Tarvacin&#153;. Under the terms of the agreement, we are required to
pay future milestone payments upon the completion of Phase II clinical trial enrollment in the amount
of 75,000 pounds sterling, the amount of which will continue as an annual license fee thereafter,
plus a royalty on net sales of any products that we market that utilize the underlying technology.
In the event we utilize an outside contract manufacturer other than Lonza to manufacture Tarvacin&#153;,
we would owe 300,000 pounds sterling per year in addition to an increased royalty on net sales. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 2003, we entered into an exclusive commercial license agreement with an unrelated entity
covering the chimeric monoclonal antibody, Tarvacin&#153;. Under the agreement, we paid a non-refundable
license fee of $50,000, and we are required to pay future development milestone fees based on the
achievement of development milestones and a royalty on net sales. Our aggregate future milestone
payments under this agreement are $1,050,000 assuming the achievement of all development milestones
under the agreement through commercialization of the product. We do not anticipate making any milestone
payments for at least the next year under this agreement.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-20</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
December 2003, we entered into a research collaboration agreement with an unrelated entity regarding
the humanization of one of our Tarvacin&#153; antibodies to be used as a possible future generation
clinical candidate. Under the terms of the research collaboration agreement, we are required to pay
a non-refundable up-front license fee, antibody development milestone fees, clinical development
milestone fees and a royalty on net sales. During January and October 2004, we issued and sold 243,101
and 107,665 shares of our common stock to the unrelated entity, respectively, for payment of the
non-refundable up-front license fee of 90,000 pounds sterling and for aggregate antibody development
milestone fees of 360,000 pounds sterling. These shares were valued at $802,000 based on the more
readily determinable value of the services received or the fair value of the common stock issued,
of which, $186,000 and $616,000 was recorded as research and development expense in the accompanying
consolidated financial statements during fiscal year 2005 and 2004, respectively. Our minimum aggregate
future milestone payments under this agreement are $3,250,000 assuming the achievement of all development&nbsp;milestones
under the agreement through commercialization of the product. We do not anticipate making any milestone
payments for at least the next year under this agreement. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Vascular Targeting Agents (&#147;VTAs&#148;)</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In April 1997, in conjunction with the acquisition of Vascular Targeting Technologies, Inc. (formerly
known as Peregrine Pharmaceuticals, Inc.), we gained access to certain exclusive licenses for Vascular
Targeting Agents (&#147;VTAs&#148;) technologies from various institutions. In conjunction with obtaining
these exclusive licenses with various unrelated entities, we are required to pay annual patent maintenance
fees of $50,000 plus milestone payments based on the development success of the technologies and
a royalty on net sales. Our aggregate future milestone payments under these exclusive licenses are
$1,238,000 assuming the achievement of all development milestones under the agreement through commercialization
of the product, which are due at various stages of clinical development in accordance with the applicable
license. We do not anticipate making any milestone payments for at least the next year under this agreement. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
July 2004, we announced that we entered into a worldwide exclusive licensing agreement for intellectual
property related to anti-phosphatidylserine (anti-PS) antibodies from The University of Texas M.
D. Anderson Cancer Center related to generating an immune response for the treatment of cancer and
other indications. Under the terms of the agreement, we paid The University of Texas M. D. Anderson
Cancer Center a non-refundable up-front fee of $150,000, which is included in research and development
expense in fiscal year 2005 in the accompanying consolidated financial statements, and we are obligated
to pay future milestone fees based on the clinical progress of products that fall under the licensed
intellectual property and a royalty on net sales as defined in the agreement. Our aggregate future
milestone payments under this licensing agreement are $1,700,000&nbsp;assuming the achievement of
all development milestones under the agreement through commercialization of the product. We do not
anticipate making any milestone payments for at least the next year under this agreement.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-21</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During December 2002, we granted the exclusive rights for the development of diagnostic and imaging
agents in the field of oncology to Schering A.G. under our Vascular Targeting Agent (&#147;VTA&#148;)
technology. Under the terms of the agreement, we received an up-front payment of $300,000 that is
being amortized over an estimated period of 48 months, of which, $125,000 is included in deferred
license revenue in accordance with SAB No. 101 and SAB No. 104 in the accompanying consolidated financial
statements at April 30, 2005. Under this license agreement, the obligation period was not contractually
defined and we exercised judgment in estimating the period of time over which certain deliverables
will be provided to enable the licensee to practice the license. The estimated period of 48 months
was primarily determined based on the historical experience with Schering A.G. under a separate license
agreement. In addition, we could also receive future milestone payments and a royalty on net sales,
as defined in the agreement. Under the same agreement, we granted Schering A.G. an option to obtain
certain non-exclusive rights to the VTA technology with predetermined up-front fees and milestone
payments as defined in the agreement. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2001, we completed a licensing deal with SuperGen, Inc. (&#147;SuperGen&#148;) to license
a segment of our VTA technology, specifically related to Vascular Endothelial Growth Factor (&#147;VEGF&#148;).
Under the terms of the licensing agreement we will receive an annual license fee of $200,000 in cash
or SuperGen common stock until SuperGen files an Investigational New Drug Application in the United
States utilizing the VEGF technology. As of April 30, 2005, SuperGen has not filed an Investigational
New Drug Application in the United States utilizing the VEGF technology. The $200,000 annual license
fee is included in license revenue in the accompanying consolidated financial statements for the
years ended April 30, 2005, 2004 and 2003 in accordance with SAB No. 101 and SAB No. 104. In addition,
we could receive additional milestone payments based on SuperGen&#146;s development success, plus
receive a royalty on net sales of all drugs commercialized by SuperGen utilizing the VEGF technology.
We could also receive additional consideration for each clinical candidate that enters a Phase III
clinical trial by SuperGen.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Anti-Angiogenesis Agents</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During August 2001, we entered into an exclusive worldwide license for a new pre-clinical compound
from the University of Texas Southwestern Medical Center. This new compound, named 2C3, added to
our anti-cancer platform technologies in the anti-angiogenesis field. Under this license agreement,
we paid an up-front license fee and are obligated to pay annual maintenance fees, future milestone
payments based on development progress, plus a royalty on net sales. Our aggregate future milestone
payments under this exclusive worldwide license are $450,000 assuming the achievement of all development
milestones under the agreement through commercialization of the product. We do not anticipate making
any milestone payments under this agreement for at least the next year. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Vasopermeation Enhancement Agents</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During February 2000, we entered into an exclusive worldwide licensing transaction with the University
of Southern California for its Permeability Enhancing Protein (&#147;PEP&#148;) in exchange for an
up-front payment plus future milestone payments and a royalty on net sales based on development success.
The PEP technology is classified under our Vasopermeation Enhancing Agent (&#147;VEA&#148;) technology,
which is designed to increase the uptake of chemotherapeutic agents into tumors. PEP is designed
to be used in conjunction with the VEA technology platform. Our aggregate future milestone payments
under this exclusive worldwide licensing agreement is $70,000 assuming the achievement of all development
milestones under the agreement through commercialization of the product. We do not anticipate making
any milestone payments for at least the next year under this agreement.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Prior to fiscal year 1996, we entered into several license and research and development agreements
with a university for the exclusive, worldwide licensing rights to use certain patents and technologies
in exchange for fixed and contingent payments and royalties on net sales of the related products.
Minimum future annual royalties under these agreements are $84,500 through the last patent to expire
under the technology. Our aggregate future milestone payments under this exclusive worldwide licensing
agreement is $45,000 based on the future achievement of product development milestones. We expensed
minimum annual royalties in the amount of $84,500 during fiscal years 2005, 2004 and 2003. We do
not anticipate making any milestone payments for at least the next year under this agreement.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-22</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Other Licenses</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition, we hold an exclusive world-wide license to manufacture and market products using our Oncolym&#174;
antibodies. In exchange for the world-wide license to manufacture and market the products, we will
pay Northwestern University a royalty on net sales. Under a separate agreement with an unrelated
entity for the same technology, we had accrued $100,000 for milestones, which amount is included
in accrued royalties and license fees in the accompanying consolidated financial statements. To date,
no product revenues have been generated from our Oncolym&#174; technology. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During June 2003, September 2004, and November 2004, we entered into various binding term sheets with
an unrelated entity regarding the production of up to six human antibodies under our platform technologies
to be used as possible future clinical candidates. Under the terms of the binding terms sheets, we
paid a non-refundable technology access fee for each human antibody and we are obligated to pay future
milestones payments based on the achievement of development milestones, plus a royalty on net sales.
In addition, we received a fixed option for the generation of up to three additional human antibodies
at a predetermined price. Our aggregate future milestone payments range from $5.75 million to $6.05
million per human antibody generated by the unrelated entity upon the achievement of certain development
milestones. During fiscal year 2005 and 2004, we expensed $150,000 and $200,000, respectively, in
non-refundable technology access fees under the binding term sheets for three human antibodies, the
amounts of which are included in research and development expense in the accompanying consolidated
financial statements. In addition, during fiscal year 2005, we paid the unrelated entity $660,000
primarily through the issuance of our shares of common stock as a prepayment for three additional
human antibodies to be generated by the unrelated entity, the amount of which is included in prepaid
expenses in the accompanying consolidated financial statements at April 30, 2005. </FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-23</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>9. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STOCKHOLDERS&#146; EQUITY</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Shelf Registration Statements On Form S-3 </I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal years 2005, 2004, and 2003, we entered into various financing transactions under the following
shelf registration statements on Form S-3 (&#147;Shelf&#148;), which were declared effective by the
Securities and Exchange Commission on various dates noted below, allowing us to issue, from time
to time, in one or more offerings the following number of shares of our common stock and warrants
to purchase shares of our common stock:</FONT></P>
<table width=70% border=0 align="center" cellpadding=0 cellspacing=0>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1><br>
      Registration <br>
      Statement<br>
      No.</font></th>
    <th>&nbsp;</th>
    <th><font face="Times New Roman, Times, Serif" size=1>Shelf Effective <br>
      Date</font></th>
    <th>&nbsp;</th>
    <th><font face="Times New Roman, Times, Serif" size=1>Number of Shares of <br>
      Common Stock<br>
      Registered</font></th>
    <th>&nbsp;</th>
    <th><font face="Times New Roman, Times, Serif" size=1>Number of <br>
      Warrants<br>
      Registered</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <td colspan="7" align=LEFT><hr size="1" color=black></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td width=20% align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>333-71086</font></div></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=20% align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>November 2001</font></div></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=20% align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>10,000,000</font></div></td>
    <td width=3% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=20% align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>2,000,000</font></div></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;333-103965</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>March 2003</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>10,000,000</font></div></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&#151;</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;333-109982</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>October 2003</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>12,000,000</font></div></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&#151;</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;333-121450</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=LEFT><div align="center"><font face="Times New Roman, Times, Serif" size=2>December 2004</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>12,000,000</font></div></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="center"><font face="Times New Roman, Times, Serif" size=2>&#151;</font></div></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The following tables summarize the various financing transactions we entered into during fiscal years
2005, 2004, and 2003 under the above shelf registration statements:</FONT></P>
<table width=100% border=0 cellpadding=0 cellspacing=0>
  <tr valign=Bottom>
    <th colspan=9><b><font size="2" face="Times New Roman, Times, serif">FISCAL YEAR 2003</font></b></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th colspan=9><hr size="1" color=black></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th><div align="left"><font face="Times New Roman, Times, Serif" size=1>&nbsp;&nbsp;&nbsp;Description of Financing Transaction</font></div></th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>Number of Shares of <br>
      Common<br>
      Stock Issued</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>Number of <br>
      Warrants Issued</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>Net Issuance <br>
      Value</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th colspan=9><hr size="1" color=black></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font size="2" face="Times New Roman, Times, serif"> Common stock purchase agreement dated August 13, 2002 </font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, serif" size=2>&nbsp;</font></td>
    <td width=10% align=RIGHT><div align="center"><font size="2" face="Times New Roman, Times, serif"> 2,900,000 </font></div></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, serif" size=2>&nbsp;</font></td>
    <td width=10% align=RIGHT><div align="center"><font face="Times New Roman, Times, serif" size=2>&#151;</font></div></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, serif" size=2>$</font></td>
    <td width=10% align=RIGHT><div align="center"><font size="2" face="Times New Roman, Times, serif"> 1,856,000 </font></div></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, serif" size=2>&nbsp;</font></td>
  </tr>
</table>
<br>
<table cellpadding=0 cellspacing=0 border=0 width=100%>
  <tr valign=Bottom>
    <th colspan=11><b><font size="2" face="Times New Roman, Times, serif">FISCAL YEAR 2004</font></b></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th colspan=11><hr size="1" color=black></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th><div align="left"><font face="Times New Roman, Times, Serif" size=1>&nbsp;&nbsp;&nbsp;Description of Financing Transaction</font></div></th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>Number of Shares of <br>
      Common<br>
      Stock Issued</font></th>
    <th>&nbsp;</th>
    <th>&nbsp;</th>
    <th><font face="Times New Roman, Times, Serif" size=1>Number of <br>
Warrants Issued</font></th>
    <th>&nbsp;</th>
    <th>&nbsp;</th>
    <th colspan=3><font face="Times New Roman, Times, Serif" size=1>Net Issuance <br>
      Value</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th colspan=11><hr size="1" color=black></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated June 6, 2003</font></td>
    <td width=12% align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>2,412,448</font></div></td>
    <td width=3% align=RIGHT>&nbsp;</td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=10% align=center><font face="Times New Roman, Times, Serif" size=2>150,000</font></td>
    <td width=2% align=RIGHT>&nbsp;</td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=6% align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 1,971,000</font></div></td>
    <td width=2% align=RIGHT><h5>&nbsp;</h5></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated June 26, 2003</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>1,599,997</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 1,739,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Option granted under the common stock purchase agreement dated June 26, 2003</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>1,599,997</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 1,786,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated July 24, 2003</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>2,000,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 2,887,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated September 18, 2003</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>2,800,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 5,273,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated November 17, 2003</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>2,000,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 4,256,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock purchase agreement dated January 22, 2004</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>1,000,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> 2,275,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock issued to unrelated entities for research services</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2>243,101</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=center><font face="Times New Roman, Times, Serif" size=2>&#151;</font></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><div align="right"><font face="Times New Roman, Times, Serif" size=2> &nbsp;&nbsp; 648,000</font></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=10 align=RIGHT><hr size="1" color=black></td>
    <td align=RIGHT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><div align="right"><b><font face="Times New Roman, Times, Serif" size=2>13,655,543</font></b></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=center><b><font face="Times New Roman, Times, Serif" size=2>150,000</font></b></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT><b><font face="Times New Roman, Times, Serif" size=2>$</font></b></td>
    <td align=RIGHT><div align="right"><b><font face="Times New Roman, Times, Serif" size=2> 20,835,000</font></b></div></td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=10 align=RIGHT><hr color=black size=2></td>
    <td align=RIGHT>&nbsp;</td>
  </tr>
</table>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-24</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<br>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=7><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>FISCAL YEAR 2005</FONT></b></TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="6" ALIGN=LEFT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH align="left" nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;&nbsp;Description of Financing Transaction</FONT></b></TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of Common<BR>
      Stock Shares Issued </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<BR>
      Warrants Issued</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Net Issuance<BR>
      Value </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="6" ALIGN=LEFT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock purchase agreement dated March 31, 2004</FONT></TD>
    <TD width="12%" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,000,000</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="12%" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="12%" ALIGN=center nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 3,207,000</FONT></TD>
    <TD width="2%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock purchase agreement dated January 31, 2005</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,000,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 3,279,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><font face="Times New Roman, Times, Serif" size=2>Common stock issued to unrelated entities for research
services</font></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,174,682</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1,449,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="5" ALIGN=center><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7,174,682</FONT></b></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></b></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 7,935,000</FONT></b></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="5" ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2005, an aggregate of 13,669,775 shares of common stock and zero warrants were available
for issuance under the various shelf registration statements noted above. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>From May 1, 2005 through June 30, 2005, we entered into the following Shelf financing transactions:</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH COLSPAN=13><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>FISCAL YEAR 2006
    (May 1, 2005 to June 30, 2005)</FONT></b></TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="12" ALIGN=LEFT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH align="left" nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;&nbsp;Description of Financing Transaction</FONT></b></TH>
    <TH align="left" nowrap>&nbsp;</TH>
    <TH colspan="3" align="center" nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of Common<BR>
    Stock Shares Issued </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<BR>
      Warrants Issued</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH colspan="4" nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Net
    Issuance<br>
    Value</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="12" ALIGN=LEFT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock purchase agreement dated January 31, 2005</FONT></TD>
    <TD width="5%" ALIGN=LEFT>&nbsp;</TD>
    <TD width="2%" ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=10% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,582,217</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=12% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=7% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,582,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD></TD>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3 align="center"></TD>
    <TD COLSPAN=4></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock purchase agreement dated May 11, 2005</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,125,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 3,000,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD></TD>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3 align="center"></TD>
    <TD COLSPAN=4></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Common stock purchase agreement dated June 22, 2005</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8,000,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 6,720,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="10" ALIGN=LEFT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12,707,217</FONT></b></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></b></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></b></TD>
    <TD ALIGN=RIGHT><b><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 11,302,000</FONT></b></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR align="left" VALIGN=Bottom>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="10"><HR color=black size="2"></TD>
    <TD>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of June 30, 2005, an aggregate of 962,558 shares of common stock were available for issuance under
the various shelf registration statements noted above.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>Financing Under Securities Purchase Agreement</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to financing transactions pursuant to our Shelf registration statements mentioned above,
on August 9, 2002, we entered into a private placement with two investors under a Securities Purchase
Agreement (&#147;SPA&#148;) and issued an aggregate of 1,923,078 shares of our common stock in exchange
for gross proceeds of $1,250,000. In conjunction with the private placement, we issued warrants to
purchase up to an aggregate of 1,442,309 shares of our common stock. The warrants have a four year
term and are exercisable six months after the date of issuance at an exercise price of $0.71 per
share. During fiscal year 2004, the two investors exercised all 1,442,309 warrants in exchange for
gross proceeds of $1,024,000 at the exercise price of $0.71 per share.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Also on August 9, 2002, we agreed to sell 3,298,462 shares of our common stock at a negotiated price
of $0.65 per share in exchange for gross proceeds of $2,144,000 to one investor. In conjunction with
this offering, we issued a four-year warrant to purchase up to 4,648,846 shares of our common stock
at an exercise price of $0.71 per share. As of April 30, 2005, warrants to purchase up to 4,648,846
shares our common stock were outstanding under the SPA.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Under all equity financing agreements entered into during August 2002, we paid combined placement agent
fees of $445,000.</FONT></P><B><I></I></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-25</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, Serif" size=2><B><I>  Shares Of Common Stock Authorized And Reserved For Future Issuance</I></B></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In accordance with our shares reserved for issuance under our Shelf registration statements, stock
option plans and warrant agreements, we have reserved 39,048,450 shares of our common stock at April
30, 2005 for future issuance, calculated as follows:&nbsp;</FONT></P>
<TABLE WIDTH=60% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1><b>Number of<BR>
    shares reserved </b></FONT></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Shares reserved under Shelf registration statements</FONT></TD>
    <TD WIDTH=14% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,669,775</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Options issued and outstanding</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,182,640</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Options available for future grant</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>654,239</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Warrants issued and outstanding</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,541,796</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><hr color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Total shares reserved</FONT></TD>
    <TD ALIGN=RIGHT><font size="2" face="Times New Roman, Times, serif">39,048,450</font></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><hr color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=2></TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>10. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; STOCK OPTIONS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We maintain three equity compensation plans, the 1996 Plan, the 2002 Plan, and the 2003 Plan. The 1996
and 2003 Plans were approved by our stockholders while the 2002 Plan was not submitted for stockholder
approval. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Equity Compensation Plan Approved by Stockholders</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>We have two incentive stock option plans with outstanding options as of April 30, 2005:&nbsp;the 1996
Plan and the 2003 Plan. The plans provide for the granting of options to purchase shares of our common
stock at prices not less than the fair market value of our common stock at the date of grant and
generally expire ten years after the date of grant.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The 1996 Plan originally provided for the issuance of options to purchase up to 4,000,000 shares of
our common stock. The number of shares for which options may be granted under the 1996 Plan automatically
increases for all subsequent common stock issuances by us in an amount equal to 20% of such subsequent
issuances up to a maximum of 10,000,000 options as long as the total shares allocated to the 1996
Plan do not exceed 20% of our authorized stock. As a result of issuances of our common stock subsequent
to the adoption of the 1996 Plan, the number of shares for which options may be granted has increased
to 10,000,000. Options granted generally vest over a period of four years with a maximum term of
ten years. As of April 30 2005, options to purchase 4,521,053 shares of our common stock were outstanding
under the 1996 Plan and 962 options were available for grant under the 1996 Plan. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During October 2003, our stockholders approved the 2003 Stock Incentive Plan (&#147;2003 Plan&#148;)
for the issuance of up to 5,000,000 options. The 2003 Plan provides for the granting of options to
purchase shares of our common stock at prices not less than the fair market value of the stock at
the date of grant and which generally expire ten years after the date of grant. As of April 30 2005,
options to purchase 4,630,775 shares of our common stock were outstanding under the 2003 Plan and
369,225 options were available for grant under the 2003 Plan. </FONT></P><I></I>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-26</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2><I>Equity Compensation Plans Not Approved by Stockholders</I></FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During June 2002, we adopted a broad-based non-qualified stock option plan (&#147;2002 Plan&#148;)
for the issuance of up to 3,000,000 options. The 2002 Plan provides for the granting of options to
purchase shares of our common stock at prices not less than the fair market value of the stock at
the date of grant and generally expire ten years after the date of grant. As of April 30 2005, options
to purchase 1,849,148 shares of our common stock were outstanding under the 2002 Plan and 284,052
options were available for grant under the 2002 Plan. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>In addition to the 2002 Plan, during 1999, we granted non-qualified options, which are not part of
any compensation plan, to purchase up to an aggregate of 1,500,000 shares of our common stock. As
of April 30, 2005, options to purchase 181,664 shares of our common stock were outstanding. The resale
of the underlying shares of common stock is registered on a registration statement on Form S-3.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Option activity for all option plans for each of the three years ended April 30, 2005 is as follows:</FONT></P>
<TABLE WIDTH=100% BORDER=0 align="center" CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=4 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=14 nowrap><HR color=black size="1"></TH>
    <TH nowrap>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH nowrap><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted <br>
      Average<BR>
      Exercise <br>
      Price</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted <br>
      Average<BR>
      Exercise <br>
      Price </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Shares</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted <br>
      Average<BR>
      Exercise Price </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="14" ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="14" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>BALANCE,
      Beginning of year</FONT></TD>
    <TD width="8%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,704,205</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="1%" ALIGN=RIGHT>&nbsp;</TD>
    <TD width="6%" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.48</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="8%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,580,458</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="1%" ALIGN=RIGHT>&nbsp;</TD>
    <TD width="6%" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.16</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="8%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>10,055,527</FONT></TD>
    <TD width="3%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD width="1%" ALIGN=RIGHT>&nbsp;</TD>
    <TD width="6%" ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.20</FONT></TD>
    <TD width="2%" ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Granted</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,149,829</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.52</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,187,947</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 2.09</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,517,800</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.94</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Exercised</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(2,120,806</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.66</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,131,242</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.61</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(109,633</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.34</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>Forfeited or Expired</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,550,588</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.77</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(932,958</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.99</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,883,236</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.25</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>BALANCE,
      End of year</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,182,640</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1. 61</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,704,205</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.48</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>9,580,458</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.16</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="2" ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
information regarding options outstanding as of April 30, 2005 is as follows:</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=3 nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options Outstanding</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Options Exercisable</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=3 nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><HR color=black size="1"></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=4 nowrap><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Range of Per <br>
      Share Exercise<BR>
      Prices </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of Shares<BR>
      Outstanding</FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>      Weighted Average <br>
      Remaining<BR>
      Contractual Life <br>
      (years) </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1><BR>
      </FONT></b><b><font face="Times New Roman, Times, Serif" size=1>Weighted Average <br>
      Per Share<br>
      Exercise Price </font></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of <br>
      Shares<BR>
      Exercisable </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH COLSPAN=2 nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted Average <br>
      Per Share <br>
      Exercise Price</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="13" ALIGN=LEFT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 0.34 - $ 1.06</FONT></TD>
    <TD WIDTH=5% ALIGN=RIGHT>&nbsp;</TD>
    <TD WIDTH=14% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,410,009</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=6% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>5.28</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT>&nbsp;</TD>
    <TD WIDTH=6% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.61</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=13% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,127,011</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT>&nbsp;</TD>
    <TD WIDTH=6% ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 0.59</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 1.13 - $ 1.41</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,421,356</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.36</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.25</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,524,766</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.28</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 1.44 - $ 2.04</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,252,760</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8.38</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.59</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>615,940</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.67</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 2.09 - $ 2.19</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>125,740</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>7.25</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 2.13</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>75,935</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 2.16</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 2.20 - $ 5.28</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,972,775</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.90</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 2.43</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2,556,570</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 2.55</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$ 0.34 - $ 5.28</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11,182,640</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6.95</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.61</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,900,222</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2> $ 1.58</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-27</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>11. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; WARRANTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>As of April 30, 2005, we had warrants outstanding to purchase up to 13,541,796 shares of our common
stock at exercise prices ranging between $0.71 and $5.00 per share with a weighted average exercise
price of $1.81 per share. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Additional
information regarding warrants outstanding as of April 30, 2005, is as follows:&nbsp;</FONT></P>
<TABLE WIDTH=100% BORDER=0 CELLPADDING=0 CELLSPACING=0>
  <TR VALIGN=Bottom>
    <TH nowrap >&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Range of Per Share<br>
      Exercise Prices </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH colspan="3" nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Number of<br>
      Warrants<BR>
    Outstanding </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Weighted <br>
      Average Per <br>
      Share Exercise<BR>
      Price </FONT></b></TH>
    <TH nowrap>&nbsp;</TH>
    <TH nowrap><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Expiration Date<BR>
      or Date Range </FONT></b></TH>
    <TH bgcolor="#FFFFFF">&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="3" ALIGN=LEFT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=CENTER><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center><HR color=black size="1"></TD>
    <TD ALIGN=LEFT >&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD WIDTH=10% ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.71</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=8% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,648,846</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=16% ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.71</FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8/8/06</FONT></TD>
    <TD WIDTH=10% ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.75</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,064,707</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.75</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8/8/06</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.78- $0.99 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>418,242</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.89</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12/31/05 &#151; 6/8/07</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,350,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>11/16/06</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.04 - $1.86 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>750,806</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.55</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12/31/05 &#151; 3/31/08</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$2.00 - $2.71 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>484,195</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$2.29</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12/31/05 &#151; 3/25/08</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$3.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,825,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$3.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12/1/05</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$5.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,000,000</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$5.00</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>12/1/05</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="3" ALIGN=LEFT><HR color=black size="1"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=CENTER bgcolor="#FFFFFF">&nbsp;</TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$0.71 - $5.00 </FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>13,541,796</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=CENTER><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$1.81</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=center><FONT FACE="Times New Roman, Times, Serif" SIZE=2>8/6/06 &#151; 3/31/08</FONT></TD>
    <TD ALIGN=LEFT bgcolor="#FFFFFF"><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD colspan="3" ALIGN=LEFT><HR color=black size="2"></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=CENTER>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <TD ALIGN=center>&nbsp;</TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal years 2005, 2004, and 2003, we granted 350,000 warrants, 150,000 warrants, and 9,399,982
warrants, respectively, under various transactions. The relative fair value of the warrants was determined
in accordance with the Black-Scholes valuation model based on the underlying warrant terms. The warrants
granted during fiscal year 2005 pertain to services being provided by a non-employee consultant.
The warrant has a three year term, an exercise price of $1.47 per share, expires March 31, 2008,
and was outstanding at April 30, 2005. We utilized the Black-Scholes valuation model to calculate
the fair value of the warrant, which was recorded as stock-based compensation in the accompanying
consolidated financial statements. The warrants granted in fiscal year 2004 to purchase up to 150,000
shares of our common stock were issued in connection with the common stock purchase agreement dated
June 6, 2003, of which, 78,612 warrants were outstanding at April 30, 2005. The warrants have a 4-year
term with an exercise price of $0.86 per share and expire in June 2007. The warrants to purchase
up to 9,399,982 shares of our common stock granted in fiscal year 2003 are related to the August
2002 Financing as further described in Notes 7 and 9. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 2005, warrants to purchase 2,495,414 shares of our common stock were exercised on
a combined cash and cashless basis under various transactions for net proceeds of $747,000 and the
issuance of 2,419,790 shares of our common stock. During fiscal year 2004, warrants to purchase 4,087,871
shares of our common stock were exercised on a combined cash and cashless basis under various transactions
for net proceeds of $2,786,000 and the issuance of 4,063,251 shares of our common stock. There were
no warrants exercised during fiscal year 2003. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 2005, Swartz Private Equity, LLC (&#147;SPE&#148;) exercised 699,000 warrants granted
in November 1999 in exchange for gross proceeds of $328,000, the exercise of which is included in
the total warrant exercises during fiscal year 2005. The warrant was originally granted on November
19, 1999 in consideration of a commitment by SPE to fund a $35,000,000 equity line financing over
a three year term at an exercise price of $0.46875 per share. This
agreement was entered into and approved by the previous Board of Directors. Mr. Eric Swartz, a member
of our Board of Directors, maintains a 50% ownership in SPE. We utilized the Black-Scholes valuation
model to calculate the fair value of the warrant, which was recorded as stock-based compensation
expense in the accompanying consolidated financial statements.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-28</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>12. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SEGMENT REPORTING </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Our business is organized into two reportable operating segments. Peregrine is engaged in the research
and development of targeted biotherapeutics for the treatment of cancer, viruses, and other diseases.
Avid is engaged in providing contract manufacturing of biologics and related services to biopharmaceutical
and biotechnology businesses. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The accounting policies of the operating segments are the same as those described in Note 2. We primarily
evaluate the performance of our segments based on net revenues, gross profit or loss (exclusive of
research and development expenses, selling, general and administrative expenses, and interest and
other income/expense) and long-lived assets. Our segment net revenues shown below are derived from
transactions with external customers. Our segment gross profit represents net revenues less cost
of sales. Our long-lived assets consist of leasehold improvements, laboratory equipment, and furniture,
fixtures and computer equipment and are net of accumulated depreciation.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Segment information for fiscal years 2005, 2004 and 2003 is summarized as follows:</FONT></P>
<table cellpadding=0 cellspacing=0 border=0 width=100%>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=2><b><font face="Times New Roman, Times, Serif" size=1>2005</font></b></th>
    <th>&nbsp;</th>
    <th colspan=2><b><font face="Times New Roman, Times, Serif" size=1>2004</font></b></th>
    <th>&nbsp;</th>
    <th colspan=2><b><font face="Times New Roman, Times, Serif" size=1>2003</font></b></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2><b>Net Revenues:</b></font></td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=5% align=LEFT>&nbsp;</td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=5% align=LEFT>&nbsp;</td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=2% align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 4,684,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,039,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,346,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=3></td>
    <td colspan=3></td>
    <td colspan=3></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Research and development of biotherapeutics</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>575,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total net revenues</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 4,959,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,314,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 3,921,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2><b>Gross Profit:</b></font></td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=5% align=LEFT>&nbsp;</td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=5% align=LEFT>&nbsp;</td>
    <td width=1% align=RIGHT>&nbsp;</td>
    <td width=10% align=RIGHT>&nbsp;</td>
    <td width=2% align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 283,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 827,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 486,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr>
    <td></td>
    <td colspan=3></td>
    <td colspan=3></td>
    <td colspan=3></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Research and development of biotherapeutics</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>275,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>575,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total gross profit</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 558,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 1,102,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 1,061,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Research and development expense of&nbsp;biotherapeutics</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(11,164,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(9,673,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(8,744,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Selling, general and administrative expense</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(5,098,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(4,225,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(2,987,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;Net interest and other income (expense)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>252,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(1,549,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(889,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net loss</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (15,452,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (14,345,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> (11,559,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
</table>
<B></B>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-29</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-lived
assets consist of the following at April 30, 2005 and April 30, 2004:</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Long-lived Assets, net:</b></FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=11% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=5% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=9% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Contract manufacturing and development of biologics</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,291,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 633,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Research and development of biotherapeutics</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>347,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>240,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total long-lived assets, net</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 1,638,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> 873,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="2"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="2"></TH>
    <TH>&nbsp;</TH>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Net revenues generated from Avid during fiscal years 2005, 2004 and 2003 were primarily from one customer
headquartered in Israel, one customer located in Germany and two customers located in the U.S as
follows:</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004</FONT></b></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></b></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2><b>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Customer revenues as a % of net revenues:</b></FONT></TD>
    <TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=3% ALIGN=RIGHT>&nbsp;</TD>
    <TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=3% ALIGN=RIGHT>&nbsp;</TD>
    <TD WIDTH=5% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2></FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT>&nbsp;</TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States (customer A)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>24</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>34</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;United States (customer B)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>51</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Germany (one customer)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>65</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Israel (one customer)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>32</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>67</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>0</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other customers</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>2</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="1"></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total customer revenues as a % of net revenues</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=RIGHT>&nbsp;</TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>100</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>%</FONT></TD>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="2"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="2"></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR color=black size="2"></TH>
    <TH>&nbsp;</TH>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>Net revenues generated from Peregrine during fiscal years 2005, 2004 and 2003 were primarily from the
amortized portion of the up-front license fee under the December 2003 license agreement with Schering
A.G. combined with the up-front license fee of $350,000 received under the Merck KGaA license agreement,
which was included in license revenue in fiscal year 2003 (Note 8). </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>13. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; INCOME TAXES </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>The provision for income taxes consists of the following for the three years ended April 30, 2005:</FONT></P>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TH><FONT FACE="Times New Roman, Times, Serif" SIZE=1></FONT></TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2005</FONT></b></TH>
    <TH width="5%">&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2004 </FONT></b></TH>
    <TH width="5%">&nbsp;</TH>
    <TH COLSPAN=2><b><FONT FACE="Times New Roman, Times, Serif" SIZE=1>2003</FONT></b></TH>
    <TH width="2%">&nbsp;</TH>
  </TR>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Provision for federal income taxes at statutory rate</FONT></TD>
    <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD width="10%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (5,254,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD width="10%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (4,877,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD width="1%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD width="10%" ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> (3,930,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other, net</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>15,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>18,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Increase of effective tax rate for net state deferred&nbsp;tax asset</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(1,941,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State income taxes, net of federal benefit</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(902,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(837,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>(347,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Expiration and adjustment of loss and carryforwards</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>4,513,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>891,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>876,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Change in valuation allowance</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>1,628,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>6,746,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>3,398,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="1"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font face="Times New Roman, Times, Serif" size="2">
    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income tax (expense) benefit</font></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><hr color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><hr color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
    <td colspan="2" align=RIGHT><HR color=black size="2"></td>
    <td align=LEFT>&nbsp;</td>
  </tr>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-30</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deferred
income taxes reflect the net effects of temporary differences between the carrying amounts of assets
and liabilities for financial reporting purposes and the amounts for income tax purposes. Significant
components of our deferred tax assets at April 30, 2005 and 2004 are as follows:</FONT></P>
<table width=90% border=0 align="center" cellpadding=0 cellspacing=0>
  <tr valign=Bottom>
    <th><font face="Times New Roman, Times, Serif" size=1></font></th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2005</font></th>
    <th>&nbsp;</th>
    <th colspan=2><font face="Times New Roman, Times, Serif" size=1>2004</font></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2>&nbsp;</th>
    <th>&nbsp;</th>
    <th colspan=2>&nbsp;</th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Net operating loss carryforwards</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=12% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 41,628,000</font></td>
    <td width=3% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td width=1% align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td width=12% align=RIGHT><font face="Times New Roman, Times, Serif" size=2> 39,355,000</font></td>
    <td width=2% align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Stock-based compensation</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,495,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,813,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>General business and research and development credits</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>118,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>118,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Deferred revenue</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>226,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>657,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Accrued liabilities</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,785,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>1,681,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=RIGHT>&nbsp;</td>
    <td align=LEFT>&nbsp;</td>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Total
    deferred tax assets</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>45,252,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>43,624,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom bgcolor="#eaf9e8">
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Less valuation allowance</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(45,252,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>(43,624,000</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>)</font></td>
  </tr>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="1"></th>
    <th>&nbsp;</th>
  </tr>
  <tr valign=Bottom>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>Net deferred tax
    assets</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2>$</font></td>
    <td align=RIGHT><font face="Times New Roman, Times, Serif" size=2> &#151;</font></td>
    <td align=LEFT><font face="Times New Roman, Times, Serif" size=2>&nbsp;</font></td>
  </tr>
  <tr valign=Bottom>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="2"></th>
    <th>&nbsp;</th>
    <th colspan=2><HR color=black size="2"></th>
    <th>&nbsp;</th>
  </tr>
</table>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>At April 30, 2005, we had federal net operating loss carryforwards and tax credit carryforwards of
approximately $113,829,000 and $118,000, respectively. The operating
loss carryforwards expire in fiscal years 2006 through 2025. The net operating losses
of $2,986,000 applicable to Vascular Targeting Technologies, our wholly-owned subsidiary, can only
be offset against future income of that subsidiary. The tax credit carryforwards
begin to expire in fiscal year 2008 and are available to offset the future taxes or our subsidiary.
We also have state net operating loss carryforwards of approximately $56,616,000
at April 30, 2005, which began to expire in fiscal year 2004.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Due
to ownership changes in our common stock, there may be limitations on our ability to utilize our
net operating loss carryforwards in the future. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>14. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; RELATED PARTY TRANSACTIONS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;During
fiscal year 2005, 2004 and 2003, we paid Equiplace Securities, LLC (&#147;Equiplace&#148;) $12,000,
$72,000 and $15,000, respectively, for Avid business development services provided by employees of
Equiplace under a Finder&#146;s Agreement. Under the Finder&#146;s Fee Agreement, Equiplace was given
a call list of potential customers which was provided by Avid. Equiplace employees then call each
contact and present Avid&#146;s manufacturing services. All contacts that show an interest in Avid&#146;s
services are then turned over to Avid&#146;s in-house Business Development Department for continued
discussions. In addition, Equiplace may receive a commission ranging from 2% to 4% of revenues generated
by Avid Bioservices, Inc. on new customers referred to Avid by Equiplace. The commissions due Equiplace
can be reduced in half if another third-party finder is jointly responsible for new customer contracts.
Mr. Swartz, a member of our Board of Directors, owns fifty percent (50%) of Equiplace. The Finder
Fee Agreement was canceled on June 30, 2004. To date, we have not paid any commissions under the
agreement. Mr. Swartz has referred one of Avid&#146;s largest customers to date without receiving
any commission or fee.</FONT></P>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-31</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top>&nbsp;</TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 (continued)</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On
November 19, 2001, we received $5,750,000 under a Common Stock Purchase Agreement in exchange for
the issuance of 5,750,000 shares of our common stock and warrants to purchase up to 1,725,000 shares
of our common stock at an exercise price of $1.00 per share. Mr. Swartz, a member of our Board of
Directors, invested $500,000 of the total amount in exchange for 500,000 shares of our common stock
and warrants to purchase up to 150,000 shares of our common stock at an exercise price of $1.00.
Subsequent to the sale, we were informed by The Nasdaq Stock Market that the sale of shares to a
member of our Board of Directors at a discount to the market price of our common stock required stockholder
approval in order for us to be in compliance with Nasdaq Market Rule 4350. On October 22, 2002, our
prior sale of common stock to Mr. Swartz did not receive stockholder approval due to insufficient
stockholder votes. As such, we were required to rescind the transaction and to return the sum of
$500,000 to Mr. Swartz in exchange for the return of 500,000 shares of our common stock and the cancellation
of a warrant to purchase up to 150,000 shares of our common stock. During December 2002, we paid
Mr. Swartz $508,000, which included interest calculated at our earned money market rates.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>15. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; BENEFIT PLAN</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT face="Times New Roman, Times, Serif" size=2>During fiscal year 1997, we adopted a 401(k) benefit plan (the &#147;Plan&#148;) for all regular employees
who are over age 21, work at least 25 hours per week and have three or more months of continuous
service. The Plan provides for employee contributions of up to 100% of their compensation or a maximum
of $14,000. We made no matching contributions to the Plan since its inception. </FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>16. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SUBSEQUENT EVENTS</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On June 17, 2005, we entered into an additional note payable agreement with GE in the amount of $267,000
collateralized by certain laboratory equipment. The note bears interest at a rate of 6.39% per annum
with payments due monthly in the amount of approximately $8,000 over 36 months commencing August
1, 2005. Under the terms of the agreement, we paid to GE a security deposit of 25%, or approximately
$67,000, which is due and payable to us at the end of the note term.</FONT></P>
<P align=left><FONT face="Times New Roman, Times, Serif" size=2>17. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)</FONT></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
<TD vAlign=top width=48>&nbsp;</TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>Selected quarterly financial information for each of the two most recent fiscal years is as follows:</FONT></TD></TR>
</TABLE>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
    <th colspan="23" ALIGN=center>&nbsp;</th>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <th colspan="23" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">Quarter Ended</font></b></th>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="24" ALIGN=LEFT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;&nbsp;&nbsp;</font></TD>
    <th colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">April 30, <br>
      2005</font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center nowrap><b><font size="1" face="Times New Roman, Times, serif">January 31, <br>
      2005</font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center nowrap><b><font size="1" face="Times New Roman, Times, serif">October 31,<br>
      2004 </font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">July 31, <br>
      2004</font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">April 30, <br>
      2004</font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center nowrap><b><font size="1" face="Times New Roman, Times, serif">January 31, <br>
    2004 </font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center nowrap><b><font size="1" face="Times New Roman, Times, serif">October 31,<br>
    2003 </font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
    <th colspan="2" ALIGN=center><b><font size="1" face="Times New Roman, Times, serif">July 31, <br>
      2003</font></b></th>
    <th ALIGN=center><font size="1" face="Times New Roman, Times, serif"></font></th>
  </TR>
  <TR VALIGN=Bottom>
    <TD colspan="24" ALIGN=LEFT><HR NOSHADE COLOR=#000000 SIZE=1></TD>
    <TD ALIGN=LEFT><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Net revenues</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 919,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,353,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 2,183,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 504,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,855,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 229,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 858,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD WIDTH=6% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 372,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Cost of sales</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,136,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>(a)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,273,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,544,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 448,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 1,005,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 223,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 666,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 318,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Gross profit (loss)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (217,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 80,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 639,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 56,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 850,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 6,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 192,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 54,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Operating expenses &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 4,498,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 3,886,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>&nbsp; </FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 4,341,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 3,537,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 4,104,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 3,819,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 3,084,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> 2,891,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> &nbsp;&nbsp;&nbsp;</FONT></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Net loss <font size="2">&nbsp;&nbsp;</font></FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (4,657,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (3,744,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (3,638,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (3,413,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (3,182,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (4,137,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (2,915,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (4,111,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT>&nbsp;</TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>Basic and
    diluted loss per common share</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.02</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.02</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, Serif" SIZE=1> (0.03</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, Serif" SIZE=1>)</FONT></TD>
  </TR>
</TABLE>
<br>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">

<TR>
  <TD colspan="2" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>______________</FONT></TD>
  </TR>
<TR>
<TD vAlign=top width=36><FONT face="Times New Roman, Times, Serif" size=2>&nbsp;</FONT></TD>
<TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2>(a)&nbsp;&nbsp;Cost of sales for the quarter ended April 30, 2005 includes the write-off of unusable
work-in-process inventory generated during the quarter ended April 30, 2005 in the amount of $605,000.</FONT></TD></TR></TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-32</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">
<a href="#TABLE_OF_CONTENTS_"><font size="2">Table of Contents</font></a>
<P></P>
<TABLE cellSpacing="0" cellPadding="0" width="100%" border="0">
  <TR>
    <TD vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B><a name="b7"></a>PEREGRINE PHARMACEUTICALS, INC.</B></FONT></TD>
    <TD colspan="2" align="right" vAlign=top><b><font size="2" face="Times New Roman, Times, serif">SCHEDULE II</font></b> </TD>
  </TR>
  <TR>
    <TD colspan="2" vAlign=top>&nbsp;</TD>
    <TD width="2%" vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="2" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>VALUATION OF QUALIFYING ACCOUNTS</B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="2" vAlign=top><FONT face="Times New Roman, Times, Serif" size=2><B>FOR EACH OF THE THREE YEARS IN THE PERIOD ENDED APRIL 30, 2005 </B></FONT></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
  <TR>
    <TD colspan="2" vAlign=top><hr color="black" size="1"></TD>
    <TD vAlign=top>&nbsp;</TD>
  </TR>
</TABLE>
<br>
<TABLE CELLPADDING=0 CELLSPACING=0 BORDER=0 WIDTH=100%>
  <TR VALIGN=Bottom>
    <td COLSPAN=3 align="left"><b><font size="1" face="Times New Roman, Times, serif">Description</font></b></td>
    <TH COLSPAN=2 align="center" nowrap><b><font size="1" face="Times New Roman, Times, serif">Balance at<br>
      Beginning<br>
      of period</font></b></TH>
    <TH align="center" nowrap>&nbsp;</TH>
    <TH COLSPAN=2 align="center" nowrap><b><font size="1" face="Times New Roman, Times, serif">Charged<br>
      to costs and<br>
      expenses</font></b></TH>
    <TH align="center" nowrap>&nbsp;</TH>
    <TH COLSPAN=2 align="center" nowrap><b><font size="1" face="Times New Roman, Times, serif">Deductions</font></b></TH>
    <TH align="center" nowrap>&nbsp;</TH>
    <TH COLSPAN=2 align="center" nowrap><b><font size="1" face="Times New Roman, Times, serif">Balance<br>
      at end<br>
      of period</font></b></TH>
    <TH align="center">&nbsp;</TH>
  </TR>
  <TR VALIGN=Bottom>
    <TH COLSPAN=3><HR align="left" width="250" SIZE=1 NOSHADE COLOR=#000000></TH>
    <TH COLSPAN=2><HR NOSHADE COLOR=#000000 SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR NOSHADE COLOR=#000000 SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR NOSHADE COLOR=#000000 SIZE=1></TH>
    <TH>&nbsp;</TH>
    <TH COLSPAN=2><HR NOSHADE COLOR=#000000 SIZE=1></TH>
    <TH>&nbsp;</TH>
  </TR>
  <TR>
    <TD COLSPAN=3><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="1" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>Valuation reserve for note and other <br>
      receivables for the year ended April 30, 2003</FONT></TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1,785,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, serif" SIZE=2> &#151;</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, serif" SIZE=2> (81,000</FONT></TD>
    <TD WIDTH=3% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>)</FONT></TD>
    <TD WIDTH=1% ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD WIDTH=10% ALIGN=RIGHT bgcolor="#eaf9e8"><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1,704,000</FONT></TD>
    <TD WIDTH=2% ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>Valuation reserve for note and other <br>
      receivables for the year ended April 30, 2004</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1,704,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> (59,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1, 645,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
    <TD COLSPAN=3><font size="2" face="Times New Roman, Times, serif">&nbsp;</font></TD>
  </TR>
  <TR VALIGN=Bottom bgcolor="#eaf9e8">
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>Valuation reserve for note and other <br>
      receivables for the year ended April 30, 2005</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1,645,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> &#151;</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> (64,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>)</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2>$</FONT></TD>
    <TD ALIGN=RIGHT><FONT FACE="Times New Roman, Times, serif" SIZE=2> 1, 581,000</FONT></TD>
    <TD ALIGN=LEFT><FONT FACE="Times New Roman, Times, serif" SIZE=2>&nbsp;</FONT></TD>
  </TR>
  <TR>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
    <TD COLSPAN=3></TD>
  </TR>
</TABLE>
<P align=center><FONT face="Times New Roman, Times, serif" size=2>F-33</FONT></P>
<HR noShade SIZE=5>

<P style="PAGE-BREAK-BEFORE: always">

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
